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Abstract 
Patients with chronic kidney disease (CKD) are at increased risk of mortality and 
cardiovascular (CV) disease and those on maintenance haemodialysis (MHD) are 
at particularly high risk. Insulin resistance (IR) is known as a contributing factor to 
many of the conditions classified as „classic CV risk factors‟ and understanding 
changes in IR is thought to be of key importance in targeting potential medication.   
A prospective observational study of individuals with CKD was designed to better 
establish the relationship between CV risk factors and events, before and after the 
onset of MHD. In addition, a subgroup study was set up to examine if changes in IR 
affect CV outcome and mortality.  
519 patients were recruited for this study, 210 were on MHD at entry and 309 had 
CKD stages 3, 4 and 5. Subjects were followed prospectively for 24 months and the 
relationship between body mass index (BMI), blood pressure (BP), total cholesterol 
(TC), triglycerides (TG), diabetes status and glycosylated haemoglobin (HbA1c) and 
CV events  analysed in both MHD and non-MHD groups using logistic regression. A 
small study was also carried out to determine the reliability of HbA1c in MHD 
subjects. 106 of these subjects were recruited into the subgroup study, where 
baseline assessment of their IR (using the HOMA-IR model) was carried out as well 
as other relevant tests.  
103 subjects reached an endpoint, and analysis of the whole cohort identified high 
SBP and diabetes as significant CV risk factors. TC was recognized as a protective 
factor as lower TC was associated with higher CV risk. The mean HOMA-IR 
increased through the CKD stages 3-5 before significantly falling in the MHD group. 
HbA1c showed poor association with glycaemia as measured by use of 48-hour 
continuous glucose monitors (CGM).   
These results suggest that CV risk factors may vary at different stages of CKD. The 
“reverse” TC result only in the non-dialysis group differs from current theories, 
where low cholesterol is considered a CV risk factor putatively as a surrogate 
marker of malnutrition. This study shows that IR increases as renal function 
deteriorates but is significantly decreased with MHD.  In this cohort changes in IR 
were not predictive of CVE or mortality.   
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CAPD: Continuous ambulatory peritoneal dialysis 
CARDS: Collaborative Atorvastatin diabetes study 
CGM: Continuous glucose monitoring 
CHF: Chronic heart failure 
CHF: Congestive heart failure 
CI: Confidence interval 
CIGMA: Continuous infusion of glucose with model assessment 
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CKD: Chronic kidney disease 
COPD: Chronic obstructive pulmonary disease 
CRH:  Cortisol releasing hormone 
CRP: C-reactive protein 
CV: Cardiovascular 
CVD: Cardiovascular disease 
CVE: Cardiovascular event 
DBP:  Diastolic blood pressure 
DCCT: Diabetes control and complications trial 
ESRD/ESRF: end-stage renal disease/end-stage renal failure 
GFR/eGFR: Glomerular filtration rate/estimated GFR 
GH: Growth hormone 
HbA1c: Glycosylated haemoglobin 
HD: Haemodialysis 
HDL: High-density lipoprotein 
HIV: Human immunodeficiency virus 
HOMA/HOMA-IR: Homeostatic model assessment/homeostatic model assessment 
index of insulin resistance 
Hs-CRP: high sensitivity c-reactive protein 
ICKTI: Imperial College kidney and transplant institute 
IGF:  Insulin-like growth factor 
IHD: Ischaemic heart disease 
20 
IL: Interleukin 
IST: Insulin sensitivity test 
ITT: Insulin tolerance test 
Kt/V: Dialysis adequacy 
LDL: Low density lipoprotein 
LPS: Lipopolysaccharide 
MHD: Maintenance haemodialysis 
MI: Myocardial infarction 
MIA: Malnutrition inflammation atherosclerosis 
MICS: Malnutrition-inflammation complex syndrome 
OGTT: Oral glucose tolerance test 
OR: Odds ratio 
PEM: Protein energy malnutrition 
PTH: Parathyroid hormone 
PVD: Peripheral vascular disease 
QUICKI: Quantitative insulin sensitivity check index 
RAS: Renin angiotensin system 
RRT: Renal replacement therapy 
SBP: Systolic blood pressure 
SD: Standard deviation 
TC:  Total cholesterol 
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TG: Triglycerides 
TIBC: Total iron binding capacity 
TNF: Tumor necrosis factor 
UKPDS: United Kingdom prospective diabetes study 
USRDS: United Stated Renal Data System 
VADT: Veterans affairs diabetes trial 
WHO: World Health Organisation 
WLRTC: West London renal and transplant centre 
  
22 
Chapter 1: Introduction 
1.1 Cardiovascular Risk Factors in ESRD 
1.1.1 Background 
Chronic kidney disease (CKD) is a public health problem that has been increasing 
in parallel to the rise of obesity and subsequent type 2 diabetes [1]. CKD is 
important because it is primarily a marker for cardiovascular disease (CVD), as 
even early stage CKD causes an estimated 40-100% increase in risk of 
cardiovascular events [2]. As CKD progresses, cardiovascular disease remains the 
main cause of mortality in these patients [3-5], but what is considered as 
cardiovascular risk factors in this group of patients has been the subject of 
controversy [6, 7]. These controversies are based on the argument that suggests 
what constitutes as a cardiovascular risk factor in individuals with normal kidney 
function, may actually have protective qualities against cardiovascular disease and 
subsequent mortality in patients who have renal impairment, and more specifically 
in recipients of renal replacement therapy in the form of haemodialysis [6-10]. 
One of the main contributors to the rise in CKD is obesity [11-13]. The obesity 
epidemic that was first noted in the U.S. has now become a pandemic, with more 
than 1.6 billion overweight and at least 400 million clinically obese people in the 
world, according to the World health Organisation (WHO) [14].  Over weight and 
obesity are at the root of many cardiovascular risk factors, including impaired 
glucose tolerance, type 2 diabetes, dyslipidaemia and hypertension. These 
conditions are chronic in nature and life-threatening as they are responsible for the 
expanding epidemics of cardiovascular disease. The association of obesity and 
cardiovascular disorders (CVD) is well documented and includes hypertension [15], 
myocardial infarction and stroke [16, 17].  It is these conditions that ultimately cause 
the increased risk of mortality in obese patients; and why there is a progressive 
increase in risk of death as adiposity increases above normal [18]. Obesity is also 
implicated, as an important factor in the emerging spread of chronic kidney disease 
(CKD) and end-stage renal disease (ESRD) [19]; it has been observed that excess 
body weight is linked to CKD by two large studies [20, 21], although the exact 
mechanisms leading to renal damage are still largely unknown.  
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Another well-established consequence of obesity is type 2 diabetes [22, 23], which 
is ranked as the leading cause of end-stage renal failure (ESRF) in the developed 
world [24]. The coexistence of obesity and chronic hyperglycaemia, as a result of 
impaired glucose tolerance or diabetes [25, 26], dramatically increases risk of 
cardiovascular disease. Type 2 diabetes alone is responsible for the majority of 
health costs associated with obesity, and as it is a facilitator of all other 
consequences of obesity, it has been dubbed „the disease of the century‟.  
Type 2 diabetes is a chronic condition that has many complications; these include 
macro-vascular disease such as cardiovascular disease (including cardiomyopathy, 
atherosclerosis and hypertension) and renovascular disease (nephropathy), as well 
as micro-vascular disease (including retinopathy and peripheral vascular disease). 
Nephropathy is perhaps one of the most costly complications, as many patients 
require chronic renal replacement therapies as a result of renal failure. About 30% 
of patients with diabetes develop nephropathy, about 10% develop renal failure as a 
cause of this disease, but nearly 44% of all end-stage renal failure (ESRF) cases 
are due to diabetes [27]. Unfortunately, despite many advances in medicine and 
renal replacement therapy, the mortality rates for these patients are still high, with 
25% first-year mortality rate for patients on maintenance haemodialysis (MHD) and 
18% for those on continuous ambulatory peritoneal dialysis (CAPD)[24].  
Perhaps the reason behind such high mortality rates in the ESRF population is the 
fact that mortality risk factors are less well understood. Despite the many studies 
that have been carried out since the 1960s, modern medicine still looks slightly 
confused as to what constitutes as a risk factor in these patients. What is known is 
that more than half of the deaths that occur in this population are attributed to 
cardiovascular disease, which means that the incidence of fatal cardiovascular 
events in ESRF is twice as high as the general population (30% vs. 15%) [24, 28].  
Identifying the causes and mechanisms of this increased incidence of 
cardiovascular disease in patients receiving renal replacement therapy will ensure 
that the required measures are taken to prevent mortality as well as improve 
patients‟ quality of life.   
  
24 
1.1.2 End Stage Renal Failure: Causes 
Chronic kidney disease (CKD) is the progressive loss of renal function over months 
or years. The Kidney Disease Outcomes Quality Initiative guidelines [29] have 
divided CKD into five stages according to the glomerular filteration rate (GFR); 
 Stage 1: patient with normal GFR but with some evidence of kidney damage 
such as microalbuminuria/proteinuria, haematuria, or histological changes 
 Stage 2: mild CKD with a GFR ranging from 89 to 60 mL/min/1.73 m2 
 Stage 3: moderate CKD with a GFR ranging from 59 to 30 mL/min/1.73 m2 
 Stage 4: severe CKD with GFR ranging from 29 to 15 mL/min/1.73 m2 
 Stage 5: kidney failure when GFR is less than 15 mL/min/1.73 m2.  
Stage 5 is when renal replacement therapy (RRT) either in the form of dialysis or 
transplantation has to be considered.  
Important notes to keep in mind are that all individuals with a GFR <60 
mL/min/1.73m2 for 3 months, whether kidney damage is present or not, are 
classified as CKD; this is because this reduction represents loss of half or more of 
the normal kidney function in adults. The other point is that all individuals with 
kidney damage, irrespective of their GFR, are classified as CKD; this is because 
despite substantial kidney damage, GFR may be maintained at 60 mL/min/1.73 m2 
or above, and these patients are at increased risk of both of the major outcomes of 
CKD: kidney failure and cardiovascular disease [29, 30]. 
As proteinuria is regarded an independent marker for deteriorating renal function 
and cardiovascular disease, British guidelines append the letter „P‟ to the stage of 
CKD in case of significant protein loss [30].  
Renal failure is the temporary or permanent loss of normal kidney function. It is 
categorised into two types: acute and chronic. Acute renal failure (ARF) is abrupt 
but potentially reversible, while chronic renal failure (CRF) progresses over time and 
is in most cases permanent. End-stage renal failure (ESRF) is the term used when 
renal function is permanently lost.  
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Causes of ESRF can also be classified by the kidney part involved [31]: 
 Vascular: includes both large vessels, as in renal artery stenosis, and small 
vessels, as in ischaemic nephropathy, vasculitis and the haemolytic-uraemic 
syndrome (HUS). 
 Glomerular: this group is further divided into primary and secondary. 
o Primary: when the problem is initiated within the glomerulus, such as 
in focal segmental glomerulosclerosis (FSGS) and IgA nephritis.  
o Secondary: when an underlying condition leads to problems within the 
glomerulus, such as in diabetic nephropathy and Lupus nephritis. 
 Tubulointerstitial: this includes polycystic kidney disease, reflux nephropathy, 
and drug-induced chronic tubulointerstitial nephritis.  
 Obstructive: causes of which include bilateral kidney stones, disease of the 
prostate and cancer.  
The most common cause of ESRF in the world today is diabetes, as it is 
responsible for 44% of new ESRF cases [32].  
1.1.2.1 Diabetic Nephropathy 
As briefly explained above, diabetic nephropathy is a secondary glomerular 
disease.  
1.1.2.1.1 Type 1 diabetes: It has been observed that after the initiation of diabetes 
in animal models with type 1 diabetes, the nephropathy develops in three stages. 
The first stage involves renal and glomerular hypertrophy, as well as glomerular 
hyperperfusion, hyperfiltration and hypertension [33]. In the second stage 
progressive mesangial expansion occurs and seems to contribute towards 
proteinuria. In the final stage degrees of glomerular sclerosis occur. In rat models, 
contrary to human diabetic nephropathy (DN), the animals remain normotensive at 
this stage. It has been noted that while the superimposition of hypertension 
accelerates the development of glomerulosclerosis, tight glycaemic control prevents 
the development of microangiopathy and nephropathy.  
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1.1.2.1.2 Type 2 diabetes and obesity: By studying the many animal models of 
type 2 diabetes, the major pathologies have been identified as thickening of the 
glomerular basement membrane (GBM), mesangial expansion and activation, 
podocyte injury as well as interstitial inflammatory infilterate [34-36]. 
The progression of diabetic nephropathy has been divided into three stages; 
microalbuminuria (incipient nephropathy), proteinuria with decreasing GFR (overt 
nephropathy), and ESRD. These stages are illustrated in figure 1.1 below. In type 1 
diabetes, two additional stages of glomerular hyperfiltration with enlarged kidneys 
and early glomerular lesions with basement membrane thickening and normal 
urinary albumin secretion also exist [37]. 
 
 
Figure 1.1 Progression of chronic renal injury; early increase in glomerular filtration 
rate (GFR) is followed by its decline with increasing proteinuria. Also indicated is the 
National Kidney Foundation K/DOQI classification of the stages of chronic kidney 
disease. Figure based on and redrawn from reference [38].   
 
Diabetic nephropathy is currently the leading cause of ESRD in the world, and it 
accounts for 40% of new ESRD cases in the USA [27]. As the number of adults with 
type 2 diabetes is progressively increasing and is projected to increase to 
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approximately 300 million in the year 2025 [39], diabetic ESRD is expected to 
become even more prevalent in the future.   
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1.1.3 End Stage Renal Disease: Outcomes 
In addition to progressive azotaemia, there are many consequences associated with 
ESRD and the uraemic syndrome, these include anaemia, osteodystrophy, 
manifestations in the nervous system and metabolic and endocrine disorders in 
addition to cardiovascular disease. To better comprehend the complexity of patients 
with ESRD, I will outline these conditions here. 
Anaemia. One of the functions of the kidney is to regulate red blood cell production 
by secreting erythropoietin. Anaemia has been recognised as an important clinical 
manifestation of progressive renal disease since the 1800s [40, 41]. The degree of 
anaemia usually increases with the fall of GFR, and tends to plateau by the time 
patients reach a stage where they require renal replacement therapy [42]. Major 
causes of anaemia in these patients include: 
-Inadequate erythrocyte production: This is the most important cause of anaemia in 
ESRD; the other factors listed below may add to the severity of anaemia, but are 
not as instrumental as the decreased production of erythropoietin by the diseased 
kidneys. 
-Shortened erythrocyte survival: It has been observed that the lifespan of 
erythrocytes reduces from 120 days in normal subjects to 70-80 days in uraemic 
ones [43]. This has been attributed to both metabolic (decreased activity of sodium 
and potassium pumps influences shape and rigidity of red blood cells) and 
mechanical factors (blood loss as explained below). However, more recent studies 
in well-dialysed patients have shown that RBC lifespan can reach nearly normal 
levels if blood losses during haemodialysis are prevented [44]. 
-Blood loss: This can be due to residual blood left in dialysers, vascular access 
punctures, occasional blood leaks, phlebotomy for routine testing and clotted 
dialysers. 
-Iatrogenic haemolysis: The membranes of the red blood cells in patients on dialysis 
are sensitive to oxidant drugs and chemicals [45, 46]. If tap water is used in the 
dialysate, the presence of copper [47], zinc [48], aluminium [49] and nitrates as well 
as chloramine [50] can lead to haemolysis. 
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-Splenic dysfunction: A significant number of patients on dialysis have 
splenomegaly [51, 52] and hypersplenism which leads to removal of red blood cells 
from the circulation [52]. 
 -Mechanical fragmentation: Red blood cells can also be injured and deformed by 
mechanical trauma and removed from the circulation [53].  
-Inhibition of erythropoiesis: It has been suggested that uraemic serum may have an 
inhibitory effect on erythroid precursors [54-56]. 
-Nutritional factors contributing to anemia: Malnutrition is a common consequence 
of ESRD and dialysis, and is mainly due to anorexia, intercurrent illnesses, dialysate 
nutrient loss and dietary restrictions [57-59].  
Osteodystrophy of chronic renal disease. Another major role of the kidneys is to 
participate in calcium and bone metabolism, by producing 1,25-
dihydrocholecalciferol (Calcitriol). Calcitriol is the active form of vitamin D which 
causes increased absorption of calcium and phosphate in both the gastrointestinal 
tract and the kidneys. In ESRD, the diseased kidneys cannot fulfil their role and 
cause bone metabolism dysfunction through three main mechanisms: 
-High turnover bone disease: this is the dominant form of osteodystrophy in renal 
disease. It was initially hypothesised that as patients developed 
hyperphosphataemia with loss of renal function, they became hypocalcaemic and 
thus developed secondary hyperparathyroidism. It has since been observed that the 
decline in serum 1,25-dihydrocholecalciferol is present prior to reduction in serum 
calcium and correlates inversely with PTH levels [60]. The prolonged half-life of 
PTH in renal failure and the direct effect of hyperphosphotaemia in increasing PTH 
secretion both contribute to secondary hyperparathyroidism in ESRD [61, 62]. The 
pathophysiology of secondary hyperparathyroidism in CKD is illustrated in figure 1.2 
below. 
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Figure 1.2 Pathophysiology of secondary hyperparathyroidism in chronic kidney 
disease. (Figure reproduced with permission) [63] 
 
-Low turnover bone disease: This is due to aluminium toxicity, which is also 
responsible for dialysis dementia [64]. Aluminium is present in small amounts in 
normal subjects (10-30 mg), and excess amounts are rapidly cleared through the 
kidneys. In subjects with renal failure, the gastrointestinal absorption of aluminium is 
enhanced and the chronic administration of high oral doses leads to significant 
accumulation and  toxicity [65-67]. The deposition of aluminium on bone surfaces 
causes a decrease in bone formation rate [68-70]. Other metals also associated 
with low turnover bone disease include iron and strontium (abundant in the water in 
some areas), both of which are much less common [71-74]. 
-Mixed uraemic osteodystrophy: As its title implies, this is caused by the 
combination of both high- and low-turnover bone disease features. The main reason 
behind it is usually due to severe secondary hyperparathyroidism in poorly 
nourished individuals with low calcium and/or low phosphate [75]. 
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Nervous system manifestations. Patients with renal failure can exhibit a variety of 
neurologic disorders, from mild sensorial clouding to delirium and coma. Although 
many symptoms subside with the onset of successful dialysis, problems such as 
generalised weakness and peripheral neuropathy may persist. The neurologic 
disorders that occur within the central nervous system (CNS) as a result of renal 
failure are referred to as uraemic encephalopathy, which in many cases is present 
even after renal replacement therapy in the form of dialysis. Dialysis disequilibrium 
[76], dialysis dementia [77], stroke [78] and sexual dysfunction [79] are usually 
associated with the onset of the dialysis process. In addition, other conditions such 
as subdural hematoma, acute stroke, certain electrolyte disorders (hyponatremia, 
hypernatremia, phosphate depletion, and hypercalcaemia), vitamin deficiencies, 
hypertensive encephalopathy and drug intoxication may also occur in these patients 
[75]. 
Metabolic and endocrine disorders. The increased half-life of insulin and its 
decreased removal by kidneys causes high plasma levels of circulating insulin, 
which in turn causes abnormal carbohydrate metabolism. As insulin resistance itself 
increases the risk of cardiovascular mortality [80-82] and also contributes to 
hypertension and lipid abnormality [83, 84] which are both known risk factors of 
cardiovascular disease, it can be argued that it may be the main reason for the 
accelerated atherogenesis in renal failure. Furthermore, the breakdown of muscle 
tissue and activation of proteolytic pathways as a result of insulin resistance [85] 
may be responsible for the increased protein catabolism and malnutrition in CKD 
patients [86]. 
Patients with renal failure also have profound dyslipidaemia, which has been noted 
for a very long time [87] and probably goes hand in hand with the increased 
prevelance of atherosclerosis in this population. 
Malnutrition. About 40 to 50% of ESRD patients are malnourished [88], and this 
contributes to increased infection, muscle wasting and increased mortality [89]. The 
causes of malnutrition in ESRD are usually divided into: 
1) those increasing nutrient requirements  
 altered lipid and amino acid metabolism,  
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 impaired glucose tolerance,  
 metabolic acidosis [90],  
 uraemia,  
 inflammation [91]  
2) those decreasing food intake 
 nausea,  
 fatigue,  
 anaemia,  
 uraemic gastroparesis   
 diabetic gastroparesis   
In addition to the metabolic disorders mentioned, patients suffering from renal 
failure also have endocrine problems, such as:  
 gonadotropin abnormalities [92, 93],  
 hyperprolactinaemia [94],  
 low plasma testosterone levels in male HD patients [95, 96],  
 low plasma estradiol concentrations which  is associated with lower bone 
density [97-99],  
 dysregulation of growth hormone (GH) [100, 101] and insulin-like growth 
factors (IGFs) [102, 103] which blunts growth in children with renal failure 
[101, 102],  
 elevated plasma vasopressin level which may play a role in hypertension and 
increased thirst in CKD patients [104, 105],  
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 mild abnormalities in adrenocorticotropic hormone (ACTH), corticotropin 
releasing hormone (CRH) and cortisol secretion [106-108],  
 decreased plasma concentrations of thyroid hormones [109, 110], which is a 
reflection of the state of chronic illness and/or malnutrition and most patients 
appear clinically euthyroid [111],  
 abnormalities in parathyroid glands and vitamin D metabolites (as already 
discussed),  
 changes in the Renin-Angiotensin-Aldosterone system (RAS) [112, 113], the 
importance of which is illustrated by the fact that blocking the system reduces 
progression and induces partial regression of cardiovascular structural 
abnormalities and hypertension [114].  
These abnormalities all contribute to the complexity of patients with renal failure. 
Cardiovascular Disease. Long-term dialysis has long been associated with 
cardiovascular disease, with about a half of all deaths in ESRD patients attributed to 
cardiovascular disease [5, 24]. This is thought to be partly due to the higher 
prevalence of many traditional CVD risk factors, such as diabetes and hypertension 
in this population. It has also been shown that renal failure itself is an independent 
risk factor for CVD [115] in addition to it causing progression of uraemia-related risk 
factors; these include anaemia, inflammation, oxidative stress, hypoalbuminaemia 
and hyperhomocysteinemia [116, 117].  
Symptomatic IHD usually results from coronary atherosclerotic disease, but may 
also be a consequence of myocardial fibrosis or left ventricular hypertrophy (LVH) 
[118, 119], which may in fact predispose to ischaemia. In renal failure patients, 
endothelial dysfunction can result from hypertension and flow overload (which 
increases stress on vascular walls) and the pro-oxidant [120] and chronic 
inflammatory state [121, 122]. In addition, hyperparathyroidism may cause vascular 
calcification and medial hypertrophy [123]. Also, small vessel disease, which is 
prevalent in LVH, diabetes and uraemia, is a common cause of IHD in this 
population [124]. A summary of the causes of IHD in CKD is illustrated in figure 1.3 
below. 
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Figure 1.3 Schematic representation of the etiology of ischemic heart disease in 
chronic kidney disease. Figure is based on and redrawn from Diseases of the 
Kidney and Urinary Tract, 2007 [125]  
 
The specific risk factors of cardiovascular disease among the ESRD population are 
a controversial topic and one that needs further elucidation. As identifying these risk 
factors is the main aim of this thesis, this topic will be discussed in detail in later 
sections.   
The majority of patients with ESRD go on to receive renal replacement therapy 
(RRT) in the form of haemodialysis [24]. Unfortunately, despite advances in the 
haemodialysis technology, the annual mortality rate for patients on haemodialysis is 
still unacceptably high, with current mortality rates reported at 20% per year in the 
US [24] and 18% per year in the UK [126].  
In the US more than half of the deaths in ESRD patients are caused by cardiac 
arrest, acute myocardial infarction (MI) and other cardiac causes. The next major 
cause is infection, which accounts for about 25%, and the third largest cause is 
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cerebrovascular disease, which contributes about 6% [24]. In the UK, these figures 
are as follows: 35% cardiac disease, 20% infection, 13% withdrawal from dialysis, 
9% malignancies and 7% from cerebrovascular disease [127].  
Cardiac and cerebrovascular disease are usually combined and referred to as one 
single category of cardiovascular disease.  
1.1.3.1 Conventional Risk Factors 
As mentioned above, the main cause of increased mortality in the ESRD population 
is cardiovascular events; therefore, the main risk factors for mortality in this 
population are cardiovascular risk factors. But as previously mentioned, these CV 
risk factors can be divided into the conventional ones which are similar to those of 
the general population, and renal-disease-specific risk factors, which will be 
discussed in the next section.  
Age. Higher age is associated with an increased risk of CVD and mortality, both in 
the general population [128] and in patients with ESRD [129].  
Diabetes. It has been shown repeatedly that diabetes is a CVD risk factor in the 
general population [130, 131]. There is a conflicting body of evidence regarding 
diabetes and ESRD, with recent studies claiming no survival benefit among the non-
diabetics or the tightly controlled diabetics in contrast to poorly controlled diabetics 
[132].  
Hypertension. Hypertension is also a well-established CVD risk factor in the 
general population [133, 134], and it has been shown that with every 6mmHg 
reduction in blood pressure (BP), the risk of developing an MI reduces by 14-16% 
[135]. Hypertension is very common in the ESRD population, with approximately 
80% of CKD patients and 86% of dialysis patients suffering from it [124, 136]. 
Despite available blood pressure reducing agent, only about half of the CKD 
population [137] and third of the dialysis population in the US have adequately 
controlled BP [138]. But surprisingly, studies that have looked at the effect of BP on 
survival, and analysed systolic and diastolic BP separately, have shown a 
paradoxical relationship in that hypertension predicts longer survival [8]. Despite 
these observations and on the basis of robust evidence in the general population, 
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hypertension is considered a CVD risk factor and therefore a risk factor for 
increased mortality in the ESRD population. 
Smoking. Smoking is a proven risk factor for CVD in the general population, as it 
doubles the risk of CVD events [139]. In the CKD population, approximately 25% of 
patients are either current or former smokers [24], and smoking has been 
associated with progression of CKD, stroke and development of IHD. In the dialysis 
population, 30-40% of patients starting dialysis are smokers [24], and this has been 
associated with an increased risk of mortality (26%) [140]. 
 Dyslipidaemia. Increased levels of total cholesterol (TC), LDL-C, lipoprotein(a), 
and triglycerides (TGs) and decreased HDL levels are associated with CVD in the 
general population, and this is regarded as an atherogenic lipid profile [141-143]. 
Such a lipid profile is particularly common in patients with renal disease [144], but 
there is almost no published data that links dyslipidaemia to CVD in CKD, and 
conflicting data for the dialysis patients. In the dialysis population, it is low levels of 
total cholesterol that are associated with increased risk of mortality [7, 145-147], but 
one has to keep in mind that low cholesterol is also a marker of poor nutrition, which 
is a prevalent condition linked to increased mortality in this population. A more 
recent study has shown that while increased cholesterol levels are associated with 
reduced all-cause mortality in “inflammatory” patients, it increases the risk in “non-
inflammatory” individuals [147]. This finding suggests that the inverse association is 
actually due to the effect of systemic inflammation and malnutrition, not the 
„protective‟ qualities of cholesterol. 
1.1.3.2 Renal Failure Specific Risk Factors 
Homocysteine. It was first observed that patients suffering from homocystinuria, a 
rare genetic disorder, have elevated serum Homocysteine (Hcy) as well as 
accelerated atherosclerosis rates. More recently, observational studies have shown 
that Hcy levels in the general population are independently associated with CVD 
[148].  83% of patients that reach ESRD have Hcy levels above the 90th percentile 
for the general population [149], and there is limited evidence that this pertains to 
CVD in both CKD and dialysis patients [150-152]. 
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Hypocalcaemia. Hypocalcaemia has been independently associated with both 
increased mortality [153] and increased development of CVD in the dialysis 
population [154]. It has been hypothesised that this maybe due to related 
hyperparathyroidism, which is associated with left ventricular hypertrophy (LVH), 
dyslipidaemia and myocardial fibrosis, all of which increase mortality [155].  
Hyperphosphataemia. It has been shown that dialysis patients with 
hyperphosphataemia have a 41% increased risk of CV death and 20% increased 
risk of sudden death in comparison to those that are euphosphataemic [156, 157]. 
This may be due to increased cardiovascular calcification, which is predictive of 
adverse cardiac events [158]. A retrospective analysis has shown that serum 
phosphate levels of above 1.13 mmol/L were associated with a significantly 
increased risk of death in a cohort of CKD patients [159].  
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1.1.4 Reverse Epidemiology 
1.1.4.1 What is Reverse Epidemiology? 
The term „reverse epidemiology‟ has been coined to describe the paradox that 
conventional CVD risk factors are protective in certain medical conditions [7, 160]. 
The Framingham Heart Study has identified obesity [161], hypertension [162], 
diabetes [130] and dyslipidaemia [163] (and several other factors) as cardiovascular 
risk factors within the general population. Recent studies involving diabetic patients 
with ESRD requiring dialysis have shown a paradoxical relationship between these 
„traditional‟ CVD risk factors and long term survival rates [7, 132, 164-166]. Similar 
findings have also been reported in other clinically vulnerable populations, namely 
those with chronic heart failure (CHF), chronic obstructive pulmonary disease 
(COPD), human immunodeficiency virus (HIV) infection / acquired immune 
deficiency syndrome (AIDS) and the elderly. Among these extremely high-risk 
populations, studies have reported that the conventional CVD risk factors, rather 
than contributing to CVD mortality are actually protective [10, 160, 167, 168]. Taking 
into account that the components of reverse epidemiology are mainly markers of 
„over-nutrition‟, their protective quality in the above mentioned „wasting‟ conditions is 
perhaps less surprising. The reverse epidemiology observations suggest that while 
over-nutrition is bad, under-nutrition is worse, but population studies have failed to 
show that these findings are limited to those suffering from under/malnutrition.  
Although these are mainly observational findings, it is important to note that these 
findings have more or less been consistent among the at-risk populations 
mentioned. Therefore, the fact that these findings are counterintuitive to today‟s 
principles of CVD risks should not bias the approach needed to examine their 
clinical implications. Investigators who oppose the term „reverse epidemiology‟ do 
so [169] mainly because such a definition may undermine the complexity of such 
patients and therefore distract from the important issues in risk factor modification. 
They argue that it is important to take into account the distinction between 
association and causation, as well as confounding and bias [169]. 
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1.1.4.2 What are the Known Components of Reverse Epidemiology? 
In the maintenance HD population, reverse epidemiology has been observed for the 
following risk factors, but is not limited to them: 
BMI. In the general population, a BMI of 20-25 kg/m² is considered ideal, and with 
every bit of increase from that target, the risk of mortality is also increased [170]. 
Paradoxically, a BMI below 25 kg/m²  has been shown to be a strong predictor of 
higher mortality in the MHD population, while a high BMI of >25 kg/m² has been 
correlated with improved survival in the same population [164, 171-177].  
Serum cholesterol. High total cholesterol, high LDL cholesterol and low HDL 
cholesterol all increase mortality in the general population [178-180], while high total 
cholesterol levels have been shown to be predictive of better outcome in MHD 
patients [6, 146, 181-184]. 
Blood pressure. Hypertension indisputably causes increased cardiovascular and 
cerebrovascular events, as well as increased mortality in the general population 
[185-187]. Similarly, a few studies have shown this same relationship between high 
BP and mortality in the ESRD population [188-191], but larger, more recent studies 
that looked at pre-dialysis systolic hypertension have failed to show such a 
relationship [6, 192-197]  
Diabetes. While diabetes is a well-known risk factor for increased mortality in the 
general population [130, 198, 199], there is at least one study that shows the same 
is not true in the MHD population [132]. It has also been observed that the presence 
of high levels of advanced glycation end products (AGE), which is normally seen in 
diabetic patients and is associated with higher mortality in the general population, 
seems to have protective qualities in the MHD population [200]. 
Energy and/or protein intake. This may be associated with obesity and increased 
mortality in the general population [201, 202], but it has been shown that in the 
MHD population increased protein intake is correlated with better survival [203-205]. 
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1.1.4.3 What are the Explanations for Reverse Epidemiology? 
There are several possible explanations for the reverse epidemiology phenomenon, 
but the presence of the malnutrition-inflammation complex syndrome (MICS) in 
dialysis patients seems to be the most plausible one. These observations are not 
restricted to MHD patients and have also been seen in the elderly population, those 
with chronic heart failure, cancer, HIV/AIDS and COPD patients [160, 206]. 
Malnutrition and subsequent cachexia is a common outcome of these conditions 
and this is the basis for the MICS theory: obesity is bad but malnutrition is worse 
[207]. 
1.1.4.3.1 Malnutrition Inflammation Complex Syndrome 
Inflammation. 
Inflammation is the dynamic response of vascularised tissue to injury [208]. It is a 
defence reaction of organs to injurious stimuli. It is a protective response which 
serves to bring defence and healing mechanisms to the site of injury [209], and 
under normal conditions will resolve the initial injury without any damage to the host. 
There are several distinct inflammatory pathways, each of which proceeds via a 
sequence of biologic events. Many of the individual events are controlled by 
cytokines or other small regulatory molecules, which in this context are called 
inflammatory mediators. Any given mediator may produce effects directly and also 
stimulate the production of other mediators, giving rise to an integrated response 
[210]. The physiological pathways of the inflammatory response to trauma is 
illustrated in figure 1.4 below. 
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Figure 1.4 The inflammatory response; each cell is committed to recruiting and/or 
activating others. Not all interactions are illustrated [211]. (Figure reproduced with 
permission)  
 
Inflammation is divided into different categories. The most commonly used 
categorizations are described in table 1.1. 
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Basis of classification 
Extent of 
inflammation 
Length of 
inflammation 
Morphology of 
inflammation 
Local 
Limited to an area of 
tissue in the vicinity of  
its port of entry 
Acute 
Immediate and early 
response to injury 
 
 
Exudative 
Purulent 
Metastatic 
Inflammatory 
pathogens are 
transmitted to other 
organs and tissue 
Sub-acute 
Longer than acute, but 
not as prolonged as 
chronic inflammation 
 
Fibrinous 
Serrous 
Generalized 
When the pathogen 
spreads diffusely 
throughout the body 
Chronic 
State of prolonged 
inflammation – causes 
include persistent 
injury and autoimmune 
disease 
 
Haemorrhagic 
Granulomatous 
Table 1.1 Categorizations of inflammation.  
Once inflammation becomes persistent, it may lead to adverse consequences such 
as decline in appetite, increased protein depletion in tissues, muscle and fat wasting 
as well as endothelial damage and atherosclerosis [212].  The cause of the chronic 
inflammatory state present among many dialysis patients has been extensively 
studied and can be briefly listed as: decreased clearance of pro-inflammatory 
cytokines, volume overload, oxidative stress, decreased levels of anti-oxidants, 
deteriorating protein-energy nutritional state and food intake, coexistence of co-
morbid conditions, and additional inflammatory factors related to the haemodialysis 
treatment itself, such as exposure to dialysis tubing, impurities in dialysis water 
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and/or dialysate, back-filtration of contaminants, foreign bodies in dialysis access 
grafts, and intravenous canulae [213].   
Activation of pro-inflammatory cytokines (such as TNF-α, IL-1 beta, IL-6 [214, 215] 
and IL-8) in these patients also causes loss of appetite which is followed by 
malnutrition [216, 217]. This known overlap between inflammation and malnutrition 
is addressed as the MICS. There is an ongoing debate about whether the 
malnutrition aspect of the MICS is a result of inflammation or an independent entity 
[218-220], and there are convincing arguments on both sides. But what is certain is 
that an increase in the markers of inflammation, such as serum CRP and pro-
inflammatory cytokines, are correlated with adverse CV events in both the general 
[221, 222] and MHD [115, 223-226] population, as well as CHF patients [227, 228].  
Therefore, the inflammation component of MICS could be responsible for the 
increased prevalence of CVD and mortality in MHD even on its own [229], but when 
combined with its counterpart, malnutrition, the result may even confound other 
conventional CVD risk factors, such as obesity, dyslipidaemia, hyperglycaemia and 
hypertension. 
The specific role of inflammation in type 2 diabetes, ESRD and CVD is discussed in 
section 1.2.2. 
Malnutrition. 
As briefly discussed, a number of studies have shown that protein-energy 
malnutrition (PEM) is a predictor of clinical outcome in MHD patients [182, 230, 
231]. The same is true for inflammation, which almost always goes hand in hand 
with PEM and is also a strong predictor of mortality in the MHD population [229, 
232-238]. As both CVD and PEM are prevalent among the dialysis population, the 
common mechanism that leads to both of these conditions may be cytokine release 
associated with renal failure and the pro-inflammatory state in this population [232, 
236]. Activation and increased release of inflammatory cytokines such as 
interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor–alpha (TNF-α) 
lead to loss of appetite as well as muscle proteolysis and ultimately cause 
atherosclerosis [229, 237]. Because PEM and inflammation are not only strongly 
associated with each other, but also with survival outcome in the dialysis population, 
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MICS is the term used to denote both their contributions to ESRD outcome [184]. 
To emphasise the main consequence of MICS, atherosclerosis, some investigators 
use the term malnutrition-inflammation atherosclerosis (MIA) when referring to the 
same phenomenon [233, 237].  
Within the renal impaired population the onset of malnutrition can be attributed to 
increased levels of TNF-alpha and IL-6 which suppress the appetite and decrease 
food intake [59]. Malnutrition in these individuals means higher susceptibility to 
infections and an increased inflammatory state, which in turn causes further 
wasting. From this perspective, the greater the initial body mass index (BMI) the 
better; because there are higher reserves for protecting against cachexia [239]. 
Patients who are under-nourished, as characterised by a low BMI, low serum 
cholesterol or homocystein, are predisposed to infection and/or other inflammatory 
processes [232], as well as inflammatory diseases [240], which are known to 
increase both cardiovascular and all-cause mortality, as well as further wasting. The 
result is a vicious circle that can hardly be stopped and leads the patient to a very 
poor prognosis. Therefore, conditions that improve the nutritional status of dialysis 
patients may improve their outcome, which may explain the presence of reverse 
epidemiology of risk factors among this population, especially when the main 
components of reverse epidemiology are all related to nutritional status. Even low 
blood pressure has been shown to be associated with and a manifestation of MICS 
in MHD patients [193]. 
Protein-energy malnutrition (PEM) is defined as: “the state of decreased body pools 
of protein with or without fat depletion or a state of diminished functional capacity, 
caused at least partly by inadequate nutrient intake relative to nutrient demand 
and/or which is improved by nutritional repletion” [213]. PEM is known as a common 
phenomenon in patients on haemodialysis, with a prevalence rate of 18 to 75 
percent depending on dialysis modality, patient population origins and nutritional 
assessment tools [241, 242], and is associated with higher rates of CV mortality 
[243]. The underlying cause of PEM in MHD patients is not well understood, but 
there is an increasing list of probable causes which includes: anorexia caused by 
uraemic toxicity, impaired gastric emptying, emotional and/or psychological 
disorders, dietary restrictions due to prescription restrictions and social constraints, 
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inability to acquire or prepare food due to physical incapacity, nutrient loss during 
dialysis, hyper-catabolism due to co-morbid illness, cardiovascular diseases, 
diabetic complications, infection and/or sepsis, and other co-morbid conditions 
[213].  It has been observed that PEM starts well before the start of dialysis, and 
hypoalbuminaemia, hypercholesterolemia and hypotransferrinaemia develop with 
the decline of GFR (glomerular filtration rate) [243].  
1.1.4.3.2 Role of Adiponectin 
Adiponectin, also known as Acrp30, AdipoQ and GPB28, is a 30-kDa adipokine, a 
cytokine which is exclusively secreted into the plasma by adipose tissue, and is 
relatively abundant compared to other hormones, accounting for approximately 0.01 
percent of total plasma protein [244]. Its role is being extensively explored and it has 
been shown to increase fatty acid oxidation and cause decreased plasma free fatty 
acid and triglyceride levels [245]. Adiponectin also improves insulin sensitivity and 
causes a transient drop in serum glucose levels [245], and is therefore regarded as 
a key molecule in the metabolic syndrome [246-248]. Its decrease in obesity may be 
relevant in obesity-linked disorders [249], especially since it is also reduced in type 
2 diabetes, dyslipidaemia and CVD [248, 250, 251].  Adiponectin has also been 
shown to inhibit the inflammatory response in-vitro, as well as possess anti-
atherogenic properties [252].   
Adiponectin may be of clinical relevance and importance in the ESRD population, 
as it has been shown to have a strong association with many of the aforementioned 
risk factors for mortality in this group. Adiponectin is inversely associated with body 
weight [253] and BMI [254], triglycerides [253-255], insulin resistance [253, 255] and 
blood pressure [254]. It also induces production of other pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-6 and IL-8) by adipose tissue and macrophages [256].  
In light of new evidence, hypoadiponectinaemia is being looked at as a novel 
potential CVD risk factor in patients with renal failure, even those with mild to 
moderate ESRD [257]. There is now more and more evidence that links 
hypoadiponectinaemia with increased mortality, CVD and recurrent ischemic heart 
disease (IHD) in ESRD patients [245, 258, 259].  
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Adiponectin seems to play a paradoxical role in patients with renal impairment; 
although its increase is associated with better overall survival and lower CV 
mortality [245], in the haemodialysis population, plasma adiponectin levels are 
markedly elevated [260-264]. It has recently been shown that this elevation is not 
due to over-secretion, but rather accumulation (Adamczak et al. personal 
unpublished data: measurements of plasma adiponectin concentrations in renal 
veins and aorta in human subjects confirmed that kidneys play an important role in 
adiponectin elimination and that the increased plasma adiponectin concentration in 
CKD is not due to oversecretion). Adiponectin levels have been shown to be 
inversely correlated with serum CRP levels in MHD patients, and low levels of 
adiponectin have also been associated with greater mortality among these patients 
[264]. Interestingly, adiponectin levels are elevated in chronic 
inflammatory/autoimmune diseases such as rheumatoid arthritis, systemic lupus 
erythromatosis, inflammatory bowel disease and cystic fibrosis [265]. Contrary to 
the general population, in these patients adiponectin has a positive, rather than 
negative, correlation with inflammatory markers. A recent study has shown that 
although plasma adiponectin levels are reduced after successful renal transplants, 
these levels are still higher than those of healthy controls [266]. 
High adiponectin has also been shown to be an independent predictor for 
progression of renal disease [267]. Although it can be argued that this may indicate 
adiponectin as part of a renal and cardio- protective mechanism that is set in motion 
to counter critical organ damage [13]. 
1.1.4.3.3 Other Explanations 
Survival bias.  There are 10 to 20 million patients with CKD due to irreversible and 
potentially progressive damage to the kidney in the USA [268], but only an 
estimated 400,000 people with ESRF [27]; this means that less than 5% of CKD 
patients go on to develop ESRF. The current explanation for this phenomenon is 
that most CKD patients don‟t live long enough to develop ESRF, as many of these 
patients suffer severe co-morbidities such as diabetes, hypertension and 
atherosclerosis. Renal disease in itself is also an independent risk factor for CVD 
mortality [115, 223]. The other point that has been highlighted is that the population 
that goes on to develop ESRF has survived many risk factors and is not necessarily 
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genetically or phenotypically similar to its CKD predecessors, and therefore may not 
share the same risk factors for mortality [239]. This is similar to the trends observed 
in patients that reach an advanced age, possibly due to survival advantages [269-
271]. 
Of note also, is that most epidemiological studies treat patients who have started 
dialysis recently (i.e. incident patients) and those who have been on dialysis for a 
number of years (i.e. prevalent patients) the same, which leads to a form of 
selection bias [272]. Because of the high annual mortality rate of 20% in ESRF 
patients, this form of bias influences longitudinal studies and even clinical trials. 
However, epidemiological studies that only look at incident dialysis patients have 
demonstrated the same risk factor reversal [126]. 
TNF-α receptors. As mentioned above, TNF-α, a pro-inflammatory cytokine, is 
elevated in dialysis patients [273] and may contribute to cachexia, as well as having 
pro-apoptopic and negative inotropic effects on the CV system [274], which all 
contribute to poor survival.   Soluble TNF-α receptors, also known as IL-1RA,  
produced by adipose tissue [275], can neutralise the effects of TNF-α by binding to 
it. Therefore, in theory, obese individuals who have more adipose tissue can 
subsequently produce more IL-1RA which neutralises the effects TNF-α, and this 
may contribute to better outcome. 
Neurohormonal changes. It has been observed that obese patients have 
diminished response of sympathetic nervous system and renin-angiotensin system 
compared to their lean counterparts [276]. As both of these responses are 
associated with poor prognosis in conditions of fluid overload [277], this diminished 
response may be a protective trait in obese MHD patients. 
Haemodynamic state. Because obese individuals have higher blood pressure 
[278], they are more tolerant of afterload-reducing antihypertensive medication, 
such as angiotensin-converting enzyme inhibitors (ACEI) which are known to 
improve survival [279]. 
Competitive risk factors: obesity vs. malnutrition. Obesity and other conditions 
associated with over-nutrition (such as hypercholesterolaemia, insulin resistance 
and type 2 diabetes) are considered risk factors for long-term cardiovascular 
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mortality in affluent societies [179, 180, 280-283]. On the other hand, in less affluent 
societies and developing countries, under-nutrition is still causing a shorter life 
expectancy [284-286]. Because of the increased mortality risk of MHD patients, the 
long-term effect of risk factors caused by over-nutrition may be overwhelmed by the 
short-term effects of risk factors of under-nutrition.  
Circulating lipoproteins. Another hypothesis is that obese individuals have a 
richer pool of lipoproteins that can actively bind to and remove circulating 
endotoxins, therefore retarding inflammation and its effects, including subsequent 
atherosclerosis [207].  
Confounding factors. Such as low BP and low BMI may be consequences of 
smoking and/or heart failure [287], which are also associated with increased 
inflammation [228, 288], malnutrition [289] and mortality [290]. Low BP may also be 
caused by autonomic neuropathy, which means the subjects may be suffering from 
other long-term effects of diabetes, as well [291].  
Other hypotheses. There are several mechanisms through which malnutrition and 
hypotension contribute towards increased mortality, such as: acute coronary 
syndrome, autoregulation dysfunction, ischaemia and arrhythmiagenecity [292, 
293]. These factors may be exaggerated in the presence of uraemia [294], and 
therefore may become more influential than conventional CVD risk factors. 
A less well-substantiated hypothesis describes that as obesity and excess weight 
become more and more prevalent in most industrialized nations, despite the 
„conventional risk factors‟ it introduces, these nations are in fact living longer than 
ever [295]. And as life-expectancy increases effectively hand-in-hand with weight 
increase in these populations, the question becomes: shouldn‟t malnutrition be 
called the paradoxical risk factor or the „reverse epidemiology‟? 
Ethnicity and Mortality 
Although African and black Caribbean individuals have higher total mortality rates 
compared to white individuals in the general population [296-298], among the 
dialysis population African and black Caribbean individuals have lower annual 
mortality rates compared to their white counterparts (18% vs. 28%) [27]. In addition, 
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several other disparities between different ethnic groups within the haemodialysis 
population have been observed in regards to their long term survival. There seem to 
be ethnic subgroups within the MHD population that do not exhibit the survival 
advantage of obesity that is associated with this population; these include white 
women [172, 299] and Asian-American patients [174, 176, 177]. Also, the usually 
observed improvement of survival with lower cholesterol levels does not seem to 
exist in black individuals, as this characteristic is associated with increased mortality 
among the black MHD population [300]. Although such cultural differences as diet 
and lifestyle may be contributing causes of these differences, there is currently not 
enough evidence to rule out biological disparities between races. 
The complexity of the mechanism involved in determining outcomes in the 
maintenance haemodialysis population is illustrated in figure 1.5 below.   
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Figure 1.5 Potential pathophysiologic mechanisms leading to the reverse 
epidemiology phenomenon in maintenance dialysis patients. [206] (figure 
reproduced with permission) 
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1.1.5 Investigating the role of different risk factors on outcomes: designing a 
Risk Engine 
Identifying generalizable risk factors for cardiovascular disease is a task that cannot 
be achieved through experimental studies in animal models or cross-sectional or 
case-control studies in small groups of patients, although these types of studies can 
lend insight to mechanisms of disease. To successfully identify such risk factors, 
large, rigorous, prospective studies in relevant clinical populations are needed. In 
the field of CVD, the Framingham Study [301] is the model population-based cohort 
study that has identified what are considered conventional cardiovascular risk 
factors that have been widely confirmed by subsequent randomised controlled trials 
[302, 303]. Unfortunately, such large prospective studies are rare among the ESRD 
population [129, 304], thus the reliance on data from retrospective cohorts, national 
registries, cross-sectional and case-control studies which provide less conclusive 
information. Conducting reliable prospective studies among the ESRD population is 
a difficult task because of the confounding effect of existing cardiovascular disease 
prior to the onset of ESRD, which is common among this population. 
The UK Prospective Diabetes Study (UKPDS) Risk Engine is another model 
population-based study for type 2 diabetes-specific risk factors [198]. The UKPDS 
risk calculator includes HbA1c and traditional CVD risk factors and while earlier 
versions calculated coronary heart disease risk and stroke risk separately, in the 
latest version equations have been derived that directly estimate CVD risk [305]. 
This novel equation has been validated by the Collaborative Atorvastatin Diabetes 
Study (CARDS) [306] to have good predictive ability. 
The Framingham and UKPDS risk equations both had an excellent ability for 
correctly identifying individuals who would develop CVD, which means they both 
had high sensitivity. However, both equations have poor specificity, with the 
Framingham risk equation having a specificity of 30% and the UKPDS Risk Engine 
a specificity of 31% [307]. The ideal risk engine would have both a high sensitivity 
and a high specificity in recognising risk factors.  
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1.2 Insulin Resistance and Inflammation in ESRD 
1.2.1 Role of Insulin Resistance 
Insulin resistance is a feature in many conditions that are regarded as well-known 
CVD risk factors, such as obesity, hypertension, dyslipidaemia and type 2 diabetes. 
As these are the same risk factors involved in the reverse epidemiology 
phenomenon, insulin resistance may be the link that can explain these 
observations. To do that, it is important to understand what insulin resistance is, 
how it develops, and how it is affected by renal failure and subsequent 
haemodialysis. 
Insulin is a hormone with many effects; it influences amino acid uptake, protein 
synthesis, proteolysis, lipolysis, hepatic triglyceride output, glucose uptake, 
glycogen synthesis and gluconeogenesis. Sensitivity to insulin is therefore crucial 
for it to regulate these effects. Insulin sensitivity and resistance is usually defined by 
an individual‟s response to an oral or IV glucose or insulin stimulus. Individuals who 
develop insulin resistance have an abnormal response to a glucose challenge or 
demonstrate impaired glucose tolerance, have elevated fasting glucose and/or overt 
hyperglycaemia, or reductions in insulin action after an IV administration of insulin 
[308]. Insulin resistant individuals in general tend to be overweight or obese, 
sedentary and consume a diet high in total or saturated fats [84, 309-311]. 
The obesity pandemic of recent decades is at the root of the increased incidence of 
insulin resistance and the metabolic syndrome, which have led to an increase in 
CVD and type 2 diabetes as well as ESRD [12, 81, 83, 312, 313]. Once individuals 
become insulin resistant, normoglycaemia is initially achieved by modest increases 
in beta-cell mass and/or an increase in insulin secretion [314]. If, over time, this 
capacity is lost type 2 diabetes will occur, and if it can be maintained in the long-
term, type 2 diabetes is prevented despite the presence of hyperinsulinaemia. 
Overt insulin resistance is the main characteristic of the metabolic syndrome, a 
concurrence of visceral obesity, dyslipidaemia, hyperglycaemia, and hypertension. 
The term „metabolic syndrome‟ was first used in 1977 by Haller to describe the 
clustering obesity, diabetes, hyperlipidaemia, hyperuricaemia and hepatic steatosis 
and their additive effect on atherosclerosis [315]. A decade later, in 1988, Reaven 
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suggested that insulin resistance is the common aetiology for impaired glucose 
tolerance (IGT), hyperinsulinaemia, hypercholesreolaemia, hypertriglyceridaemia 
and hypertension, which together he referred to as Syndrome X to stress the 
unknown aspects of this syndrome [316]. In 1989 Kaplan recognised central obesity 
as an important factor in the syndrome described by Reaven [317]. The presence of 
chronic subclinical inflammation in subjects with metabolic syndrome was identified 
in the year 2000 by Festa et al [318] and increased levels of CRP, TNF-alpha, IL-6 
and IL-8, and decreased levels of the cardio-protective anti-inflammatory adipokine 
adiponectin were subsequently described [253, 255, 319, 320]. As mentioned 
previously (section 1.4.3.2), adiponectin may be an inducer of other pro-
inflammatory cytokines, and its levels are elevated in classic chronic 
inflammatory/autoimmune disease. But in the metabolic syndrome, adiponectin 
levels correlate negatively rather than positively with inflammatory markers, and are 
reduced. That is why presently, it is of great interest to know whether the primary 
proinflammatory defect in adipose tissue is in fact the reduction in adiponectin or 
whether this reduction is secondary to the inflammatory state already present [265, 
321, 322]. 
1.2.1.1 Insulin Resistance in Type 2 Diabetes 
Most patients with type 2 diabetes have insulin resistance and metabolic syndrome 
before its onset, and in fact, in 75 to 85% of these patients insulin resistance, 
hyperinsulinaemia, dyslipidaemia and obesity precede the disease[323]. In addition, 
it has been observed that the risk for developing type 2 diabetes is increased 
fivefold in individuals with the metabolic syndrome in comparison with those without 
[324]. And of all the components of the metabolic syndrome, hyperinsulinaemia is 
by far the strongest predictor for progression to type 2 diabetes [325]. 
1.2.1.2 Insulin Resistance and ESRD 
One of the characteristics of the uraemic state is insulin resistance, which is 
accompanied by hyperinsulinaemia, glucose intolerance and dyslipidaemia [326-
329]. Although insulin resistance is well studied and quite well understood in the 
general population, the same cannot be said for insulin resistance in ESRD. It has 
long been established that insulin resistance and the conditions that usually follow, 
i.e. hypertension, obesity, dyslipidaemia and type 2 diabetes, are among the leading 
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causes of CV mortality. They are also known as leading causes of chronic kidney 
disease (CKD) and renal failure [27, 330].  
The renal clearance of insulin is significantly greater than the GFR due to significant 
uptake and degradation of insulin in the peritubular epithelial and endothelial cell 
membranes. Peritubular insulin uptake increases as renal function deteriorates, and 
insulin clearance is maintained until the GFR reaches 15-20 ml/min. From this point 
on, insulin clearance falls rapidly [331]. The accumulation of uraemic toxins is 
thought to cause an inhibition of the insulin degradation system, especially by the 
liver which is responsible for clearing about 50% of the insulin secreted into the 
portal system, causing increased half-life of insulin [331]. Theoretically, both of 
these mechanisms are reversible through dialysis, but whether insulin resistance 
improves with the commencement of dialysis is yet to be confirmed.  
Other causes of insulin resistance in ESRD include physical inactivity [332], and the 
accumulation of adipokines in uraemic plasma such as TNF-alpha [333, 334]. The 
increase in these molecules may be responsible for the presence of insulin 
resistance, especially in non-obese ESRD patients. These factors are summarized 
in table 1.2. 
 
Contributing factors to insulin resistance in ESRD 
Reduced renal clearance (peritubular clearance maintained until GFR reaches 15-20 
ml/min) 
Increased half-life (uraemia causes reduced hepatic degradation of insulin) 
Accumulation of insulin resistance inducing adipokines 
Physical inactivity due to illness 
Table 1.2 Contributing factors to insulin resistance in ESRD 
Assessment of insulin sensitivity using more modern techniques such as the 
euglycaemic hyperinsulinaemic clamp has allowed researchers to document 
diminished insulin-stimulated glucose uptake by extrahepatic tissue [335, 336]. 
Although insulin sensitivity seems to be reduced early on in the natural history of 
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renal failure, in fact when GFR is still within the normal range, it is not problematic in 
most patients as the pancreatic beta-cells continue to secrete enough insulin to 
overcome this state, thus leading to hyperinsulinaemia [337]. But as renal failure 
progresses, with the anaemia, acidosis and hyperparathyroidism in many, the beta-
cells fail to secrete sufficient insulin to counter the reduced insulin sensitivity which 
leads to impaired glucose tolerance thereby becoming glucose intolerant and 
hyperglycaemic [338-340]. Current literature suggests that the increased 
intracellular calcium concentration due to PTH imbalance may contribute to the 
insulin secretion impairment in renal failure [341, 342], especially since 
parathyroidectomy in patients with secondary hyperparathyroidism appears to 
ameliorate insulin secretory defects in pre-haemodialysis patients [343, 344]. 
Insulin resistance in the early stages of CKD has been implicated as a cause, rather 
than a consequence, of CKD, in the general population. Chen et al. have shown a 
strong, positive, significant, and dose-response relationship between insulin 
resistance, insulin level and risk of CKD among non-diabetic subjects  [345]. Other 
studies, mostly prospective, have also shown that non-diabetic nephropathies are 
more likely to reach ESRD if the subject has diabetes [346-348]. Although data on 
the relationship between insulin resistance and non-diabetic CKD is sparse, several 
small studies have shown the presence of insulin resistance in non-diabetic CKD 
patients [349-351], and one prospective study has shown that insulin resistance 
appears earlier than microalbuminuria in non-diabetic subjects [352]. These findings 
suggest that early detection and correction of insulin resistance may benefit patients 
in delaying the onset of CKD, even in non-diabetic patients. But to definitively 
establish the causal effect of insulin resistance in CKD and ESRD warrants further 
studies. 
1.2.1.3 Insulin Resistance and Cardiovascular Outcomes  
Insulin resistance clusters CVD risk factors such as hypertension, dyslipidaemia 
and glucose intolerance. Several large epidemiological prospective studies on CVD 
have shown insulin resistance occurs alongside other risk factors for atherosclerosis 
and CVD, including hypertension, dyslipidaemia and glucose intolerance or type 2 
diabetes. Many of these studies have also shown hyperinsulinaemia and other 
indices of IR to be associated with CVD (listed in table 1.3). 
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IR associated with: References 
Prevalent atherosclerosis Folsom et al, 1994 [353] 
Agewall et al, 1995 [354] 
Bavenholm et al, 1995 [355] 
Kahn et al, 1995 [356] 
Bressler, 1996 [80] 
Howard et al, 1996 [82] 
Haffner et al, 1998 [357] 
Incident CHD Despres et al, 1996 [358] 
Incident stroke Pyorala et al, 1998 [359] 
Risk of death from CHD Welborn and Wearne, 1979 [360] 
Rosselin et al, 1985 [361] 
Grandits et al, 1994 [362] 
Table 1.3 Conditions known to be associated with increased insulin resistance 
 
Current evidence suggests that a quantified value of insulin resistance, such as the 
homeostatic model assessment index of insulin resistance or HOMA-IR (detailed in 
section 1.6.4) is an independent predictor of cardiovascular disease in patients with 
type 2 diabetes [363] as well as in individuals without diabetes [364, 365].  
The clustering of CVD and insulin resistance with other CVD risk factors 
synergistically increases the risk of atherosclerosis, as was shown by Neaton et al 
that CVD risk increases with each added factor [366]. It is therefore expected that 
the effect of insulin resistance on CV mortality is dependent on these other risk 
factors, as it is the underlying mechanism for their clustering. Since this landmark 
study, it has also been shown that insulin resistance is an independent risk factor 
for CVD in ESRD patients without diabetes [367]. As the role of insulin resistance in 
predicting CVD in non-diabetic ESRD patients is independent of BMI, and BMI 
seems to be negatively associated with CVD and mortality in the ESRD population, 
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it would be safe to assume that insulin resistance and adiposity per se have 
different roles in CV death in the ESRD population [368].  
1.2.1.4 Insulin Resistance and Inflammation in ESRD 
Interaction between insulin resistance and inflammation was first suggested in the 
1990s. Insulin resistance may also be a consequence of inflammation, and chronic 
inflammation has also been shown to be an independent risk factor for CV mortality 
in the general population [369, 370]. To what extent chronic inflammation would 
influence insulin resistance in non-diabetic patients is not known, however, in non-
diabetic ESRD patients, the effects of insulin resistance could be attributed to the 
presence of the inflammatory state induced by uraemia. However, the Shinohara et 
al. study showed that the increased insulin resistance was independent of C-
reactive protein, and also that there is no significant association between insulin 
resistance and CRP [368]. 
1.2.1.5 Insulin Resistance and MHD 
Although there have been recent studies looking at HOMA-IR values among MHD 
patients [371, 372], and other studies looking at insulin resistance in patients with 
mild to moderate kidney failure [32, 337]  we have not been able to find any 
prospective study looking at HOMA-IR values and how they change with 
progression of renal failure in patients with and without diabetes. What would be 
even more interesting would be to see whether whatever effect ESRD and MHD 
have on insulin resistance is reversed once patients successfully receive a renal 
transplant, but unfortunately the effects of transplantation on insulin resistance are 
confounded by the effects of the immunosuppressive drugs [373], this will be a 
more difficult task.  
1.2.1.6 Quantification of Insulin Resistance 
The concept of insulin resistance is the lack of insulin‟s ability to regulate its 
functions following a stimulus (e.g. meal ingestion). Its measurement, therefore, 
must describe the circumstances in which it is assessed as well as the methodology 
used [374]. A number of different methods have been described for quantifying 
insulin resistance for clinical assessment; listed below is a simplified list of these 
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methods with a short summary of the methodology used in each case, with a 
summary in table 1.4. 
Model assessments: 
Homeostasis Model Assessment (HOMA). This method was developed by Robert 
Turner at the Oxford University in the late 1970s [375], and refined to its current 
nature in 1998 by Jonathan Levy et al [376]. A measurement of insulin resistance is 
derived from fasting plasma glucose and insulin concentrations, using the formula:  
HOMA index = insulin (mU/L) x glucose (mmol/L)/22.5 
Its simplicity and practicality make it the most widely used method for estimating 
insulin resistance, and it has been shown to correlate well with the euglycaemic 
clamp technique in both the general population and those with renal impairment 
[377]. To achieve a more accurate insulin measurement to incorporate into the 
above formula, 3 insulin measurements are usually obtained at five minute intervals; 
this is because insulin secretion is pulsatile and the average of the three 
measurements is a more accurate indication of true insulin levels. It has, however, 
been argued that in studies where HOMA values are being compared within a 
certain population, a single sample could be enough [378].  
Continuous Infusion of Glucose with Model Assessment (CIGMA). This is a 
steady-state mathematical model where following a low-dose, constant rate glucose 
infusion over one hour, samples are taken to measure glucose and insulin at 50, 55 
and 60 minutes into infusion [379].  
Minimal Model. This is essentially an intravenous glucose tolerance test that is 
followed by injecting a bolus dose of insulin. It requires two canulae and frequent 
blood sampling (12 or 22 samples, depending on the protocol), and may take up to 
four hours [380]. Although it has also been validated against the gold standard, 
which is the euglycaemic clamp (below) [381], its difficult and time-consuming 
nature reduce its practicality in clinical research. 
Clamp techniques: 
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Euglycaemic Clamp. This method is known as the gold standard of insulin 
quantification and uses an exogenous infusion of insulin to maintain a 
hyperinsulinaemic level while simultaneously infusing sufficient glucose to „clamp‟ 
its level at fasting concentration (5 mmol/L) [382]. The only problem with this 
technique is its difficulty; it takes two hours to perform, requires the use of two 
intravenous lines, retrograde cannulation of a vein as well as the use of a calibrated 
pump, all of which make it quite impractical for clinical research purposes. 
Hyperglycaemic Clamp. In this method, glucose is infused intravenously at a 
variable rate to clamp its concentration at a predetermined plasma glucose 
concentration, and plasma samples are obtained toward the end of the infusion to 
be assayed for insulin.  Insulin sensitivity is calculated by dividing glucose amount 
required to maintain the hyperglycaemic clamp by mean insulin concentration over 
the last 20-30 minutes of the test [382-384]. 
Insulin infusion techniques: 
Insulin Tolerance Test (ITT). This method measures the decay of plasma glucose 
after a bolus dose of insulin is injected. Although it has been validated against the 
euglycaemic clamp [385], this technique is cast as inferior because counter-
regulatory hormones are invoked, as well as the profound risk of hypoglycaemia 
[372]. 
Insulin Sensitivity Test (IST). In this method, glucose, insulin and somatostatin are 
continuously infused over a period of 150-180 minutes at a constant rate. The mean 
plasma concentration of glucose over the last 30 minutes of the test is calculated 
and used as a reflection of the insulin sensitivity [386, 387]. 
Other: 
Oral Glucose Tolerance Test (OGTT). This test has long been used for the 
diagnosis of diabetes, but can also be used to derive an estimate of insulin 
resistance. This is done by calculating an estimate of insulin resistance based on 
plasma insulin concentration 2 hours after a 75g oral glucose load [384]. 
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Quantification method References 
Homeostasis Model Assessment (HOMA) Turner et al, 1979 [375] 
Levy et al, 1998 [376] 
Continuous Infusion of Glucose with Model 
Assessment (CIGMA) 
Hosker et al, 1985 [379] 
Minimal Model Bergman et al, 1987 [380] 
Euglycaemic Clamp DeFronzo et al, 1979 [382] 
Hyperglycaemic Clamp Defronzo et al, 1979 [382] 
Matthews and Hosker, 1989 
[383] 
Nijpels et al, 1994 [384] 
Insulin Tolerance Test (ITT) Gelding et al, 1994 [385] 
Akinmokun et al, 1992 [388] 
Insulin Sensitivity Test (IST) Heine et al, 1985 [386] 
Yeni-Komshian et al, 2000 [387] 
Oral Glucose Tolerance Test (OGTT) Nijpels et al, 1994 [384] 
Table 1.4 Common techniques for quantifying insulin resistance. 
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1.2.2 Role of Inflammation 
The basic background for the role of inflammation in the MHD population has been 
discussed in section 1.1.4.3.1. 
1.2.2.1 Inflammation in Type 2 Diabetes 
The first observations that linked diabetes and inflammation were made over a 
century ago by Ebstein, who demonstrated that using high doses of sodium 
salicyalte reduces glycosuria in the diabetic patient [389], and were confirmed by 
Williamson 25 years later [390]. And although subsequent trials in the mid 20th 
century reconfirmed these findings [391-393], it wasn‟t until the 1990s that the 
mechanisms behind these findings were elucidated [394-399]. 
It was first shown in 1993 that TNF-alpha, a pro-inflammatory cytokine produced by 
adipose tissue and over-produced in obesity, was able to induce insulin resistance 
[395, 399]. Within a few years, the concept of adipose tissue as a site for cytokine 
production was well-established, and the list included leptin, IL-6, resistin, and 
adiponectin, to name a few [398, 400-404]. TNF-alpha, IL-6 and other cytokines 
induce and sustain the sub-acute inflammatory state that is present in obesity, and 
they activate intracellular pathways that lead to the development of insulin 
resistance and subsequent type 2 diabetes [405]. Studies in insulin-resistant groups 
other than those with diabetes, i.e. individuals with obesity and hypertension, have 
lent further support to the adverse effect of TNF-alpha in the development of insulin 
resistance [406, 407]. Figure 1.6 illustrates the potential mechanisms through which 
these cytokines induce an inflammatory response. 
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Figure 1.6 Potential cellular mechanisms for activating inflammatory signalling 
[408]. (Figure reproduced with permission)  
 
Not only has inflammation been linked to the key features of insulin resistance 
syndrome [409-412], the presence of chronic low-grade inflammation is probably 
the main cause of CVD in insulin resistant individuals [405]. 
1.2.2.2 Inflammation and ESRD 
Current evidence shows that CRP levels are elevated in 30-50% of predialysis, 
MHD and CAPD patients, which indicates an inflammatory state [413]. As this is 
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present in predialysis patients as well, the inflammatory response is probably aided 
by factors not related to the dialysis process, such as residual renal function, 
ethnicity, gender and age [414]. Loss of renal function has been shown to be 
associated with elevated serum cytokine levels [415], and creatinine clearance has 
a positive correlation with a number of cytokines, including IL-1, IL-6 and TNF-
alpha, and their soluble receptors in the predialysis population [416-418].  
That said, the presence of the inflammatory state is primarily found in patients 
undergoing the dialysis procedure, whether in the form of MHD or CAPD [419, 420]. 
In addition to the factors mentioned above, the inflammatory response in the 
dialysed population is enhanced by non-biocompatible membranes, non-sterile 
dialysates and the back-leak of dialysate across the dialysis membrane [421-423]. 
1.2.2.3 Inflammation and Cardiovascular Outcome 
The association between inflammation and CVD is well documented in both renal 
and non-renal patients. Evidence suggests that CRP alone may contribute to 
atherogenesis, as it is deposited in the arterial wall of early atherosclerotic lesions 
[424], it is co-localized with complement in heart tissue during acute MI [425], and it 
can induce adhesion molecule expression, which means it has a direct pro-
inflammatory effect on human endothelial cells [426]. IL-6 is also regarded as a pro-
atherogenic cytokine, as it mediates the attachment and migration of leukocytes 
across endothelial surfaces by stimulating soluble intercellular adhesion molecule 1 
(sICAM-1) [427], induces hepatic production of CRP [428] which is also directly 
involved in atherogenesis, as well as other metabolic, endothelial and coagulant 
mechanisms [429]. Other acute-phase reactants with known direct role in 
atherogenesis are serum amyloid A (SAA), Lp(a), and fibrinogen [430-432]. Figure 
1.7 illustrates the role of inflammation in the different stages of atherosclerosis. 
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Figure 1.7 Participation of inflammation in all stages of atherosclerosis. A, 
Leukocyte recruitment to the nascent atherosclerotic lesion. Blood leukocytes 
adhere poorly to the normal endothelium. When the endothelial monolayer becomes 
inflamed, it expresses adhesion molecules that bind cognate ligands on leukocytes. 
Selectins mediate a rolling, or saltatory, interaction with the inflamed luminal 
endothelium. Integrins mediate firmer attachment. Proinflammatory cytokines 
expressed within atheroma provide a chemotactic stimulus to the adherent 
leukocytes, directing their migration into the intima. Inflammatory mediators such as  
Macrophage Colony Stimulating Factor (M-CSF) can augment expression of 
macrophage scavenger receptors leading to uptake of modified lipoprotein particles 
and formation of lipid-laden macrophages. M-CSF and other mediators produced in 
plaques can promote the replication of macrophages within the intima as well. B, T 
lymphocytes join macrophages in the intima during lesion evolution. These 
leukocytes, as well as resident vascular wall cells, secrete cytokines and growth 
factors that can promote the migration and proliferation of Smooth Muscle Cells 
(SMCs). Medial SMCs express specialized enzymes that can degrade the elastin 
and collagen in response to inflammatory stimulation. This degradation of the 
arterial extracellular matrix permits the penetration of the SMCs through the elastic 
laminae and collagenous matrix of the growing plaque. C, Ultimately, inflammatory 
mediators can inhibit collagen synthesis and evoke the expression of collagenases 
by foam cells within the intimal lesion. These alterations in extracellular matrix 
metabolism thin the fibrous cap, rendering it weak and susceptible to rupture. 
Cross-talk between T lymphocytes and macrophages heightens the expression of 
the potent procoagulant tissue factor. Thus, when the plaque ruptures, as shown 
here, the tissue factor induced by the inflammatory signaling triggers the thrombus 
that causes most acute complications of atherosclerosis [433]. (Figure reproduced 
with permission) 
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In the ESRD population, it is thought that the accumulation of pro-inflammatory and 
proatherogenic cytokines, such as TNF-alpha and IL-6, with deteriorating renal 
function is a key mechanism for CVD [418, 434, 435].  
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1.2.2.4 Quantification of Inflammation 
There are numerous measurable markers of inflammation, but perhaps the most 
widely used marker by clinicians is C-reactive protein or CRP.  CRP is a protein that 
is synthesised by the liver in response to adipokines and found in the blood [436, 
437]. It is an acute-phase reactant that rises up to 50,000 times during acute 
inflammation. Normal levels of CRP are less than 5 mg/L. To detect low and 
intermediate levels of CRP more accurately a high-sensitivity CRP (hs-CRP) test is 
used. 
Adiponectin is also a quantifiable marker of inflammation, although adiponectin‟s 
role in inflammation is quite complex. While adiponectin is classified as an anti-
inflammatory molecule, its levels are elevated in individuals with high inflammatory 
scores [438]. 
Other markers of inflammation include monocyte chemo-attractant protein 1 (MCP-
1), TNF-alpha, IL-1, IL-6, IL-8, ferritin, white blood cell count, ceruloplasmin, Serum 
amyloid A, haptoglobin, orosomucoid, salic acid, fibrinogen and complement factors 
among many others. 
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1.3 Glycaemic Control in ESRD 
As the leading cause of ESRD is diabetes, and nearly half of the ESRD population 
suffers from this condition [24], adequate glycaemic control is a key component in 
the effective treatment of this at-risk population.  
1.3.1 Targets for Glycaemic Management  
Even in the non-CKD population, there seems to be more and more controversy 
surrounding this topic. Recently published data from large randomised controlled 
trials such as the Action to Control Cardiovascular Risk in Diabetes study 
(ACCORD) [439], the Action in Diabetes and Vascular Disease study (ADVANCE) 
[440], and  the Veterans Affairs Diabetes Trial (VADT) [441] have only added to the 
dispute on „how low is too low?‟ when it comes to glycaemic control.  
Early intervention to lower glycaemia and HbA1c in both type 1 and type 2 diabetic 
patients is regarded as beneficial; this was reconfirmed recently by both the UKPDS 
[198] and the DCCT [442] follow-up studies. Lower HbA1c lowers the incidence of 
both macrovascular disease, i.e. CVD, and microvascular disease, which in turn 
improves survival and reduces mortality. 
In late intervention, however, it is very important to achieve as low a level of 
glycaemia as possible without pushing the patient toward hypoglycaemia, which in 
fact increases mortality [443]. Aiming to achieve HbA1c values close to that of the 
general population (<6.5%) has been associated with increased mortality and no 
benefit to CVD [439], and even targeting long-established target of <7.0% in the 
diabetic population has been shown harmful in those with long standing type 2 
diabetes [441]. Even trials that claim to show improved survival with lower HbA1c 
levels [440], only do so marginally. 
There are several guidelines in regards to glycaemic targets in the general 
population; the American Diabetes Association (ADA) recommends aiming to 
achieve an HbA1c of less than 7.0%, while its European equivalent, the European 
Association for the Study of Diabetes (EASD) targets HbA1c values of below 6.5% 
[444]. Although concerns have been raised over the safety of these targets in light 
of the recent new evidence, the guidelines have not been altered by either party, 
yet.  
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As there are no specific glycaemic guidelines for the ESRD population, the same is 
taken to apply to this group of patients. And, the subject of glycaemic control is an 
equally controversial one in ESRD and MHD patients. No solid evidence can show 
beneficial effects of tight glycaemic control on diabetic nephropathy in CKD stages 3 
to 5. However, clinicians are always urged to pursue tight glycaemic control in order 
to reduce development and progression of other diabetic complications, such as 
retinopathy, neuropathy and macroangiopathy[445]. And although there is evidence 
that associates poor glycaemic control with increased mortality in the MHD 
population [446, 447], there is also data from large epidemiological studies that 
shows glycaemic control has no effect on survival and outcome of such patients 
[132]. 
1.3.2 Tools for Assessment of Glycaemic Management 
Perhaps the most widely used tool for assessing patients‟ glycaemic management 
is the HbA1c, or glycosylated haemoglobin. Glycosylated haemoglobin is the 
product of the irreversible non-enzymatic glycation of one or both amino-terminal 
valines of the beta-haemoglobin chain [448]. The reason it is widely used is that it 
shows plasma glucose values averaged over the half-life of the red blood cells 
(RBC), which is about 50-55 days in the general population. But an important fact to 
keep in mind is that it is believed that the major proportion of the HbA1c value is 
attributed to the younger RBCs, those two to four weeks old, and that the oldest 
RBCs, those aged 90-120 days only attribute about 10% to total HbA1c values 
[449].  
In addition to the HbA1c, most clinicians also use random glucose values as 
measured by a finger prick test carried out by the patients or a healthcare 
professional. Finger-prick results are much less reliable, because they not only 
depend on the manufacturer of the monitor in use, but also the time in relationship 
to medication and food, the age of the strips used and the expertise of the person 
carrying out the test that effect the results.  
The most reliable method for assessing glycaemic management may become 
continuous glucose monitoring. Continuous glucose monitors (CGM) are usually 
portable devices that can be worn by the patients without restricting their physical 
mobility and daily routine. They generally measure interstitial glucose every few 
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minutes and record the results in their internal chip, or transmit them wirelessly to 
another device; a mobile phone, a computer or an insulin pump. Emergence and 
spread of use of CGM for assessing glycaemic control, has the potential to 
revolutionise the monitoring of diabetic patients. 
1.3.3 The Reliability of HbA1c 
Generally, HbA1c has proven to be an invaluable tool in assessing long-term 
glycaemic control. However, certain conditions have long been known to decrease 
this reliability as they either interfere with the HbA1c assay, or effect RBC survival 
and in turn cause a „disproportionate‟ HbA1c value. ESRD causes both of the 
above; uraemia interferes with assays as it produces carbamylated haemoglobin 
which caused problems with older HPLC assays of HbA1c [450], and it reduces 
RBC half-life and therefore produces under-estimated HbA1c results [451]. But, in 
the absence of any other method for a long-term estimation of glycaemic control, 
clinicians continue to use the HbA1c, despite its known shortcomings in the ESRD 
population. Small studies have even shown that contrary to its theoretical problems, 
the HbA1c assay is sufficiently reliable in the ESRD population [452]. The ADAG 
(A1c Derived Average Glucose Study Group) investigators recently reported [453] 
that HbA1c levels can be converted to average glucose levels in T2DM. However, 
CKD patients were excluded from this study and it is possible that the metabolic 
fluctuations seen around haemodialysis may weaken the relationship between 
HbA1c and average glucose. 
In keeping with the recent concerns surrounding the reliability of HbA1c in subjects 
with ESRD, glycated albumin has been proposed as a surrogate marker of 
glycaemic control in patients with renal anaemia and in receipt of erythropoietin 
[454, 455]. Recent reports have shown improved survival among subjects with 
lower glycated albumin levels [456]. 
1.3.4 The Role of Continuous Glucose Monitors  
One of the alternative methods of glycaemic assessment to HbA1c is continuous 
glucose monitoring. First introduced in the 1990s, continuous glucose monitoring 
systems are becoming more and more advanced and common. They can usually 
stay on for 3 to 7 days (depending on the system used), and they measure and 
70 
record glucose values about every 3-5 minutes. CGMs usually measure interstitial 
glucose, not plasma glucose, and this does mean that it does not really reflect real-
time plasma glucose. The lag-time differs according to the system used and the 
technique that system uses to pick up glucose signals. At present, it is thought that 
systems that use the microdialysis technique are most accurate, as they have the 
shortest lag time. Another problem in measuring interstitial glucose as opposed to 
plasma glucose is that the devices lose their accuracy as the glucose level drops to 
hypoglycaemia level, and because of the discussed lag time are not optimal for 
picking up imminent hypoglycaemia, and generally over-estimate the duration of 
hypoglycaemia as the lag-time increases during recovery [457]. Nevertheless, many 
studies have shown that using a CGM to guide diabetes treatment significantly 
improves HbA1c and diabetes control [458-461]. 
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1.4 Hypothesis 
1) Patients on haemodialysis have different cardiovascular risk factors compared to 
CKD patients. 
2) Although the MHD population is known to be insulin resistant, insulin sensitivity is 
improved once patients commence haemodialysis compared to the preceding late 
CKD stages. 
3) HbA1c may not be an accurate measurement of glycaemic control among the 
haemodialysed population with diabetes, thus warranting new methods for 
assessing glycaemic control in this population. 
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1.5 Aims and Objectives 
Aim 1: 
To re-assess the „reverse epidemiology‟ hypothesis by identifying cardiovascular 
risk factors in a cohort of patients with a spectrum of renal impairment, mainly 
before and after haemodialysis. 
Objectives: 
To identify and categorise patients within the ICKTI into the following groups: pre-
dialysis patients (those with CKD stages 3, 4 and 5 who are not yet on renal 
replacement therapy) and patients on haemodialysis. Both groups will have patients 
with and without diabetes. To document their baseline phenotypic, demographic 
and biochemical data and monitor predefined cardiovascular events during the 24-
month follow-up period. To calculate the risk associated with baseline data and 
compare the results between and with event rates in the general population.  
Aim 2:  
To evaluate insulin resistance and inflammation at different stages of ESRD, and to 
examine its relationship, if any, to degree of renal disease, mode of treatment and 
cardiovascular events. 
Objectives:  
To quantify insulin resistance among patients within the groups mentioned above by 
use of the homeostatic model assessment (HOMA) technique, and evaluate 
inflammation by measuring plasma adiponectin and high sensitivity CRP in a subset 
of the aforementioned cohort. To compare results for before and after 
haemodialysis groups.   
Aim 3:  
To re-assess the glycaemic control in patients with diabetes and on haemodialysis. 
Objectives:  
To identify and recruit a subgroup of diabetic patients on MHD, fit them with 
continuous glucose monitoring devices and look at glycaemic profiles and identify 
factors that affect it. Also, to compare mean blood glucose values over 48 hours 
with relevant HbA1c values to determine the accuracy of HbA1c in this group.  
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Chapter 2: Methods 
2.1 Identifying Cardiovascular Risk Factors in ESRD 
The study is a prospective case-controlled cohort study. 
2.1.1 Ethics 
The study was approved by the Hammersmith Hospital Research Ethics 
Committee (Registration Number: 06/Q0406/148). As the data being used 
was retrieved from existing hospital records and databases, written informed 
consent was not necessary for enrollment into the database. At 24 months, 
patients were sent questionnaires to complete and return in order to detect 
endpoints that may not have been recorded in hospital records. A copy of the 
questionnaire is supplied in the appendix (6.3.4). 
2.1.2 Study objectives 
To identify and categorise patients within the ICKTI into the following groups: pre-
dialysis patients (those with CKD stages 3, 4 and 5 who are not yet on renal 
replacement therapy) and patients on haemodialysis. Both groups will have patients 
with and without diabetes. To document their baseline phenotypic, demographic 
and biochemical data and monitor predefined cardiovascular events during the 24-
month follow-up period. To calculate the risk associated with baseline data and 
compare the results between and with event rates in the general population. 
2.1.3 Subjects 
Subjects were recruited from the Imperial College Kidney & Transplant Institute 
(ICKTI), which is sited at Hammersmith Hospital in London. This is where renal 
services for the whole of north-west London has been centralised, and forms the 
hub of a network connecting the major hospitals across this sector of London; these 
include Hammersmith, Charing Cross, Northwick Park, St Charles, Central 
Middlesex, Watford, Ealing, West Middlesex and Ashford Hospitals. The WLRTC 
provides renal care for a population of 3.5 million people residing in north-west 
London, and renal replacement therapy to approximately 2000 patients (data from 
internal audit, March 2007), making it the largest programme of its kind in Europe. 
For the purposes of this study, patients were mainly recruited from Hammersmith 
and Charing Cross hospitals.  
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Inclusion Criteria: Competent adults (age 18 or greater) within the ICKTI; 
individuals with an estimated glomerular filtration rate (eGFR) of less than 60 
mL/min/1.73m², with and without diabetes; patients currently receiving renal 
replacement therapy in the form of maintenance haemodialysis, with and without 
diabetes. 
Exclusion Criteria: Age less than 18; eGFR > 60 mL/min/1.73m²; RRT other than 
maintenance haemodialysis (haemodiafilteration, continuous ambulatory peritoneal 
dialysis (CAPD)); and known pregnancy were prospectively determined exclusion 
criteria. 
Subjects were identified from a central index of patient records and clinic notes and 
recruited subjects were enrolled into a database where relevant clinical data was 
recorded. Subjects were then prospectively monitored for 24 months from date of 
entry into the database. The list of documented characteristics can be found below. 
Recruitment, data collection and follow-up of subjects was facilitated by volunteer 
medical students. 
2.1.3.1 Demographics: Hospital number: The unique number assigned to each 
subject for identifying and retrieving information from hospital records. 
Hospital site: As patients were recruited from multiple sites within ICKTI, the specific 
location was recorded for reference. 
Date of birth: As specified within the subjects‟ hospital records. This was recorded 
both for identification purposes as well as to calculate subjects‟ age. 
Gender: Also recorded as specified within the subjects‟ hospital records. 
Ethnicity: This factor was retrieved from the subjects‟ hospital records, which is 
based on a self-reported questionnaire. The results were reclassified to fewer 
groups with larger numbers to facilitate statistical calculations. The reclassification 
method is outlined below in figure 2.1. 
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Figure 2.1 Classification of ethnicity in the cohort, based on the data collect by the 
Trust at admission. 
 
2.1.3.2 Baseline Characteristics: Body mass index (BMI): Most subjects had their 
weights recorded at every clinic appointment. Heights were also recorded in most 
cases. Where either weight, height or both were missing for a subject, the aim was 
to ascertain this information the subject‟s next scheduled clinic visit. 
Diabetes status: Ascertained from subjects‟ clinic notes. For diabetic subjects, the 
date of first diagnosis and type of diabetes (type 1 or type 2) was also recorded. 
Smoking status: As reported by the patient and recorded in clinic notes. 
•White – British
•White – Irish  
•White – Any other 
•Mixed – White and Black Caribbean 
•Mixed – White and Black African
•Mixed – White and Asian
•Mixed – Any other 
•Asian – Indian 
•Asian – Pakistani  
•Asian – Bangladishi
•Asian – Any other
•Black – Caribbean
•Black – African 
•Black – Any other 
•Chinese 
•Other 
•Not stated
•Unknown 
WHITE
MIXED
ASIAN
BLACK
OTHER
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Cause of renal failure: As recorded in clinic notes; in some cases renal biopsies had 
been obtained while others were either based on the physicians‟ deduction from 
patients‟ history or unknown. 
Stage of ESRD: This was classified as CKD 3 (eGFR 59 to 30 mL/min/1.73 m2), 
CKD 4 (eGFR29 to 15 mL/min/1.73 m2), CKD 5 (eGFR < 15 mL/min/1.73 m2), and 
MHD if receiving maintenance haemodialysis.  
Dialysis adequacy: For subjects who were on MHD, dialysis adequacy, as 
measured by the Kt/V formula (where K=dialyser clearance (L/min), t=time (min) 
and V=body volume of urea (L). Kt/V is a dimensionless number, as (L/min x 
min)/L=1) was obtained from hospital notes as a measurement of quality of dialysis 
[462].  
Existing co-morbidities: Other existing conditions and diseases were retrieved from 
hospital and clinic notes. Of special priority were pre-existing cardiovascular 
conditions. 
Current medication: A list of the patients‟ medication at entry into database was 
obtained from their hospital records and clinic notes. 
Blood pressure: The patients‟ last recorded blood pressure at entry into the study 
was ascertained from patients‟ notes and recorded in the database. In case of 
haemodialysed subjects, both pre- and post-dialysis blood pressure was recorded. 
2.1.3.3 Subject Classification: To observe changes throughout the course of end 
stage renal disease, patients were classified into groups of those losing kidney 
function and those on haemodialysis: 
1-the pre-dialysis group: this group comprises of patients with CKD stages 3, 4 and 
5.  
2-the on dialysis group: this group includes patients who are currently receiving 
maintenance haemodialysis at an ICKTI unit. 
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2.1.4 Laboratory analysis 
The most recent biochemistry and blood count results for patients were used to 
ascertain the following factors for each subject at entry into the study.  
Haemoglobin: measurements were performed in the hospital‟s routine haematology 
laboratory using a XE2100 auto-analyzer (Sysmex, Toa Medical Electronics, Kobe, 
Japan) running a variation of the CyMet-haemoglobin absorbtimetric method. 
Total cholesterol: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses an enzymatic methodology where 
cholesterol esters are hydrolyzed by cholesterol esterase to cholesterol and free 
fatty acids. The free cholesterol is then oxidized and hydrogen peroxide is released, 
which goes on to form a chromophore (quinoneimine dye) which is quantitated. 
High density lipoprotein (HDL) cholesterol: measurements were performed by the 
hospital‟s routine clinical biochemistry laboratory using the Architect c SystemsTM 
(Abbott Diagnostics, Illinois, USA). The assay uses an accelerator selective 
detergent to accelerate the reaction of cholesterol oxidase with non-HDL 
unesterified cholesterol and dissolves HDL cholesterol selectively. The reagent 
consists of a chromogenic coupler that develops colour for the quatitative 
determination of HDL cholesterol. 
Triglycerides: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses an enzymatic methodology where 
triglycerides are hydrolyzed to free fatty acids and glycerol. The glycerol is 
phosphorylated to produce glycerol-3-phosphate, which is then oxidized to produce 
hydrogen peroxide (H2O2) which reacts with reagents to produce a red coloured 
dye. The absorbance of this dye is proportionate to the concentration of triglycerides 
in the sample. 
Glycosylated haemoglobin (HbA1C): The HbA1c measurements were performed in 
the hospital‟s clinical biochemistry laboratory using a DCCT-aligned HA-8160 
HbA1c auto-analyser (A.Menarini Diagnostics). This analyzer is not subject to 
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interference by urea as this reverse-phase cation exchange high-performance liquid 
chromatography method provides good separation of HbA1c from carbamylated 
HbA1. 
Urea: Serum urea tests were performed were performed by the hospital‟s routine 
clinical biochemistry laboratory using an Architect ci8200 multi-channel analyser 
(Abbott Diagnostics, Illinois, USA). This method uses an enzymatic methodology 
where urea is hydrolysed to ammonia and carbon dioxide; ammonia is then 
converted to glutamate and water with the concurrent oxidation of reduced 
nicotinamide adenine dinucleotide (NADH) to nicotinamide adenine dinucleotide 
(NAD). Two moles of NADH are oxidized for every mole of urea present. 
Creatinine: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses alkaline picrate to form a creatinine-
picrate complex. The rate of increase in absorbance at 500nm due to the formation 
of this complex is directly proportionate to the concentration of creatinine in the 
sample. 
Ferritin: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c 8000® System (Abbott 
Diagnostics, Illinois, USA). The assay uses a latex reagent coated with rabbit IgG 
anti-ferritin. When a sample containing ferritin is mixed with the reagent, 
agglutination occurs and its degree is directly proportionate to the concentration of 
ferritin in the sample and is determined by the decrease of transmitted light caused 
by the aggregates. 
Total iron binding capacity (TIBC): measurements were performed by the hospital‟s 
routine clinical biochemistry laboratory using the Architect c 8000® System (Abbott 
Diagnostics, Illinois, USA). The assay uses ferric chloride saturating solution to bind 
all available apotransferrin binding sites with iron and alumina adsorbent to remove 
excess iron from the serum mixture. The mixture is then analysed for total iron using 
the iron assay and the result is multiplied by the dilution factor of 3 to compensated 
for dilution of the serum by the saturating solution. 
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C-reactive protein (CRP): measurements were performed by the hospital‟s routine 
clinical biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses an immuneturbidimetric methodology 
where anti-C-reactive protein antibody is adsorbed to latex particles and reacts with 
CRP to result in agglutination. This agglutination is detected as an absorbance 
change, where the magnitude of the change is proportionate to the quatity of CRP 
in the sample. 
Calcium: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses Arsenazo III dye which reacts with 
calcium in an acid solution to form a blue-purple complex. The colour developed is 
measured at 660nm and is proportionate to the calcium concentration in the 
sample. 
Phosphate: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses ammonium molybdate which reacts with 
inorganic phosphate to form a heteropolyacid complex, and the absorbance at 
340nm is directly proportionate to the inorganic phosphate level in the sample. 
Glucose: measurements were performed by the hospital‟s routine clinical 
biochemistry laboratory using the Architect c SystemsTM (Abbott 
Diagnostics, Illinois, USA). The assay uses hexokinase to phosphorylate glucose 
into glucose-6-phosphate (G-6-P) which is oxidized with concurrent reduction of 
nicotinamide adenine dinucleotide (NAD) to nicotinamide adenine dinucleotide 
reduced (NADH). One micromole of NADH is produced for every micromole of 
glucose consumed.  
The subjects within the database were routinely monitored at 12 month intervals for 
predefined endpoints, which are listed below. This was derived mainly from the 
Trust‟s centralised database (ICHIS) as well as from clinic notes, discharge 
summaries, telephone enquiries and death certificates. 
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2.1.5 Endpoints 
The study endpoints were divided into primary and secondary endpoints. 
Primary endpoints: Any cardiovascular event was classified as a primary endpoint. 
Cardiovascular events were defined as: myocardial infarction, aortocoronary 
bypass, percutaneous transluminal coronary angioplasty, angiographically verified 
stenosis of the coronary arteries, stroke, or a symptomatic stenosis of the peripheral 
arterial vessels (carotids, aorto-iliac, or femoral arteries). Admission for any of the 
above during the course of the study was considered a primary endpoint. In 
addition, admission to hospital with a primary diagnosis of „chronic ischaemic heart 
disease‟ or any other pre-existing condition that exasperated during the monitoring 
period was constituted as a primary endpoint. In the event of multiple events during 
the monitoring period, the fist event was used for the statistical calculations. 
Secondary endpoint: Death due to all causes was categorised as the secondary 
endpoint. As subjects may have had a cardiovascular event prior to this, it is 
possible for subjects to reach both a primary and secondary endpoint within the 
study timeframe. 
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2.2 Measuring Insulin Resistance and Inflammation 
There are a number of techniques for quantifying insulin resistance (See section 
1.6.4). For the purposes of this study the homeostatic model assessment (HOMA) 
technique was used.  
The reasons for choosing the HOMA technique and its principles have already been 
discussed. The protocol that was designed for this study is described here. 
2.2.1 Ethics 
The study was approved by the Hammersmith Hospital Research Ethics 
Committee (Registration Number: 06/Q0406/148) and written informed 
consent obtained in all cases. A copy of the patient invitation letter and 
information sheet, as well as the consent form are supplied in the appendix 
(section 6.3) 
2.2.2 Study objectives 
To explore the relationship between insulin resistance, adiponectin and hs-CRP 
with cardiovascular events in a group of subjects with varying degrees of renal 
impairment; to compare levels of insulin resistance, hs-CRP and total adiponectin 
before start of MHD with their levels 8 weeks into MHD. 
2.2.3 Subjects 
106 subjects agreed to come in after an overnight fast to participate in the study. 
They were recruited from the haemodialysis and renal outpatient units at 
Hammersmith and Charing Cross hospitals. Subjects included patients with CKD 3, 
CKD 4, CKD 5 (not on HD) and on MHD. Both diabetic and non-diabetic subjects 
were included in the analysis.   
To analyse changes in insulin resistance, hs-CRP and total adiponectin levels 
before and after MHD, a number of subjects scheduled to start MHD were identified 
and approached, 7 of who agreed to participate in this subgroup study. They had 
their first sample taken on the day of their first haemodialysis session, prior to its 
initiation. All subjects gave informed written consent to repeat the procedure 8 
weeks into MHD. Of the seven subjects, one was transplanted before reaching 8 
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weeks, one died before reaching 8 weeks, and four refused to take part on the day. 
Only one patient successfully completed both pre- and post-dialysis sampling.  
2.2.4 Exclusion criteria 
The exclusion criteria were prospectively defined as: age less than 18, eGFR > 60 
mL/min/1.73m², RRT other than maintenance haemodialysis (haemodiafilteration, 
continuous ambulatory peritoneal dialysis (CAPD)), and known pregnancy. 
2.2.5 Blood samples and laboratory analysis 
For the insulin measurements three blood samples were taken at five minute 
intervals after an overnight fast of at least 12 hours. The samples were drawn into 
Lithium Heparin (LH) tubes to inhibit coagulation and enable plasma separation. 
The samples were chilled on ice and centrifuged immediately at 500g (3500 rpm) 
for 10 minutes. The plasma was then separated and each sample was stored as 3 
aliquots of > 0.5 ml at -80 degrees Celcius. At the end of the study period, one 
aliquot from each sample was sent to the laboratory to be assayed for insulin levels; 
the samples were analysed in two parts by the same laboratory to minimise inter 
assay errors. The insulin assays were done using the Abbott Axsym; this is a well 
established fully automated immunometric assay employing an enzyme label and 
microparticle separation; % coefficients of variation are 4-6% across the diagnostic 
range of the assay and the functional sensitivity is 0.5mlU/l.  
For the glucose measurement needed for the HOMA calculation, blood was drawn 
into fluoride oxalate tubes and immediately sent to the chemical pathology 
department for analysis. A number of medical students volunteered to help with 
recruitment and sample collection. 
As almost half of the population studied were haemodialysis patients who are 
usually quite ill and have already undergone many invasive procedures, to minimise 
the discomfort of taking three consecutive blood samples, samples were taken out 
of the haemodialysis circuit. To make sure that this would not compromise our 
results I had to make sure that no insulin was being dialysed out. This was done by 
testing the outgoing dialysate fluid for insulin. As expected, no insulin was detected 
in this fluid and thus samples were collected from the dialysis circuit.   
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As mentioned in the section above, 9 plasma aliquots of > 0.5 ml were stored for 
each subject (3 samples per subject, 3 aliquots per sample) at -80 ºC. One of these 
aliquots was used to measure total adiponectin and high sensitivity CRP levels in 
each subject. Adiponectin was measured by ELISA (RayBiotech, Norcross, GA, 
USA) and performed according to manufacturers‟ instructions. This assay employs 
an antibody specific for human adiponectin coated on a 96 well plate. Standards or 
diluted serum were added to the microtitre wells and adiponectin present in the 
sample bound to the immobilised antibody. Following incubation the wells were 
washed and biotinylated anti-human adiponectin antibody added. Following a 
further incubation unbound biotinylated antibody was washed away and HRP 
streptavidin was added to the wells. After further incubation the wells are washed 
and bound HRP visulaised using TMB substrate solution. The colour that developed 
is proportional to the amount of adiponectin present in the sample. After incubation 
the reaction is stopped by the addition of sulphuric acid and the optical density of 
the reactive solution was read at 450nm. The concentration of adiponectin was 
calculated by reference to a standard curve of known adiponectin concentration. 
The assays were carried out by the Translational Research Laboratory at the 
Kennedy Institute of Rheumatology of Imperial College London. 
CRP was measured by a high sensitivity CRP ELISA (Kalon Biological, Guildford 
UK) and performed according to manufacturers‟ instructions. This assay employs an 
antibody specific for CRP coated on a 96 well plate. Standards or diluted serum 
were added to the microtitre wells and CRP present in the sample bound to the 
immobilised antibody. Following incubation the wells are washed and alkaline 
phosphatase labelled anti-human CRP antibody was added. After further incubation 
the wells were washed and bound alkaline phosphatase visualised using 4-
nitrophenylphosphate substrate solution. The colour that developed is proportional 
to the amount of CRP present in the sample. After incubation the reaction was 
stopped by the addition of EDTA solution and the optical density of the reactive 
solution was read at 405nm. The concentration of CRP was calculated by reference 
to a standard curve of known CRP concentration. The assays were carried out by 
the Translational Research Laboratory at the Kennedy Institute of Rheumatology of 
Imperial College London.  
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2.3 Assessing Glycaemic Control in ESRD 
A 48-hour continuous glucose monitoring device called the GlucoDay® S from 
Menarini Diagnostics (Florence, Italy) was used to assess glycaemic control in 
haemodialysed patients with type 2 diabetes (figure 2.2). This device measures and 
records glucose values every 3 minutes for up to 48 hours. It uses a microdialysis 
mechanism that is delivered via a microfibre that is inserted into the peri-umbilical 
subcutaneous adipose tissue. The biosensor, which consists of a 20µm membrane 
of cellulose acetate, a nylon net with the immobilised glucose oxidase enzyme and 
a polycarbonate membrane [463].  
 
 
Figure 2.2 Photograph of the GlucoDay® S continuous glucose monitor 
device (left) and subject wearing the device with the supplied belt and pouch 
(right). 
 
2.3.1 Ethics 
The study was initially approved by the Hammersmith Hospital Research Ethics 
Committee in 2002 for continuous glucose monitoring in free living people with type 
2 diabetes treated with insulin and on a low glycaemic index diet (Registration 
Number: 2002/6260). A substantial amendment application was put forward and 
approved by the same committee to extend the project to include haemodialysed 
subjects. Written informed consent obtained in all cases. Copies of the amendment, 
patient information sheet and consent form are available in the appendix (section 
6.5). 
2.3.2 Study objectives 
To compare glucose profiles from days on and off dialysis using 48-hour 
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CGM in type 2 diabetic patients; to examine the association between self-
reported food intake and the CGM values; to evaluate glycaemic assessment 
obtained using 48-hour CGM in type 2 diabetic MHD patients. 
2.3.3 Subjects 
Nineteen (14 male) Type 2 diabetic subjects were recruited from the MHD 
program at Imperial College Kidney and Transplant Institute (ICKTI). Subjects 
were dialysed against a <2 g/l glucose containing dialysate (equivalent to 
<11.1 mmol/l of glucose) for 4-51/2 hours either during the morning, afternoon 
or early evening.  Inclusion criteria were a stable haemoglobin (Hb) level, 
defined as <10% change in Hb value and no blood transfusion in the 
preceding 3 months, a stable dose of erythropoietin and no 
haemoglobinopathy. History of cardiovascular disease was established as 
documented ischaemic heart disease (history of myocardial infarction, 
revascularisation procedure or angiographically proven coronary disease), 
cerebrovascular disease (history of cerebrovascular accident or transient 
ischaemic attack) or peripheral vascular disease (history of amputation due to 
gangrene, revascularisation procedure or angiographically or doppler proven 
peripheral vascular disease). 
Subjects were fitted with the device (figure 2.2) at the prior to their dialysis session 
and instructed to keep a complete diary of their diet, physical activity, medication 
and finger prick test results (at least one). A copy of the food diary is available in the 
appendix (section 6.4.4). The device was taken out before the start of the next 
session of dialysis, 48 hours later. As patients are heparinised during dialysis, the 
device was fitted before and also removed before the session to minimise the risk of 
bleeding.  
2.3.4 Exclusion criteria 
Exclusion criteria were prospectively defined as: Type 1 diabetes, inter current 
illness, changes to medication regimen during the monitoring period or occurrence 
of prolonged hypoglycaemia. 
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2.3.5 Blood samples and laboratory analysis 
Blood samples were taken for HbA1c, haemoglobin, albumin and urea at the start of 
dialysis. The HbA1c measurements were performed in the hospital‟s clinical 
biochemistry laboratory using a DCCT-aligned HA-8160 HbA1c auto-analyser (A. 
Menarini Diagnostics). This analyzer is not subject to interference by urea as this 
reverse-phase cation exchange high-performance liquid chromatography method 
provides good separation of HbA1c from carbamylated HbA1. 
The haemoglobin measurements were performed in the hospital‟s routine 
haematology laboratory using a XE2100 auto-analyzer (Sysmex, Toa Medical 
Electronics, Kobe, Japan) running a variation of the CyMet-haemoglobin 
absorbtimetric method. 
Serum urea and serum albumin tests were performed on an Architect ci8200 multi-
channel analyser (Abbott Diagnostics, Illinois, USA). 
2.3.6 Glucose profiles 
The 48-hour glucose profiles were quantified using dedicated software 
(GlucoDay®S Data Presentation Software) as the area under the 3-minute glucose 
curve (AUC) and the mean glucose value.  The time periods studied were the first 
24-hour period starting the first hour of dialysis (day on dialysis) and the 24-hour 
period ending one hour prior to the next dialysis session (day off dialysis). The 6-
hour nocturnal periods from midnight to 6:00 a.m. for each of these 24-hour periods 
were also examined in order to examine the effect of dialysis. Hypoglycaemia, 
defined as a continuous glucose reading <2.5 mmol/l for more than 30 minutes, was 
identified from the CGM profiles. Subjects were questioned regarding symptoms of 
hypoglycaemia at the end of the CGM period. 
2.3.7 Patient diaries and dietetic analysis 
On the first day subjects were given a 48-hour diary to record the exact time and 
amount of food, drink and medications taken during the entire CGM monitoring 
period, together with any episodes of symptomatic hypoglycaemia and all capillary 
blood glucose results. Completed food diaries were checked during a dietary 
consultation with a registered dietitian. Food portions were verified using a pictorial 
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food atlas (MAFF Publications 1997). Comparisons of dietary intake during the 24-
hour periods on and off dialysis were performed by a data-analyst blinded to the 
study using the Dietplan 6 software package (Forestfield Software). Daily energy 
requirement was calculated at 30-35 kCal/kg ideal body weight (Renal Association 
2002). A registered dietician helped with dietary data analysis.  
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2.4 Statistical Calculations 
All data was exported into PASW Statistics versions 14-17 software (SPSS for 
Windows, Release 17.0.2 [11 March 2009], Copyright 1993-2007 Polar Engineering 
and Consulting). The Shapiro-Wilk test was used to test normality of data and 
comparisons of means were carried out using Student‟s t-test, ANOVA, and non-
parametric test were applicable.  
Power calculations to determine the required sample size for the cohort are mainly 
based on Van Belle‟s book, Statistical Rules of Thumb [464], which states that “in 
logistic regression situations about 10 events per variable are necessary in order to 
get reasonably stable estimates of the regression coefficients.” As the current 
mortality rate for patients on haemodialysis in the UK is reported to be 20% annually 
[465], according to this rule, if we are looking to analyse 8 prognostic factors, we will 
need a sample population that will give us 80 events, in this case death. With a 20% 
annual mortality rate, an initial population of at least 220 haemodialysis patients are 
needed to achieve 80 events in 2 years (calculations: 20% die in year 1, 0.8 x 
220=176 left 20% of those left die in year 2, 0.8 x 176=141 left  =79 deaths). 
The present database holds 210 haemodialysed subjects and 308 non-
haemodialysed subject for comparison.  
Since it is more likely that subjects develop a non-fatal cardiovascular event [27], 
this outcome was categorised as the primary endpoint; this ensures that the study 
produces significant results as it is powered to produce results for the less common 
outcome of death, which is categorised as the secondary endpoint for this study. 
Logistics model was used to calculate odds ratios associated with each studied risk 
factor for primary and secondary endpoints. Odds ratios were calculated for BMI, 
total cholesterol, triglycerides, systolic and diastolic blood pressure and diabetes 
status. The calculations were carried out for the two subgroups within the whole 
population as well; the CKD and MHD groups. Logistic model was also used to 
calculate odds ratios associated with HOMA-IR, adiponectin and hs-CRP for 
primary and secondary endpoints in the group of patients they were measured in. 
These calculations were also done for the two subgroups within this population; the 
CKD and MHD groups. 
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There are also different statistical methods of analysing this data: logistic regression 
(which is used to express the present results), which calculates an odds ratio which 
is independent of time and Cox regression, which calculates hazard ratios in 
relation to time from start of disease to endpoint. The reason logistic regression is 
used to express the results of the present study is that although time of endpoint is 
recorded for all subjects, time of start of disease was impossible to record in some 
cases, as CKD is a gradual process that develops, in some instances, over very 
long periods of time. Also, as many patients had multiple co-morbidities such as 
diabetes and pre-existing cardiovascular disease, the definition of the „start of 
disease‟ was too broad to accommodate these subjects; i.e. start of which disease? 
Nevertheless, Cox regression was carried out to make sure that its results were not 
contradictory to those achieved by logistic regression. To that end, time of start of 
disease was defined as time of recruitment into the present study; therefore the 
start date for all subjects was recorded as March 10th, 2007. The results of Cox 
regression analysis were very similar, and in some cases identical, to that of logistic 
regression. Neither the direction of effect nor the statistical significance calculated 
were different from those achieved by logistic regression. It was therefore decided 
to use the logistic regression results to express the risks, as this method was 
scientifically more suitable for the present dataset in light of the above explanation. 
The Cox regression analysis was used to draw the cumulative hazard plots for the 
risk factors, in which case continuous variables (such as BMI, BP, TC, TG, HOMA-
IR, hs-CRP and total adiponectin) were transformed into categorical variables of 
above or below a certain cut-off point (either the upper limit of normal range or the 
median within the cohort). 
Statistical help and advice was sought from the Imperial College Statistical Advisory 
Service, who were actively involved in the statistical calculations for this part of the 
study. The final report from the statistician is available in the appendix (Appendix II). 
The CGM data was also exported into SPSS versions 14.0 to 17.0.2 software 
(SPSS for Windows, Release 14.0.0 to 17.0.2 [5 September 2005 to 11 March 
2009], LEAD Technologies, Inc.) and tested for normality using the Shapiro-Wilk 
test. All normally distributed data is expressed as mean and standard deviation (SD) 
and non-normally distributed data as median and range. All comparisons of the 
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glycaemic profiles and dietary intake between days on and off dialysis was analysed 
using paired Student‟s t-tests.  
Linear regression analysis was used to assess the relationship between laboratory 
HbA1c, and weekly EPO dose, serum urea and serum albumin. Linear regression 
was also used to look at relationships between different risk factors throughout the 
study. 
The level of significance was defined as p<0.05 throughout the study. 
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Chapter 3: Results 
3.1 Cardiovascular Risk Factors in ESRD 
3.1.1 Distributions and comparison of subgroups 
A total of 518 patients were recruited into the database. Of these, 210 subjects are 
classified as MHD subjects as they were on HD at recruitment, and 308 are 
categorised as CKD as they were CKD 3 or above and not on HD at recruitment. 
The characteristics of this cohort are as follows.  
3.1.1.1 Age. Birth date was recorded for 518 subjects in the database. The 
minimum recoded age is 22 years while the maximum is 98 years old. The mean 
age is 66 with 15.0 years standard deviation.  
The mean age for CKD subjects not on haemodialysis is 67 years ± 14.7 years with 
the same range as the whole population, while in the haemodialysis group the mean 
age is 64 years ± 15.3 years with a slightly narrower range of 24 to 94 years (table 
3.1.1). 
 
 
Table 3.1.1 Demographic details at recruitment for the CKD and MHD subgroups 
 
3.1.1.2 Gender. Gender was recorded for all subjects in the database, and of the 
518 subjects, 301 were male. This means the cohort consists of 42% female and 
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58% male subjects. In the CKD group 187 subjects (60.7%) are male while in the 
HD group 113 subjects (53.8%) are male (figure 3.1.1 and table 3.1.1). 
 
 
 
Figure 3.1.1 Male to female ratio within the CKD, MHD and the whole cohort of 
ESRD patients recruited. The CKD group (n=308) consists of 60.7% males, the 
MHD group (n=210) 53.8%, and the whole group (n=518) 58% males.    
 
3.1.1.3 Diabetes Status. Diabetes status is unknown for eleven subjects in the 
database and of the remaining subjects, 275 patients (53.0%) have diabetes. In the 
CKD group, 10 subjects have unknown status and 183 subjects (59.4%) have 
diabetes. In the HD group only one subject has unknown diabetic status and of the 
remaining 210 subjects, 91 (43.3%) have diabetes (figure 3.1.2 and table 3.1.1). 
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Figure 3.1.2 Ratio of subjects with and without diabetes within the CKD, MHD and 
the combined cohort of ESRD patients recruited. The percentage of subjects with 
diabetes in the CKD group (n=308) is 59.4%, in the MHD group (n=210) 43.3%, and 
in the whole group (n=518) 53%. 
 
3.1.1.4 CKD Stage. The 518 subjects on the database are divided into different 
groups in regard to their diagnosed CKD stage at recruitment. Subjects on 
haemodialysis are categorised as CKD stage 5. As being stage 3 or above was one 
of the inclusion criteria, only one CKD stage 2 subject is present in the database, 
whose results are deleted from analysis. 169 subjects are stage 3, 99 subjects are 
stage 4 and 247 subjects are stage 5. Of the subjects in the stage 5 group, 210 are 
recipients of maintenance haemodialysis at recruitment, which leaves 37 subjects 
(7% of entire cohort) with virtually no kidney function (eGFR below 15 mL/min/1.73 
m2) and no form of renal replacement therapy (figure 3.1.3).  
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Figure 3.1.3 Number of subjects in each group within the cohort of ESRD patients 
recruited. The CKD group (n=308) is broken down by CKD stage into CKD 3 
(n=170), CKD 4 (n=99) and CKD 5 (n=37), while the MHD group is a single group 
(n=210).    
 
3.1.1.5 Dialysis Adequacy. As stated above, of the 518 subjects within the 
database, 210 were on MHD at recruitment into the study. Dialysis adequacy, as 
measured by Kt/V was recorded for 166 (79%) of these. The mean Kt/V was 1.73 
units (range 0.92 – 2.80) ± 0.34, which is well above the target (1.3 units [29]). 
3.1.1.6 Ethnic Distribution. Ethnicity is recorded for 502 subjects (96.7% of the 
entire cohort). Of these 35.5% are of white background (British, Irish, or any other 
white), 19.5% are Asian (Indian, Pakistani, Bangladishi, or any other Asian), 17.7% 
are of black background (African, Caribbean, or any other black), 7.5% are of other 
ethnic background, 0.8% (4 subjects) have mixed background, and 15.8% have not 
disclosed their ethnicity to hospital records. 
In the CKD group ethnicity is recorded for 292 subjects (94.8% of entire group), and 
the distribution of present ethnicities in regards to frequency is slightly different from 
the whole cohort. The most prevalent ethnicity is still white (37.3%), but unlike the 
whole group analysis, the second is black (13.6%) and third is Asian (12.3%). In 
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comparison, the HD group has the biggest proportion of Asians (30.0%), although it 
still ranks second by only a small amount from the white population (32.4%). In the 
HD group, the blacks make up 23.8% of the population, which is again a bigger 
proportion than the previously mentioned groups (figure 3.1.4 and table 3.1.1). 
 
 
 
Figure 3.1.4 Ethnic distribution in each group within the cohort of ESRD patients 
recruited. The CKD group (n=308) consists of 115 (37.3%) white subjects, 42 
(13.6%) black African and black Caribbean, 38 (12.3%) Asian, 22 (7.6%) other 
ethnic background, and 75 (25.7%) subjects with unknown or undisclosed ethnic 
background. The MHD group (n=210) consists of 68 (32.4%) white subjects, 50 
(23.8%) black African and black Caribbean, 63 (30%) Asian, 21 (10%) other ethnic 
background, and 7 (3.3%) subjects with unknown or undisclosed ethnic 
background.   
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The characteristics of the study population in regards to the cardiovascular risk 
factors that were aimed to be analyzed are described at this point. In order to better 
understand the differences between the haemodialysed and the non-haemodialysed 
populations, these characteristics are broken down for the CKD and MHD groups. 
Analysis of each factor is summarized at the end of each section as a 2 panel figure 
consisting of box plots comparing distribution of the specific factor within the 
different subgroups (CKD and MHD as well as CKD 3, CKD 4, CKD 5 and MHD), 
and significant statistical differences are marked by asterisks (*). Comparison tables 
are also available for each factor in the appendix III.  
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3.1.1.7 Body Mass. Weight and height values at entry into study were recorded for 
476 subjects in the database and BMI was calculated accordingly. The minimum 
recorded BMI was 15 kg/m2 and the maximum recorded value is 54.3 kg/m2. The 
mean ± SD for BMI in this cohort is 27.5 ± 6.4 kg/m2. 
Comparing the CKD group and the MHD group, it is evident that the MHD group is 
lighter than the CKD group with the mean BMI at 25.3 ± 5.9 kg/m2 (range: 15.0 – 
44.0) for the MHD group (available for 201 subjects, 95.7%) and 29.1 ± 6.2 kg/m2 
(range: 16.3 – 54.3) for the CKD group (available for 263 subjects, 85.3%). The 
comparison of means (ANOVA) between these two groups shows statistically 
significant lower BMI in the MHD group with a p-value of <0.001. Analysis of BMI 
means between the different CKD stages, where MHD is classified as the final 
stage, showed mean BMI ± SD for CKD 3 at 29.9 ± 6.2 kg/m2, for CKD 4 at  29.1 ± 
6.3 kg/m2 and for CKD 5 at 26.0 ± 5.2 kg/m2.  Comparison of means (ANOVA) is 
still statistically significant in these subgroups (figure 3.1.5, and supplementary table 
1 available in appendix III). 
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A) 
 
 
B) 
 
Figure 3.1.5 Box and whisker plot comparing BMI value distribution. Panel A 
compares BMI in CKD and MHD groups (p<0.001) and panel B compares BMI 
between different CKD stages and MHD (p<0.001). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
99 
3.1.1.8 Blood Pressure. Last recorded value for both systolic and diastolic blood 
pressure were extracted from hospital records and recorded in the database. In the 
case of MHD patients, pre-dialysis blood pressure was used. Mean ± SD (range) for 
systolic blood pressure (available for 422 subjects, 81.3%) is 144.2 ± 22.4 (87.0 – 
229.0) mmHg and for diastolic blood pressure (available for 414 subjects, 79.8%) is 
77.2 ± 13.5 (47.0 – 123.0) mmHg. 
In the CKD group BP values were present for 241 subjects (78.2%), where the 
mean systolic BP (SBP) is 138.0 ± 18.1 mmHg (range: 93.0 – 199.0) and the mean 
diastolic BP (DBP) is 73.9 ± 12.1 mmHg (range: 47.0 – 123.0). In the MHD group 
BP values are available for 172 subjects (81.9%), and the mean systolic BP is 152.4 
± 25.0 mmHg (range: 87.0 – 229.0) while the mean diastolic BP is 81.7 ± 14.2 
mmHg (range: 48.0 – 120.0). The comparison of means (ANOVA) between these 
two groups shows statistically significant higher SBP and DBP in the MHD group 
with a p-value of <0.001 for both analyses. Analysis of SBP means between the 
different CKD stages, where MHD is classified as the final stage, showed mean 
SBP ± SD for CKD 3 at 137.2 ± 17.0 mmHg, for CKD 4 at 137.9 ± 18.9 mmHg and 
for CKD 5 at 143.1 ± 21.0 mmHg.  Comparison of means (ANOVA) is still 
statistically significant in these subgroups with p<0.001(figure 3.1.6 and 
supplementary table 2 available in appendix III). Analysis of mean DBP between the 
different CKD stages, where MHD is classified as the final stage, showed mean 
SBP ± SD for CKD 3 at 73.0 ± 11.7 mmHg, for CKD 4 at 74.7 ± 12.6 mmHg and for 
CKD 5 at 76.5 ± 12.1 mmHg.  Comparison of means (ANOVA) is still statistically 
significant in these subgroups with p<0.001(figure 3.1.7 and supplementary table 3 
available in appendix III). 
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A) 
 
 
B) 
 
Figure 3.1.6 Box and whisker plot comparing systolic BP value distribution. Panel A 
compares SBP in CKD and MHD groups (p<0.001) and panel B compares SBP 
between different CKD stages and MHD (p<0.001). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
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A) 
 
 
B) 
 
Figure 3.1.7 Box and whisker plot comparing diastolic BP value distribution. Panel 
A compares DBP in CKD and MHD groups (p<0.001) and panel B compares DBP 
between different CKD stages and MHD (p<0.001). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
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3.1.1.9 Lipids. To look at serum lipid status, data was collected in the form of total 
cholesterol, HDL cholesterol and triglycerides. Unfortunately, some physicians still 
prefer requesting total cholesterol and triglycerides instead of a complete lipid 
profile, which is why HDL values were only found for 310 subjects (60%). Total 
cholesterol values were present for 462 subjects (89%) and the mean total 
cholesterol for the entire cohort is 4.2 ± 1.3 mmol/l (range: 0.1 – 13.5), while 
triglyceride values are available for 448 subjects (86.5%) and the mean TG for the 
cohort is 1.78 ± 0.98 mmol/l (range: 0.31 – 6.0). 
Looking at lipid profiles in the CKD group, the mean total cholesterol (available for 
86% of the group) is 4.5 ± 1.5 mmol/l (range: 2.1 – 13.5). In the MHD group, the 
mean total cholesterol (available for 93% of the group) is 3.8 ± 0.95 mmol/l (range: 
0.1 – 6.5). The comparison of mean TC (ANOVA) between these two groups shows 
statistically significant lower TC in the MHD group with a p-value of <0.001. Analysis 
of mean TC between the different CKD stages, where MHD is classified as the final 
stage, showed mean TC ± SD for CKD 3 at 4.4 ± 1.3 mmol/l, for CKD 4 at 4.7 ± 1.7 
mmol/l and for CKD 5 at 4.3 ± 1.6 mmol/l.  Comparison of means (ANOVA) is still 
statistically significant in these subgroups with p<0.001(figure 3.1.8 and 
supplementary table 4 available in appendix III). 
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A) 
 
 
B) 
 
Figure 3.1.8 Box and whisker plot comparing total cholesterol value distribution. 
Panel A compares TC in CKD and MHD groups (p<0.001) and panel B compares 
TC between different CKD stages and MHD (p<0.001). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
104 
Looking at lipid profiles in the CKD group, the mean TG (available for 85%) is 1.86 ± 
1.06 mmol/l (range: 0.5 – 6.0). In the MHD group, the mean TG (available for 88%) 
is 1.67 ± 0.85 mmol/l (range: 0.31 – 5.09). The comparison of TG means (ANOVA) 
between these two groups is not statistically significant with a p-value of 0.051. 
Analysis of mean TG between the different CKD stages, where MHD is classified as 
the final stage, showed mean TG ± SD for CKD 3 at 1.81 ± 0.99 mmol/l, for CKD 4 
at 1.92 ± 1.12 mmol/l and for CKD 5 at 1.88 ± 1.17 mmol/l.  Comparison of means 
(ANOVA) is not statistically significant in these subgroups with p = 0.261 (figure 
3.1.9 and supplementary table 5 available in appendix III). 
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A) 
 
 
B) 
 
Figure 3.1.9 Box and whisker plot comparing triglycerides value distribution. Panel 
A compares TG in CKD and MHD groups (p=0.051) and panel B compares TG 
between different CKD stages and MHD (p=0.216). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
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3.1.1.10 Glycaemic Control. Glycaemic control as assessed by glycosylated 
haemoglobin (HbA1c) was recorded for subjects with diabetes at entry into study. 
Of the 275 subjects with diabetes in the cohort, 258 (94%) have a corresponding 
HbA1c value. The mean HbA1c in the total population is 7.3% ± 1.9% (range: 0.9% 
– 14.8%).  
The CKD group has 183 subjects with diabetes (59.4%) and 171 (93.4%) of these 
subjects have a corresponding HbA1c value. The mean HbA1c in the CKD 
population is 7.5% ± 2.0% (range: 0.9% – 14.8%), where mean haemoglobin level 
is 12.1 ± 1.6 g/dL (range: 7.2 – 16.5). In the MHD group, of the 91 subjects with 
diabetes (43.3% of MHD group) 86 (94.5%) have a corresponding HbA1c value. 
The mean HbA1c in the MHD population is 6.8% ± 1.6% (range: 4.5% – 13%), 
where mean haemoglobin level is 11.4 ± 1.4 g/dL (range: 7.6 – 15.3). The 
comparison of HbA1c means (ANOVA) between these two groups shows that the 
MHD group has significantly lower HbA1c with a p-value of 0.003. Analysis of mean 
HbA1c between the different CKD stages, where MHD is classified as the final 
stage, showed mean HbA1c ± SD for CKD 3 at 7.4 ± 1.7 %, for CKD 4 at 7.8 ± 2.4 
% and for CKD 5 at 7.0 ± 2.3 %.  Comparison of means (ANOVA) is still statistically 
significant in these subgroups with p = 0.009 (figure 3.1.10 and supplementary table 
6 available in appendix III).  
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A) 
 
 
B) 
 
 
Figure 3.1.10 Box and whisker plot comparing HbA1c value distribution. Panel A 
compares HbA1c in CKD and MHD groups (p=0.003) and panel B compares TG 
between different CKD stages and MHD (p=0.009). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
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3.1.1.11 Summary of group comparisons 
Comparison of mean BMI, blood pressure, total cholesterol, triglycerides and HbA1c 
between the CKD and MHD group revealed that the MHD group has significantly 
lower BMI, total cholesterol and HbA1c and significantly higher systolic and diastolic 
blood pressure. Only triglyceride levels were not significantly different between the 
two groups (table 3.1.2).  
 
 
 
Table 3.1.2 Summary of comparison of mean values for each risk factor in the two 
subgroups of CKD and MHD. „>‟ indicates higher mean values in the CKD subgroup 
while „<‟ indicates higher mean values in the MHD population, and „~‟ indicates no 
statistically significant difference.  
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3.1.2 Analysis of Primary Endpoint 
As the primary endpoint, predefined cardiovascular events data was gathered for 
subjects over the two year follow up period and risk analysis was carried out in 
regard to each of the predetermined risk factors. These included: myocardial 
infarction, aortocoronary bypass, percutaneous transluminal  coronary angioplasty, 
angiographically verified stenosis of the coronary arteries, stroke, or a symptomatic 
stenosis of the peripheral arterial vessels (carotids, aorto-iliac, or femoral arteries), 
admission to hospital with a primary diagnosis of „chronic ischaemic heart disease‟ 
or any other pre-existing condition that exasperated during the monitoring period.  
These analyses were carried out for the whole population as well as separately for 
CKD and MHD groups. The results in this section are described in that specific 
order: whole cohort, CKD group and then MHD group and are expressed as odds 
ratio (OR), 95% confidence interval (CI) and p-values. As mentioned in section 2.4, 
hazard ratios were also calculated for each risk factor using Cox regression 
analysis, and the results were in agreement with and very similar to logistic 
regression results (odds ratios). Although logistic regression was ultimately chosen 
for data presentation as it was statistically better suited to this population, calculated 
hazard ratios were used to draw the cumulative hazard plots presented in this 
section. 
Over the course of the 24-month follow up period, a total of 103 subjects reached a 
primary endpoint, bringing the event rate to nearly 20%. Of these, 47 subjects were 
in the CKD group and 56 subjects were in the MHD group, meaning the CV event 
rate in the CKD group was 15.3% while in the MHD group this was at 26.7% (figure 
3.1.11).  
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Figure 3.1.11 Follow-up data for each group within the cohort of ESRD patients 
recruited. In the combined cohort (n=518) 103 (19.9%) subjects had a CVE (primary 
endpoint) and 59 (11.4%) subjects died (secondary endpoints).The CKD group 
(n=308) had 47 (15.3%) CVEs and 21 (6.8%) deaths, while the MHD group (n=210) 
had 56 (26.7%) CVEs and 38 (18.1%) deaths.   
 
Results for each risk factor were calculated with and without adjusting for the 
confounding effect of pre-existing cardiovascular disease, but as this had negligible 
effect on the results, the adjusted results are not mentioned here (available in 
appendix section II). 
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3.1.2.1 Body Mass. The risk associated with increased BMI and CV events was 
calculated for the whole cohort using logistic regression. This did not show a 
significant impact of BMI on CV events, with an odds ratio (OR[BMI]) of 1.017 with 
the 95% confidence interval (CI) of OR between 0.984 and 1.050 and a p-value of 
0.318.  
In the CKD group, OR(BMI) = 1.037 with 95% CI of 0.988 and 1.088, p-value = 
0.137, and in the MHD group, OR(BMI) = 1.047 with 95% CI of 0.997 and 1.100, p-
value = 0.066. Figure 3.1.12 shows the distribution of BMI in CKD and MHD 
subgroups, categorised by whether they developed a CVE or not. Although BMI has 
not reached significance in predicting CV events in either group, the trends seems 
to be in the same direction, although as the lower limit of the CI is below 1 (even if 
slightly) means that we cannot conclude that this is in line with that of the general 
population where increased BMI increases the risk of CV events.  
  
112 
 
 
 
Figure 3.1.12 Box and whisker plot comparing BMI distribution between subjects 
who developed CVE and those who did not by subgroup. Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. 
 
To illustrate the effect of BMI on CVE risk, the cumulative hazard was plotted using 
the Cox regression calculations (available in appendix II). The subjects were 
classified as either overweight or not overweight, using the cut off point of 25 kg/m2. 
Figure 3.1.13 demonstrates the lack of effect of BMI on CVE risk.  These plots could 
not be drawn for the CKD and MHD subgroups due to the much smaller numbers. 
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Figure 3.1.13 Cumulative hazard plot for CVE in the whole cohort over time 
stratified by BMI above or below 25 kg/m2. There is no statistically significant 
difference between the two groups. 
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3.1.2.2 Blood Pressure. Both systolic and diastolic blood pressure were analysed 
to calculate the risk associated with each in regards to CV events.  
For systolic BP in the combined population, significant impact was seen on CV 
events, with an odds ratio (OR[SBP]) of 1.011 with the 95% confidence interval (CI) 
of OR between 1.002 and 1.021 and a p-value of 0.023. This can be interpreted as 
greater risk of CV events with increasing systolic BP in the group as whole, which 
follows the trend of the general population. 
When broken down for the CKD and MHD groups, however, systolic BP loses 
significant association with CV events, as in the CKD group, OR(SBP) = 1.012 with 
95% CI of 0.993 and 1.031, p-value = 0.217, and in the MHD group, OR(SBP) = 
1.001 with 95% CI of 0.989 and 1.014, p-value = 0.830. As the lower limit of the CI 
is less than 1, we cannot conclude that increase in systolic BP leads to an increase 
in CV events. 
For diastolic BP in the combined population, no significant impact was seen on CV 
events, with an odds ratio (OR[DBP]) of 1.004 with the 95% confidence interval (CI) 
of OR between 0.989 and 1.021 and a p-value of 0.560.  
In the CKD group, OR(DBP) = 1.000 with 95% CI of 0.972 and 1.028, p-value = 
0.981, and in the MHD group, OR(DBP) = 0.988 with 95% CI of 0.967 and 1.010, p-
value = 0.299. The fact that the OR in the MHD group is below 1 indicates that 
diastolic blood pressure may be inversely associated with CV events, and although 
this result is not significant its direction is important and in line with reverse 
epidemiology. Figure 3.1.14 shows the distribution of SBP and DBP in CKD and 
MHD subgroups, categorised by whether they developed a CVE or not. 
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A) 
 
 
B) 
 
Figure 3.1.14 Box and whisker plot comparing SBP and DBP distribution between 
subjects who developed CVE and those who did not in the CKD (panel A) and MHD 
(panel B) subgroups. Box and whiskers indicate median and interquartile range, 
while outliers are shown as circles.  
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To illustrate the effect of SBP and DBP on CVE risk, the cumulative hazard was 
plotted using the Cox regression calculations (available in appendix II). The subjects 
were classified as either hypertensive or not, with 140 mmHg as the upper limit of 
normal for SBP and 90 mmHg as the upper limit for DBP. Figure 3.1.15 
demonstrates the hazard plots for CVE in regards to SBP and DBP.  These plots 
could not be drawn for the CKD and MHD subgroups due to the much smaller 
numbers. 
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A) 
 
 
B) 
 
Figure 3.1.15 Cumulative hazard plot for CVE in the whole cohort over follow-up 
time in months stratified by SBP cut off of 140.0 mmHg (panel A) and DBP cut off of 
90.0 mmHg (panel B). Subjects with higher SBP have a significantly higher risk of 
CVE (p=0.023). 
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3.1.2.3 Lipids. Both total cholesterol (TC) and triglycerides (TG) were analysed to 
calculate the risk associated with each in regards to CV events. 
For TC in the combined population, significant impact was seen on CV events, with 
an odds ratio (OR[TC]) of 0.681 with the 95% confidence interval (CI) of OR 
between 0.550 and 0.844 and a p-value of <0.001. This means that increase in TC 
reduces the risk of CV events; in other words, increased TC or 
hypercholesterolaemia is protective against CV events. This is contrary to a rich 
body of literature that identifies hypercholesterolaemia as a definite CV risk factor in 
the general population. 
When broken down for the two groups, in the CKD group, OR(TC) = 0.589 with 95% 
CI of 0.419 and 0.828, p-value = 0.002, and in the MHD group, OR(TC) = 0.924 with 
95% CI of 0.676 and 1.262, p-value = 0.619. This means that the trend observed in 
the whole group is probably led by the effect of TC on CV events in the CKD group, 
as this subgroup demonstrates significant reverse relationship with CV events, while 
the MHD subgroup does not. However, the fact that the OR in the MHD group is 
also below 1, and the lower limit of the CI is well below 1, means we cannot 
conclude that increase in TC leads to an increase in CV events in this subgroup. 
For TG in the combined population, no significant impact was seen on CV events, 
with an odds ratio (OR[TG]) of 0.897 with the 95% confidence interval (CI) of OR 
between 0.717 and 1.123 and a p-value of 0.344.  
When broken down for the two groups, in the CKD group, OR(TG) = 0.921 with 95% 
CI of 0.679 and 1.248, p-value = 0.594, and in the MHD group, OR(TG) = 0.952 
with 95% CI of 0.667 and 1.357, p-value = 0.784. The fact that the OR below 1 in 
both groups means that we cannot conclude that increase in TG leads to an 
increase in CV events these subgroups. In fact, TG seems to be mimicking the 
trend of TC in both groups, with stronger tendency toward being protective in the 
CKD group and less so but in the same direction in the MHD group. Figure 3.1.16 
shows the distribution of TC and TG in CKD and MHD subgroups, categorised by 
whether they developed a CVE or not. 
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A) 
 
 
B) 
 
Figure 3.1.16 Box and whisker plot comparing TC and TG distribution between 
subjects who developed CVE and those who did not in the CKD (panel A) and MHD 
(panel B) subgroups. Box and whiskers indicate median and interquartile range, 
while outliers are shown as circles.  
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To illustrate the effect of TC and TG on CVE risk, the cumulative hazard was plotted 
using the Cox regression calculations (available in appendix II). The subjects were 
classified as either above or below the median value for TC (4.00 mmol/l) and TG 
(1.53 mmol/l) in the cohort. Figure 3.1.17 demonstrates the hazard plots for CVE in 
regards to TC and TG.  These plots could not be drawn for the CKD and MHD 
subgroups due to the much smaller numbers. 
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A) 
 
 
B) 
 
Figure 3.1.17 Cumulative hazard plot for CVE in the whole cohort over follow-up 
time in months stratified by TC cut off of 4.00 mmol/l (panel A) and TG cut off of 
1.53 mmol/l (panel B). Subjects with higher TC have a significantly lower risk of 
CVE (p<0.001). 
  
122 
It is important to rule out the effect of lipid-lowering drugs, specifically statins, when 
looking at outcomes in relation to lipid levels. In the present study, to rule out the 
effects of statin therapy, the differences between the MHD and CKD groups in 
relation to statin use and lipid levels were analysed. The results showed similar TC 
and TG levels in those on statin therapy and not on statin therapy in both groups 
(Figure 3.1.18).  
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A) 
 
 
B) 
  
Figure 3.1.18 Box and whisker plot of TC (panel A) and TG (panel B) values in the 
CKD and MHD group in regards to statin use, where TC and TG values are 
expressed as mmol/l. Box and whiskers indicate median and interquartile range, 
while outliers are shown with corresponding identification numbers. Distribution is 
almost identical in the different subgroups.  
  
124 
Furthermore, the hazard ratio for CVE was plotted over time stratifying by presence 
or absence of statin therapy to look at its effect on the primary endpoint (figure 
3.1.19). It is evident by looking at this plot that statin therapy does not have a 
significant effect on CVE in this cohort (Hazard Ratio: 1.145, 95%CI: 0.715, 1.834, 
p=0.574 for CVE). 
 
 
Figure 3.1.19 Cumulative hazard plot for CVE in the whole cohort over follow-up 
time in months stratified by statin use. There was no statistically significant 
difference between the two groups in regard to risk of CVE. 
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3.1.2.4 Diabetes. The risk associated with the presence of diabetes and CV events 
was significant, with an odds ratio (OR[DM]) of 1.622 with the 95% CI between 
1.074 and 2.449 and a p-value of 0.021 in the whole cohort.  
In the CKD group, OR(DM) = 1.488 with 95% CI of 0.792 and 2.795, p-value = 
0.217, and in the MHD group, OR(DM) = 2.538 with 95% CI of 1.417 and 4.546, p-
value = 0.002. This shows that in the MHD group, the presence of diabetes 
increases the risk of CV events significantly. Similarly, the CKD group results imply 
that the presence of diabetes increases the risk of CV events, although this finding 
does not reach statistical significance and the lower limit of the 95% CI s below 1, 
which means that this result is inconclusive. 
To illustrate the effect of diabetes on CVE risk, the cumulative hazard was plotted 
using the Cox regression calculations (available in appendix II). Figure 3.1.20 
demonstrates the hazard plot for CVE in regards to diabetic status.  This plot could 
not be drawn for the CKD and MHD subgroups due to the much smaller numbers. 
 
 
Figure 3.1.20 Cumulative hazard plot for CVE in the whole cohort over follow-up 
time in months stratified by diabetes status. Subjects with diabetes have a 
significantly higher risk of CVE (p = 0.021).  
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3.1.2.5 Summary of regression analyses for primary endpoint 
Regression analyses were carried out to determine odds ratios (OR) for CVE in 
regard to the risk factors in question: BMI, blood pressure, total cholesterol, 
triglycerides and diabetes. In the combined cohort, high systolic BP had a significant 
effect in increasing the risk of CVE, which is similar to observations in the general 
population. The other significant result in this group was the effect of increasing TC 
in reducing the risk of CVE, which is in contrast to what is observed in the general 
population and can be described as reverse epidemiology. A summary of the 
regression analyses in the whole cohort is available in table 3.1.3 below.  
 
 
 
Table 3.1.3 Summary of regression analyses results for primary endpoint (CVE) in 
the combined cohort, looking at the effects of all the factors studied. 
 
In the CKD subgroup the only statistically significant finding was the effect of 
increasing TC in reducing the risk of CVE, which is again contrary to what is 
observed in the general population and can be described as reverse epidemiology. 
A summary of the regression analyses in the CKD subgroup is available in table 
3.1.4.  
 
 
 
127 
 
 
Table 3.1.4 Summary of regression analyses results for primary endpoint (CVE) in 
the CKD subgroup, looking at the effects of all the factors studied. 
 
In the MHD subgroup the only statistically significant finding was the effect of 
presence of diabetes which significantly increases the risk of CVE. This is similar to 
observations in the general population, and can therefore be described as classic 
epidemiology. A summary of the regression analyses in the MHD subgroup is 
available in table 3.1.5 below.  
 
 
Table 3.1.5 Summary of regression analyses results for primary endpoint (CVE) in 
the MHD subgroup, looking at the effects of all the factors studied.  
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3.1.3 Analysis of Secondary Endpoint 
Mortality was defined as our secondary, or perhaps better to say exploratory, 
endpoint. Date of death as well as cause of death data was gathered for subjects 
over the two year follow up period and risk analysis was carried out in regard to 
each of the predetermined risk factors. Again, these analyses were carried out for 
the whole population as well as separately for CKD and MHD groups. The results in 
this section are described in that specific order: whole cohort, CKD group and then 
MHD group and are expressed as odds ratio (OR), 95% confidence interval (CI) and 
p-values.  
Over the course of the 24-month follow up period, a total of 59 subjects reached a 
primary endpoint, bringing the death rate to 11.4%. Of these, 21 subjects were in 
the CKD group and 38 subjects were in the MHD group, meaning the death rate in 
the CKD group was 6.8% while in the MHD group this was at 18.1% (see figure 
3.1.11).  
Results for each risk factor were calculated with and without adjusting for the 
confounding effect of pre-existing cardiovascular disease, but as this had negligible 
effect on the results, the adjusted results are not mentioned here.  
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3.1.3.1 Body Mass. The mortality risk associated with increased BMI was 
calculated for the whole cohort using logistic model. This did not show a significant 
impact for BMI on mortality, with an odds ratio (OR[BMI]) of 0.982 with the 95% 
confidence interval (CI) of HR between 0.937 and 1.028 and a p-value of 0.428 in 
the combined cohort.  
In the CKD group, OR(BMI) = 1.028 with 95% CI of 0.955 and 1.105, p-value = 
0.465, and in the MHD group, OR(BMI) = 0.994 with 95% CI of 0.934 and 1.059, p-
value = 0.856. As evident, BMI did not reach significance in predicting mortality in 
either group, and because the OR for the MHD group is below 1 while the OR for 
the CKD group is above 1, we cannot conclude that the relationship between BMI 
and mortality in the two groups is in a similar direction. Figure 3.1.21 shows the 
distribution of BMI in CKD and MHD subgroups, categorised by whether they 
developed a CVE or not. 
 
 
Figure 3.1.21 Box and whisker plot comparing BMI distribution between subjects 
who died and those who did not by subgroup. Box and whiskers indicate median 
and interquartile range, while outliers are shown as circles. 
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To illustrate the effect of BMI on risk of mortality, the cumulative hazard was plotted 
using the Cox regression calculations (available in appendix II). The subjects were 
classified as either overweight or not overweight, using the cut off point of 25 kg/m2. 
Figure 3.1.22 demonstrates the lack of effect of BMI on risk of mortality.  This plot 
could not be drawn for the CKD and MHD subgroups due to the much smaller 
numbers. 
 
 
 
Figure 3.1.22 Cumulative hazard plot for mortality in the whole cohort over time 
stratified by BMI above or below 25 kg/m2. There is no statistically significant 
difference between the two groups. 
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3.1.3.2 Blood Pressure. Both systolic and diastolic blood pressure were analysed 
to calculate the risk associated with each in regards to mortality.  
For systolic BP in the whole cohort, the calculations showed an odds ratio 
(OR[SBP]) of 1.010 with the 95% confidence interval (CI) of OR between 0.997 and 
1.023 and a p-value of 0.146. This shows no significant impact of systolic BP on 
mortality in the cohort. 
When broken down for the CKD and MHD groups, however, systolic BP gains 
significant association with mortality in the CKD group, with OR(SBP) = 0.958 and 
95% CI of 0.926 and 0.990, p-value = 0.011, in the direction opposite that of the 
general population. In the MHD group, OR(SBP) = 1.013 with 95% CI of 0.998 and 
1.029, p-value = 0.095, and although this result does not reach significance, its 
importance is in its direction, which is opposite that of the CKD group and therefore 
in line with that of the general population. 
For diastolic BP in the whole cohort, no significant impact was seen on mortality, 
with an OR(DBP) of 0.985 with the 95% confidence interval (CI) of OR between 
0.962 and 1.009 and a p-value of 0.230.  
In the CKD group, OR(DBP) = 0.929 with 95% CI of 0.879 and 0.982, p-value = 
0.010, which is reflecting the results of systolic BP in this group. In the MHD group, 
OR(DBP) = 0.986 with 95% CI of 0.958 and 1.014, p-value = 0.327, this result does 
not reach significance (as for systolic BP in this group), but of note is that its 
direction is not similar to that of systolic BP in this group. Figure 3.1.23 shows the 
distribution of SBP and DBP in CKD and MHD subgroups, categorised by whether 
they reached a secondary endpoint or not. 
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Figure 3.1.23 Box and whisker plot comparing SBP and DBP distribution between 
subjects who died and those who did not in the CKD (panel A) and MHD (panel B) 
subgroups. Box and whiskers indicate median and interquartile range, while outliers 
are shown as circles. 
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To illustrate the effect of SBP and DBP on risk of mortality, the cumulative hazard 
was plotted using the Cox regression calculations (available in appendix II). The 
subjects were classified as either hypertensive or not, with 140 mmHg as the upper 
limit of normal for SBP and 90 mmHg as the upper limit for DBP. Figure 3.1.24 
demonstrates the hazard plots for death in regards to SBP and DBP.  These plots 
could not be drawn for the CKD and MHD subgroups due to the much smaller 
numbers. 
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Figure 3.1.24 Cumulative hazard plot for mortality in the whole cohort over follow-
up time in months stratified by SBP cut off of 140.0 mmHg (panel A) and DBP cut 
off of 90.0 mmHg (panel B). There is no statistically significant difference between 
the two groups for either factor. 
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3.1.3.3 Lipids. Both total cholesterol (TC) and triglycerides (TG) were analysed to 
calculate the risk associated with each in regards to mortality. 
For TC in the combined cohort, significant impact was seen on mortality, with an 
OR(TC) of 0.635 with the 95% confidence interval (CI) of OR between 0.466 and 
0.864 and a p-value of 0.004. This suggests that increase in TC reduces the risk of 
mortality, which is similar to the finding in regard to CV risk, and contrary to what is 
seen in the general population. 
In the CKD group, OR(TC) = 0.500 with 95% CI of 0.284 and 0.880, p-value = 
0.016, and in the MHD group, OR(TC) = 0.864 with 95% CI of 0.576 and 1.296, p-
value = 0.480. This shows that what we see in the whole group is probably being 
led by the CKD group, as this group shows significant lowering of mortality risk with 
increased TC, while the MHD group does not follow this trend. 
For TG in the combined cohort, a significant impact was seen on mortality, with an 
odds ratio (OR[TG]) of 0.504 with the 95% confidence interval (CI) of OR between 
0.322 and 0.788 and a p-value of 0.003. This means that increased TG are 
associated with lower risk of death in our study population.  
When TG is broken down in the two groups, in the CKD group, OR(TG) = 0.468 with 
95% CI of 0.219 and 0.998, p-value = 0.049, and in the MHD group, OR(TG) = 
0.546 with 95% CI of 0.310 and 0.964, p-value = 0.037. As evident from these 
results, increased TG in both groups leads to a decreased risk of mortality. Figure 
3.1.25 shows the distribution of TC and TG in CKD and MHD subgroups, 
categorised by whether they developed a secondary endpoint or not. 
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Figure 3.1.25 Box and whisker plot comparing TC and TG distribution between 
subjects who died and those who did not in the CKD (panel A) and MHD (panel B) 
subgroups. Box and whiskers indicate median and interquartile range, while outliers 
are shown as circles. 
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To illustrate the effect of TC and TG on risk of mortality, the cumulative hazard was 
plotted using the Cox regression calculations (available in appendix II). The subjects 
were classified as either above or below the median value for TC (4.00 mmol/l) and 
TG (1.53 mmol/l) in the cohort. Figure 3.1.26 demonstrates the hazard plots for 
CVE in regards to TC and TG.  These plots could not be drawn for the CKD and 
MHD subgroups due to the much smaller numbers. 
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A) 
 
 
B) 
 
 
Figure 3.1.26 Cumulative hazard plot for mortality in the whole cohort over follow-
up time in months stratified by TC cut off of 4.00 mmol/l (panel A) and TG cut off of 
1.53 mmol/l (panel B). Subjects with higher TC have significantly lower risk of death 
(p=0.004) and subjects with higher TG also have a lower risk of death (p=0.003). 
139 
Furthermore, the hazard ratio for death was plotted over time stratifying by 
presence or absence of statin therapy to look at its effect on the secondary endpoint 
(figure 3.1.27). It is evident by looking at this plot that statin therapy does not have a 
significant effect on CVE in this cohort (Hazard Ratio: 1.540, 95%CI: 0.780, 3.041, 
p=0.213 for mortality). 
 
 
 
Figure 3.1.27 Cumulative hazard plot for mortality in the whole cohort over follow-
up time in months stratified by statin use. There is no statistically significant 
difference between the two groups in regard to risk of death. 
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3.1.3.4 Diabetes. The risk associated with the presence of diabetes and mortality 
was significant, with an OR(DM) of 1.869 with the 95% CI between 1.047 and 3.334 
and a p-value of 0.034.  
For diabetes, in the CKD group OR(DM) = 3.846 with 95% CI of 1.101 and 13.433, 
p-value = 0.035, and in the MHD group OR(DM) = 2.032 with 95% CI of 0.997 and 
4.146, p-value = 0.051. This shows that while in the CKD group, the presence of 
diabetes increases the risk of mortality significantly, the MHD group results lose 
statistical significance and fall just below the cut-off point, implying that the 
presence of diabetes does increase the risk of mortality in this group, as well. 
To illustrate the effect of diabetes on risk of death, the cumulative hazard was 
plotted using the Cox regression calculations (available in appendix II). Figure 
3.1.28 demonstrates the hazard plot for mortality in regards to diabetic status.  This 
plot could not be drawn for the CKD and MHD subgroups due to the much smaller 
numbers. 
 
 
Figure 3.1.28 Cumulative hazard plot for mortality in the whole cohort over follow-
up time in months stratified by diabetes status. Subjects with diabetes have a 
significantly higher risk of death (p = 0.034). 
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3.1.3.5 Summary of regression analyses for secondary endpoint 
Regression analyses were carried out to determine odds ratios (OR) for mortality in 
regard to the risk factors in question: BMI, blood pressure, total cholesterol, 
triglycerides and diabetes. In the combined cohort, high TC had a significant effect 
in reducing the risk of death, which is in contrast to what is observed in the general 
population and can be described as reverse epidemiology. The same situation 
applied to TG, where its increase resulted significant lowering of risk of death. The 
other significant result in this group was the effect of presence of diabetes in 
increasing the risk of death, which is in similar to what is observed in the general 
population and can be described as classic epidemiology. A summary of the 
regression analyses in the whole cohort is available in table 3.1.6 below.  
 
 
Table 3.1.6 Summary of regression analyses results for secondary endpoint (death) 
in the combined cohort, looking at the effects of all the factors studied. 
 
In the CKD subgroup, both high systolic and diastolic BP had a significant effect in 
decreasing the risk of death, which is in contrast to observations in the general 
population, and therefore can be described as reverse epidemiology. Increasing TC 
and TG also both decrease the risk of death in this group, which is also in contrast 
to what is observed in the general population and can be described as reverse 
epidemiology. The final significant result in the CKD group was the effect of 
presence of diabetes which increased the risk of death, which is similar to what is 
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observed in the general population and can be described as classic epidemiology. A 
summary of the regression analyses in the CKD subgroup is available in table 3.1.7.  
 
 
Table 3.1.7 Summary of regression analyses results for secondary endpoint (death) 
in the CKD subgroup, looking at the effects of all the factors studied. 
 
In the MHD subgroup, increasing TG resulted lowering of risk of mortality, which is 
contrary to what is observed in the general population, and therefore can be 
described as reverse epidemiology. The result for this effect was not statistically 
significant for TC in the MHD group. The other statistically significant finding in the 
MHD group was the effect of presence of diabetes which significantly increased the 
risk of death. This is similar to observations in the general population, and can 
therefore be described as classic epidemiology. A summary of the regression 
analyses in the MHD subgroup is available in table 3.1.8.  
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Table 3.1.8 Summary of regression analyses results for secondary endpoint (death) 
in the MHD subgroup, looking at the effects of all the factors studied.  
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3.1.3.6 Other risk factors 
Ethnicity. The ethnic diversity of the present cohort allows for detailed analysis of 
the effects of ethnicity on both primary and secondary endpoints. Cox regression 
analysis for effects of ethnicity on CVE shows the „Black‟ ethnic group to have the 
highest risk of developing CVEs (Hazard Ratio=6.154, 95%CI: 2.141, 17.684, 
p=0.001), while the „White‟ ethnic group has the highest risk for mortality (Hazard 
Ratio=10.558, 95%CI: 1.388, 80.314, p=0.023) (figure 3.1.29).  
It is interesting that in this population, the White ethnic group has the lowest risk of 
CVE but the highest risk of mortality, and this is almost completely opposite the 
Black ethnic group, who have the highest risk for CVE but the lowest risk for 
mortality (after Mixed and Unknown ethnic groups). 
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A) 
 
 
B) 
 
Figure 3.1.29 Cumulative hazard ratio for CVE (panel A) and mortality (panel B) in 
the whole cohort over follow-up time in months stratified by ethnicity; statistically 
significant HRs for CVE are: White: HR=5.075, 95%CI:1.813,14.205, p=0.002, 
Black: HR=6.154, 95%CI: 2.141, 17.684, p=0.001, Asian: HR=5.220, 95%CI: 1.798, 
15.151, p=0.002, Other: HR=5.307, 95%CI: 1.634, 17.235, p=0.005 and the only 
statistically significant HRs for mortality are for the White group: HR=9.135, 95%CI: 
2.191, 38.080, p=0.002 and for the Other group: HR=9.074, 95%CI: 2.105, 39.112, 
p=0.003. 
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When the population is broken down into the subgroups, regression analyses show 
that the risk of CVE is higher among the Black ethnic group in comparison to the 
White ethnic group in both the CKD and MHD groups. Figure 3.1.30 illustrates risk 
of CVE stratified by ethnicity (significant hazard ratios available in the figure 
legend).  
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A) 
 
 
B) 
 
Figure 3.1.30 Cumulative hazard ratio for CVE in the CKD (panel A) and MHD 
(panel B) subgroups over follow-up time in months stratified by ethnicity; statistically 
significant HRs for the CKD group are: White: HR=5.672, 95%CI:1.702, 18.890, 
p=0.005, Black: HR=6.419, 95%CI: 1.766, 23.328, p=0.005, and there are no 
statistically significant HRs for the MHD group. 
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White ethnicity has the highest risk of mortality in both CKD and MHD groups, 
although the risk is greater in the MHD group, and Black ethnicity has much lower 
risk in both groups in comparison. Figure 3.1.31 illustrates risk of mortality stratified 
by ethnicity (significant hazard ratios available in the figure legend).  
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A) 
 
B) 
 
Figure 3.1.31 Cumulative hazard ratio for mortality in the CKD (panel A) and MHD 
(panel B) subgroups over follow-up time in months stratified by ethnicity; the 
statistically significant HR for the CKD group is the White group: HR=10.558, 
95%CI:1.388, 80.314, p=0.023 and there are no statistically significant hazard ratios 
for mortality in the MHD group. 
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3.2 Sub-cohort Study: Insulin Resistance and Inflammation in ESRD 
A subgroup of the cohort (dubbed „the sub-cohort‟) was recruited and asked to 
donate blood samples for quantification of insulin resistance, inflammation and total 
adiponectin. 106 subjects were recruited, 56 from the CKD subgroup and 50 from 
the MHD subgroup. While insulin resistance was quantified by the HOMA-IR model 
in all of these subjects, hs-CRP and total adiponectin levels were only available for 
92 of the subjects, 47 of which belonged to the CKD subgroup and 44 were from the 
MHD subgroup.  
3.2.1 Distributions and comparison of subgroups 
3.2.1.1 Insulin Resistance (HOMA-IR). Insulin resistance was quantified in a 
subgroup of patients using the HOMA model (explained in section 1.2.1.6). The aim 
was to measure insulin resistance in 50 CKD patients, 50 MHD patients and 10 
patients about to start MHD, where the latter group would be re-measured after 8 
weeks into HD. 
HOMA-IR was measured for 106 subjects in total. The overall mean ± SD (range) 
HOMA-IR was 2.08 ± 2.02 (0.40 – 11.50); 56 subjects were in the CKD group where 
the overall mean ± SD (range) HOMA-IR was 2.63 ± 2.31 (0.40 – 11.50), and 50 
subjects were in the MHD group whose overall mean ± SD (range) HOMA-IR was 
1.50 ± 1.46 (0.40 – 6.60).  Comparison of mean HOMA-IR between CKD and MHD 
groups was significant, with p = 0.004. HOMA-IR values were also compared 
between subjects with and without diabetes. In the diabetic group, mean ± SD 
HOMA-IR was 2.94 ± 2.34 and in the non-diabetic group mean ± SD HOMA-IR was 
1.22 ± 1.13. Comparison of mean HOMA-IR between the two groups was 
significant, with p < 0.001. Comparison of mean HOMA-IR between the different 
CKD stages, where MHD is classified as the final stage, showed mean HOMA-IR ± 
SD for CKD 3 at 1.78 ± 1.30, for CKD 4 at 2.52 ± 2.73 and for CKD 5 at 3.57 ± 2.33.  
Comparison of means (by Kruskal-Wallis test, as data not normally distributed in the 
smaller subgroups) is statistically significant in these subgroups, p=0.001 (figure 
3.2.1 and supplementary table 7 available in appendix III). 
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A) 
 
 
B) 
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C) 
 
Figure 3.2.1 Box and whisker plot comparing HOMA-IR value distribution. Panel A 
compares HOMA-IR in CKD and MHD groups (p=0.004) and panel B compares 
HOMA-IR between subjects with and without diabetes (p<0.001) and panel C 
compares HOMA-IR between different CKD stages and MHD (p=0.001). Box and 
whiskers indicate median and interquartile range, while outliers are shown with 
corresponding identification numbers. Horizontal bars indicate comparison of means 
between groups and ** indicates statistically significant finding. 
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3.2.1.2 Inflammation (hs-CRP). High sensitivity C-reactive protein (hsCRP) was 
used to quantify inflammation for 92 subjects in total. Of these, 47 subjects were 
classified into the CKD subgroup and 44 into the MHD subgroup.  
The mean value ± SD for hs-CRP in the whole sub-cohort was 8.92 ± 18.95 mg/l 
with a range of 0.17 mg/l to 157.13 mg/l. In the CKD subgroup within the sub-
cohort, the mean value ± SD for hs-CRP was 5.62 ± 11.35 mg/l with a range of 0.19 
mg/l to 72.47 mg/l, while in the MHD subgroup of the sub-cohort it was 12.64 ± 
24.37 mg/l with a range of 0.37 mg/l to 157.13 mg/l. The difference between the 
CKD and MHD groups within the sub-cohort was not statistically significant, with p = 
0.103. Comparison of mean hs-CRP between the different CKD stages, where MHD 
is classified as the final stage, showed mean hs-CRP ± SD for CKD 3 at 7.97 ± 
17.57 mg/l, for CKD 4 at 5.43 ± 7.62 mg/l and for CKD 5 at 2.98 ± 3.28 mg/l.  
Comparison of means is statistically significant in these subgroups, p=0.003 (figure 
3.2.2 and supplementary table 8 available in appendix III). As hs-CRP was not 
normally distributed in this sub-cohort (Shapiro-Wilk test, p<0.001), the Kruskal 
Wallis non-parametric test was used to compare means between subgroups 
(instead of the ANOVA, which assumes normality). For comparison between the 
larger subgroups, the student‟s t-test was used [466].  
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A) 
 
 
B) 
 
Figure 3.2.2 Box and whisker plot comparing hs-CRP value distribution. Panel A 
compares hs-CRP in CKD and MHD groups (p=0.103) and panel B compares hs-
CRP between different CKD stages and MHD (p=0.003). Box and whiskers indicate 
median and interquartile range, while outliers are shown with corresponding 
identification numbers. Horizontal bars indicate comparison of means between 
groups and ** indicates statistically significant finding. 
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3.2.1.3 Total Adiponectin. Serum total adiponectin was measured for 92 subjects 
in total. Of these, 47 subjects were classified into the CKD subgroup and 44 into the 
MHD subgroup.  
The mean value ± SD for total adiponectin in the whole sub-cohort was 46.56 ± 
25.73 ug/ml with a range of 9.3 ug/ml to 150.00 ug/ml. The CKD group within the 
sub-cohort had a mean ± SD of 47.92 ± 25.78 ug/ml with a range of 10.80 ug/ml to 
149.10 ug/ml, while the MHD group within the sub-cohort had a mean ± SD of 45.08 
± 26.20 ug/ml with a range of 9.30 ug/ml to 150.00 ug/ml. The difference between 
the CKD and MHD groups within the sub-cohort was not statistically significant, with 
p = 0.861. Comparison of mean total adiponectin between the different CKD stages, 
where MHD is classified as the final stage, showed mean total adiponectin ± SD for 
CKD 3 at 39.67 ± 32.54 ug/ml, for CKD 4 at 50.81 ± 21.48 ug/ml and for CKD 5 at 
54.05 ± 20.64 ug/ml.  Comparison of means is between the CKD stages did not 
reveal statistically significant difference when the MHD group was included as the 
final stage of CKD (p = 0.060), but the difference was statistically significant when 
the comparison was made only between CKD stage 3 to 5, excluding MHD (p = 
0.041) (figure 3.2.3 and supplementary table 9 available in appendix III). 
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B) 
 
Figure 3.2.3 Box and whisker plot comparing total adiponectin value distribution. 
Panel A compares total adiponectin in CKD and MHD groups (p=0.861) and panel B 
compares total adiponectin between different CKD stages (p=0.041) as well as with 
MHD (p=0.060). Box and whiskers indicate median and interquartile range, while 
outliers are shown with corresponding identification numbers. Horizontal bars 
indicate comparison of means between groups and ** indicates statistically 
significant finding. 
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3.2.1.4 Summary of group comparisons 
Comparison of mean HOMA-IR, hs-CRP and total adiponectin between the CKD 
and MHD groups within the sub-cohort revealed that the MHD group has 
significantly lower HOMA-IR, and other factors did not differ significantly between 
the two groups (table 3.2.1).  
 
 
 
Table 3.2.1 Summary of comparison of mean values for each potential risk factor in 
the two subgroups of CKD and MHD within the sub-cohort. „>‟ indicates higher 
mean values in the CKD subgroup while „<‟ indicates higher mean values in the 
MHD population, and „~‟ indicates no statistically significant difference. 
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3.2.2 Analysis of Primary Endpoint 
The follow-up data gathered for the cohort study was used for the subjects in the 
sub-cohort study to determine the effect of HOMA-IR, hs-CRP and total adiponectin 
on the primary endpoint, predefined cardiovascular events. These events included: 
myocardial infarction, aortocoronary bypass, percutaneous transluminal  coronary 
angioplasty, angiographically verified stenosis of the coronary arteries, stroke, or a 
symptomatic stenosis of the peripheral arterial vessels (carotids, aorto-iliac, or 
femoral arteries), admission to hospital with a primary diagnosis of „chronic 
ischaemic heart disease‟ or any other pre-existing condition that exasperated during 
the monitoring period.  
These analyses were carried out for the whole sub-cohort as well as separately for 
CKD and MHD groups within the sub-cohort. The results in this section are 
described in the same order as in section 3.1.2 (risk analysis of primary endpoints in 
the entire population studied): whole sub-cohort, CKD subgroup and then MHD 
subgroup and are expressed as odds ratio (OR), 95% confidence interval (CI) and 
p-values. As mentioned in section 2.4, hazard ratios were also calculated for each 
risk factor using Cox regression analysis, and the results were in agreement with 
and very similar to logistic regression results (odds ratios). Although logistic 
regression was ultimately chosen for data presentation as it was statistically better 
suited to this population, calculated hazard ratios were used to draw the cumulative 
hazard plots presented in this section. 
Over the course of the 24-month follow up period, a total of 23 subjects (out of 106) 
reached a primary endpoint in the sub-cohort, bringing the event rate to 21.6%. Of 
these, 12 subjects were in the CKD subgroup (out of a total 55 subjects in this 
group) and 11 subjects were in the MHD subgroup (out of the total 51 subjects in 
this group), meaning the CV event rate was almost identical between these two 
subgroups, with the CKD group event rate at 21.8% and the MHD group event rate 
at 21.6% (figure 3.2.4).  
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Figure 3.2.4 Follow-up data for each group within the sub-cohort. In the combined 
sub-cohort (n=106) 23 (21.6%) subjects had a CVE (primary endpoint) and 6 (5.6%) 
subjects died (secondary endpoints).The CKD subgroup (n=55) had 12 (21.8%) 
CVEs and 3 (5.5%) deaths, while the MHD subgroup (n=51) had 11 (21.6%) CVEs 
and 3 (5.9%) deaths.   
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3.2.2.1 HOMA-IR. The odds ratio (OR) for cardiovascular event in regard to HOMA-
IR in the sub-cohort was calculated at 1.171, with a 95% CI of 0.937 and 1.464, and 
a p-value of 0.165; this result is not significant and we cannot conclude whether an 
increase in HOMA-IR value causes an increase or decrease in the risk of suffering a 
CV event.  
In the CKD group within the sub-cohort, the odds ratio (OR) for cardiovascular 
events in regard to HOMA-IR was 1.315, with a 95% CI of 0.963 and 1.796 and a p-
value of 0.085; although statistically insignificant, this result suggests that an 
increase in HOMA-IR value may cause an increase in the risk of suffering a CV 
event. The odds ratio (OR) for CVE in regard to HOMA-IR in the MHD group within 
the sub-cohort was 0.996, with a 95% CI of 0.655 and 1.513 and a p-value of 0.986; 
this result is inconclusive on whether an increase in HOMA-IR value causes an 
increase or a decrease in the risk of suffering a CV event.  
Figure 3.2.5 shows the distribution of HOMA-IR in sub-cohort, categorised by 
whether they developed a CVE or not. 
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Figure 3.2.5 Box and whisker plot comparing HOMA-IR distribution between 
subjects who developed CVE and those who did not by subgroup. Box and 
whiskers indicate median and interquartile range, while outliers are shown as 
circles. 
 
To illustrate the effect of HOMA-IR on CVE risk, the cumulative hazard was plotted 
using the Cox regression calculations (available in appendix II). The subjects were 
classified as either above or below the cut off point of 1.35, which is the median for 
HOMA-IR in the sub-cohort. Figure 3.2.6 demonstrates the lack of effect of HOMA-
IR on CVE risk in the whole sub-cohort, as well as in the CKD and MHD groups 
within the sub-cohort. 
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163 
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Figure 3.2.6 Cumulative hazard plot for CVE the whole sub-cohort (panel A), the 
CKD subgroup (panel B) and MHD subgroup (panel C) stratified by HOMA-IR level 
above or below the cut-off point (median value for the whole sub-cohort=1.35). 
There are no statistically significant differences between any of the groups. 
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3.2.2.2 hs-CRP. As the values for hs-CRP were not normally distributed, the log 
transformation of the value was used to look at the effect of hs-CRP value on 
endpoints. Normality was determined by using the Shapiro-Wilk test. 
The odds ratio (OR) for cardiovascular event in regard to log-hsCRP in the sub-
cohort was 1.485, with a 95% CI of 0.982 and 2.246, and a p-value of 0.061; 
although this result is not significant the trend suggests that an increase in hs-CRP 
value may increase the risk of CV events. In the CKD group within the sub-cohort, 
the odds ratio (OR) for cardiovascular event in regard to log-hsCRP was 2.008 with 
a 95% CI of 1.005 and 4.010 with a p-value of 0.048; this is a borderline statistically 
significant result that suggests there may be an increased risk of CV events in 
subjects with increased hs-CRP levels. The odds ratio (OR) for cardiovascular 
event in regard to log-hsCRP in the MHD group within the sub-cohort was 1.273, 
with a 95% CI of 0.717 and 2.262 with a p-value of 0.409; this statistically 
insignificant result means that an increase in hs-CRP value cannot be associated 
with either an increase or a decrease in the risk of suffering a CV event. 
Figure 3.2.7 shows the distribution of hs-CRP in the sub-cohort, categorised by 
whether subjects developed a CVE or not. 
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Figure 3.2.7 Box and whisker plot comparing hs-CRP distribution between subjects 
who developed CVE and those who did not by subgroup. Box and whiskers indicate 
median and interquartile range, while outliers are shown as circles. 
 
To illustrate the effect of hs-CRP on CVE risk, the cumulative hazard was plotted 
using the Cox regression calculations (available in appendix II). The subjects were 
classified as either above or below the cut off point of 4.27 mg/l, which is the 
median for hs-CRP in the sub-cohort. Figure 3.2.8 demonstrates the lack of effect of 
hs-CRP on CVE risk in the whole sub-cohort and the MHD subgroup, and also the 
presence of an effect in the CKD subgroup. 
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C) 
 
Figure 3.2.8 Cumulative hazard plot for CVE in the whole sub-cohort (panel A), the 
CKD subgroup (panel B) and MHD subgroup (panel C) stratified by hs-CRP level 
above or below the cut-off point (median value for the whole sub-cohort=4.27 
mg/dl). Subjects with higher hs-CRP have significantly higher risk of CVE in the 
CKD subgroup (p=0.048). Other differences are not significant. 
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3.2.2.3 Total Adiponectin. The odds ratio (OR) for cardiovascular event in regard 
to total adiponectin in the sub-cohort was 0.982, with a 95% CI of 0.959 and 1.005, 
with a p-value of 0.118; this result is not significant and we cannot conclude whether 
an increase in total adiponectin causes an increase or decrease in the risk of 
suffering a CV event. In the CKD group within the sub-cohort, the odds ratio (OR) 
for cardiovascular event in regard to total adiponectin was 0.979, with a 95% CI of 
0.944 and 1.014 with a p-value of 0.240. As this result is statistically insignificant, it 
suggests no association between increased total adiponectin levels and CV events. 
The odds ratio (OR) for cardiovascular event in regard to total adiponectin in the 
MHD group within the sub-cohort was 0.984, with a 95% CI of 0.954 and 1.014 with 
a p-value of 0.292; this means that an increase in total adiponectin value cannot be 
associated with either an increase or a decrease in the risk of suffering a CV event. 
Figure 3.2.9 shows the distribution of total adiponectin in the sub-cohort, 
categorised by whether subjects developed a CVE or not. 
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Figure 3.2.9 Box and whisker plot comparing total adiponectin distribution between 
subjects who developed CVE and those who did not by subgroup. Box and 
whiskers indicate median and interquartile range, while outliers are shown as 
circles. 
 
To illustrate the effect of total adiponectin on CVE risk, the cumulative hazard was 
plotted using the Cox regression calculations (available in appendix II). The subjects 
were classified as either above or below the cut off point of 45.65 ug/ml, which is 
the median for total adiponectin in the sub-cohort. Figure 3.2.10 demonstrates the 
lack of effect of total adiponectin on CVE risk in the whole sub-cohort, as well as in 
the CKD and MHD groups within the sub-cohort. 
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Figure 3.2.10 Cumulative hazard plot for CVE the whole sub-cohort (panel A), the 
CKD subgroup (panel B) and MHD subgroup (panel C) stratified by total adiponectin 
level above or below the cut-off point (median value for the whole sub-cohort=45.65 
ug/mL). There are no statistically significant differences between any of the groups. 
  
172 
3.2.2.4 Summary of regression analyses for primary endpoint 
Regression analyses were carried out to determine odds ratios (OR) for CVE in 
regard to the potential risk factors in question: HOMA-IR, hs-CRP and total 
adiponectin. In the whole sub-cohort, none of the factors studied had a significant 
effect on CVE. A summary of the regression analyses in the whole sub-cohort is 
available in table 3.2.2 below.  
 
 
Table 3.2.2 Summary of regression analyses results for primary endpoint (CVE) in 
the combined group, looking at the effects of the factors studied. 
 
In the CKD group within the sub-cohort, the only statistically significant finding was 
the effect of increasing inflammation as quantified by log-hsCRP in increasing the 
risk of CVE, which is similar to what is observed in the general population and can 
be described as classic epidemiology. A summary of the regression analyses in the 
CKD group is available in table 3.2.3 below.  
 
 
Table 3.2.3 Summary of regression analyses results for primary endpoint (CVE) in 
the CKD subgroup, looking at the effects of the factors studied. 
173 
In the MHD group within the sub-cohort, none of the factors studied had a 
significant effect on CVE. A summary of the regression analyses in the whole cohort 
is available in table 3.2.4 below.  
 
 
 
Table 3.2.4 Summary of regression analyses results for primary endpoint (CVE) in 
the MHD subgroup, looking at the effects of the factors studied. 
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3.2.3 Analysis of Secondary Endpoint 
The follow-up data gathered for the cohort study was used for the subjects in the 
sub-cohort study to determine the effect of HOMA-IR, hs-CRP and total adiponectin 
on the secondary endpoint, death. These analyses were carried out for the whole 
sub-cohort as well as separately for CKD and MHD groups within the sub-cohort. 
The results in this section are described in the same order as in section 3.1.3 (risk 
analysis of secondary endpoints in the entire population studied): whole sub-cohort, 
CKD subgroup and then MHD subgroup and are expressed as odds ratio (OR), 
95% confidence interval (CI) and p-values. As mentioned in section 2.4, hazard 
ratios were also calculated for each risk factor using Cox regression analysis, and 
the results were in agreement with and very similar to logistic regression results 
(odds ratios). Number of deaths was too small in the sub-cohort to draw the hazard 
plots for mortality. 
Over the course of the 24-month follow up period, a total of 6 subjects (out of 106) 
reached a primary endpoint in the sub-cohort, bringing the death rate to 5.6%. Of 
these, 3 subjects were in the CKD subgroup (out of a total 55 subjects in this group) 
and 3 subjects were in the MHD subgroup (out of the total 51 subjects in this 
group), meaning the death rate was almost identical between these two subgroups, 
with the CKD group death rate at 5.5% and the MHD group event rate at 5.9% 
(figure 3.2.4).  
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3.2.3.1 HOMA-IR. The odds ratio (OR) for mortality in regard to HOMA-IR in the 
sub-cohort was calculated at 1.146 with a 95% CI of 0.823 and 1.597 and a p-value 
of 0.419, which is inconclusive in regards to its effect on mortality. In the CKD group 
within the sub-cohort, the OR for mortality in regards to HOMA-IR is 1.415 with a 
95% CI of 0.909 and 2.201 and a p-value of 0.123, which is also not statistically 
significant but the trend suggests that an increase in HOMA-IR increases the risk of 
death in this group. In the MHD group within the sub-cohort, the OR is 0.866 with a 
95% CI of 0.374 and 2.001 and a p-value of 0.736, which is also inconclusive of 
HOMA-IR‟s effect on mortality in the MHD subgroup. 
Figure 3.2.11 shows the distribution of HOMA-IR in the sub-cohort, categorised by 
whether they subjects died or not. 
 
 
Figure 3.2.11 Box and whisker plot comparing HOMA-IR distribution between 
subjects who died and those who did not by subgroup. Box and whiskers indicate 
median and interquartile range, while outliers are shown as circles. 
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3.2.3.2 hs-CRP. As the values for hs-CRP were not normally distributed, the log 
transformation of the value was used to look at the effect of hs-CRP value on 
endpoints. Normality was determined by using the Shapiro-Wilk test. 
As for the effect of log-hsCRP on mortality, the OR was 1.032 with a 95% CI of 
1.000 and 1.064 and a p-value of 0.051, which is statistically insignificant, but the 
strong trend again suggests that greater hs-CRP levels are associated with an 
increased risk of death in the sub-cohort. In the CKD group within the sub-cohort, 
the OR for effect of log-hsCRP on mortality is 1.025 with a 95% CI of 0.936 and 
1.123 with a p-value of 0.592. In the MHD group within the sub-cohort, the OR is 
1.797 with a 95% CI of 0.715 and 4.518 with a p-value of 0.213. These results are 
statistically insignificant in both subgroups, which mean that hs-CRP level is not 
associated with risk of death in either group. 
Figure 3.2.12 shows the distribution of hs-CRP in the sub-cohort, categorised by 
whether they subjects died or not. 
 
 
Figure 3.2.12 Box and whisker plot comparing hs-CRP distribution between 
subjects who died and those who did not by subgroup. Box and whiskers indicate 
median and interquartile range, while outliers are shown as circles. 
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3.2.3.3 Total Adiponectin. As for the effect of total adiponectin on mortality, the OR 
is 1.031 with a 95% CI of 1.004 and 1.058 with a p-value of 0.024, which means 
that an increase in total adiponectin is associated with an increased risk of death in 
this study population. In the CKD group, the OR for the effect of total adiponectin on 
mortality is 1.016 with a 95% CI of 0.961 and 1.074 with a p-value of 0.575, which 
suggests that there is no association between an increase in total adiponectin and 
the risk of death. In the MHD group, however, the OR is 1.042 with a 95% CI of 
1.001 and 1.083 with a p-value of 0.041, which is statistically significant and implies 
that an increase in total adiponectin level is associated with an increase in the risk 
of death in the MHD group of our study population.  
Figure 3.2.13 shows the distribution of total adiponectin in the sub-cohort, 
categorised by whether they subjects died or not. 
 
 
Figure 3.2.13 Box and whisker plot comparing total adiponectin distribution 
between subjects who died and those who did not by subgroup. Box and whiskers 
indicate median and interquartile range, while outliers are shown as circles. 
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3.2.2.4 Summary of regression analyses for secondary endpoint 
Regression analyses were carried out to determine odds ratios (OR) for mortality in 
regard to the potential risk factors in question: HOMA-IR, hs-CRP and total 
adiponectin. In the whole sub-cohort, increasing total adiponectin had a statistically 
significant effect on increasing the risk of death. As adiponectin is thought to have 
protective qualities, this result seems to be in contrast to what is seen in the general 
population, and therefore can be described as reverse epidemiology. However, as 
adiponectin is a complex substance with many regulatory effects, its increased level 
maybe a consequence of other conditions that increase mortality, rather than a 
cause for mortality. A summary of the regression analyses in the whole sub-cohort 
is available in table 3.2.5 below.  
 
 
 
Table 3.2.5 Summary of regression analyses results for secondary endpoint (death) 
in the whole sub-cohort, looking at the effects of the factors studied. 
 
In the CKD group within the sub-cohort, none of the factors studied had a significant 
effect on mortality. A summary of the regression analyses in the whole sub-cohort is 
available in table 3.2.6.  
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Table 3.2.6 Summary of regression analyses results for secondary endpoint (death) 
in the CKD subgroup, looking at the effects of  the factors studied. 
 
In the MHD group within the sub-cohort, the only statistically significant finding was 
the effect of increasing total adiponectin on increasing the risk of death. Again, this 
finding may be categorized as reverse epidemiology, although the physiologic 
nature of adiponectin makes it difficult to interpret these results. A summary of the 
regression analyses in the whole cohort is available in table 3.2.7 below.  
 
 
 
Table 3.2.7 Summary of regression analyses results for secondary endpoint (death) 
in the MHD subgroup, looking at the effects of all the factors studied. 
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3.2.4 Pre- & Post Haemodialysis Group Analysis 
As explained in section 2.2.2, one of the objectives of the sub-cohort study was to 
compare levels of insulin resistance, hs-CRP and total adiponectin before start of 
MHD with their levels 8 weeks into MHD. Unfortunately, this part of the study was 
not completed as the follow-up data was not available for the 7 subjects recruited. 
Nonetheless, the results available are presented in this section. 
3.2.4.1 HOMA-IR. HOMA-IR was measured for 7 subjects on the day of their first 
HD session, right before initiation of HD. These values were constituted as „pre-
dialysis‟ HOMAs, where the post-dialysis HOMAs would be measured in 8 weeks. 
Unfortunately, of the 7 subjects with „pre-dialysis‟ values, only one has a „post-
dialysis‟ value. One patient was transplanted before reaching the 8 week target, one 
died and 4 did not agree to re-testing, although they had initially given written 
informed consent and understood that the study required them to complete both 
parts.  
For the pre-dialysis values, the overall mean ± SD (range) HOMA-IR was 3.40 ± 
2.54 (0.80 – 7.60). Table 3.2.8 outlines the data for this group. 
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Pre-dialysis 
HOMA-IR 
Post-dialysis 
HOMA-IR 
Case 1 
0.8 
Did not agree 
Case 2 
1.6 
Did not agree 
Case 3 
2.8 
Did not agree 
Case 4 
7.6 
Did not agree 
Case 5 
4.1 
1.4 
Case 6 1.2 Transplanted 
Case 7 5.7 Died 
 
Table 3.2.8 HOMA-IR measurements for the pre- and post- dialysis study. Only one 
subject has a post-dialysis HOMA-IR value. 
 
3.2.4.2 hs-CRP. hs-CRP was available for 5 subjects on the day of their first HD 
session, right before initiation of HD. These values were constituted as pre-dialysis 
hs-CRP, where the post-dialysis hs-CRP would be measured in 8 weeks. 
Unfortunately, of the 5 subjects with pre-dialysis values, only one has a post-dialysis 
value, as the other 4 did not agree to re-testing, although they had initially given 
written informed consent and understood that the study required them to complete 
both parts.  
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For the pre-dialysis values, the overall mean ± SD (range) hs-CRP was 1.43 ± 1.32 
mg/l (0.28 – 3.49 mg/l). Table 3.2.9 outlines the data for this group. 
 
 
Pre-dialysis 
hs-CRP 
Post-dialysis 
hs-CRP 
Case 1 
0.28 
n/a 
Case 2 
0.48 
n/a 
Case 3 
3.49 
n/a 
Case 4 
0.97 
n/a 
Case 5 
1.93 
7.08 
 
Table 3.2.9 hs-CRP measurements for the pre- and post- dialysis study. Only one 
subject has a post-dialysis hs-CRP value. 
 
3.2.4.3 Total Adiponectin. Total adiponectin was measured for 5 subjects on the 
day of their first HD session, right before the beginning of HD. These values were 
constituted as pre-dialysis total adiponectins, where the post-dialysis total 
adiponectins would be measured in 8 weeks. Unfortunately, of the 5 subjects with 
pre-dialysis values, only one has a post-dialysis value, as the other 4 did not agree 
to re-testing, although they had initially given written informed consent and 
understood that the study required them to complete both parts.  
For the pre-dialysis values, the overall mean ± SD (range) total adiponectin was 
69.78 ± 15.90 ug/ml (45.2 – 84.0 ug/ml). Table 3.2.10 outlines the data for this 
group.  
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Pre-dialysis 
adiponectin 
Post-dialysis 
adiponectin 
Case 1 
84.0 
n/a 
Case 2 
64.6 
n/a 
Case 3 
72.2 
n/a 
Case 4 
82.9 
n/a 
Case 5 
45.2 
29.6 
Table 3.2.10 Total adiponectin measurements for the pre- and post- dialysis study. 
Only one subject has a post-dialysis total adiponectin value. 
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3.3 Glycaemic Control in ESRD 
3.3.1 Continuous Glucose Monitoring 
20 (14 male) subjects were recruited and three were subsequently excluded; 
one due to repeated hypoglycaemia during both monitoring periods that were 
caused by underlying acute illness, one due to CGM technical failure and the 
third was confirmed as a type 1 after the monitoring period.  
The age, duration of diabetes and years of dialysis [mean ± SD, (range)] of 
the 17 (13 male) subjects included were 61.5 yrs ± 8.8 yrs, (42-79); 18.8 ±7.6 
yrs (4-30) and 4± 2.6 yrs (0.5-10.2), respectively. Previous CVD history, 
diabetic medications, erythropoietin dose, HbA1c, haemoglobin and urea 
values are given in the table below.  
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N
o
 
Age 
(yrs) 
M/F 
Yrs of 
diabetes 
Urea 
(mmol/L) 
CVD 
(Y/N) 
Medication 
Hb 
(g/dL) 
HbA1c 
(%) 
Yrs on 
dialysis 
Erythropoietin dose 
(g/week) 
1 53 M 20 5.1 Y Gliclazide, 40mg BD 13.4 5.1 1.2 30 
2 59 M 18 19.3 Y Gliclazide, 80mg OD 11.3 5.3 3.7 80 
3 65 M 6 15.1 Y Diet 12.9 6 1.3 15 
4 72 M 16 22.3 Y Gliclazide, 80mg OD 9.9 6 3 100 
5 63 M 20 23.0 Y Humulin M3 (8u BD) 14.6 6.4 3.6 30 
6 52 M 18 28.2 Y Gliclazide, 40mg BD 15.1 6.5 3.7 30 
7 65 M 24 14.0 Y 
Novorapid (10u am), 
Glargine (35u pm) 
12.1 6.6 2.8 60 
8 68 M 26 14.0 Y Novomix 30 (10u BD) 10.9 5.6 7.7 30 
9 65 M 30 17.9 Y Mixtard 30 (10u, 8u) 12 6.7 5.4 10 
10 67 M 18 24.0 Y Gliclazide, 40mg BD 13.1 6.7 10.2 60 
11 58 F 9 17.0 N Mixtard 50 (23u, 24u) 9.3 7.4 0.5 80 
12 53 M 13 26.7 Y Gliclazide, 160mg BD 11.7 7.9 2.7 40 
13 79 M 22 21.9 Y Mixtard 30 (18u, 12u) 14 8 6.8 20 
14 42 M 26 16.0 Y Mixtard 30 (18u, 12u) 13.4 8.5 3.9 15 
15 65 F 30 13.2 Y Mixtard 30 (6u BD) 13.8 7.3 6.2 50 
16 65 F 4 14.5 Y Gliclazide, 160mg BD 12.4 8.9 3.3 30 
17 54 F 19 17.8 N 
Novomix 30 (16u, 
10u) 
11.7 9.2 1.7 60 
 
Table 3.3.1 Clinical details of 17 subjects whose CGM data was included in the final analysis. Abbreviations used: CVD, 
documented history of vascular disease defined as ischaemic heart disease (history of MI, revascularisation procedure or 
angiographically proven coronary disease), cerebrovascular disease (history of CVA or TIA) or peripheral vascular disease 
(history of amputation due to gangrene, revascularisation procedure or angiographically/Doppler proven peripheral vascular 
disease).
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HbA1c values. The HbA1c (Mean SD) was 6.9 ± 1.2%, (range 5.1-9.2 %), 
with 7 subjects having an HbA1c of ≤6.5% (Table 1). 
Linear regression analysis between HbA1c and erythropoietin dose, serum albumin 
and urea were not significant, (r2=0.17, p=0.0995; r2=0.161, p=0.536 and r2=0.163, 
p=0.533, respectively.) 
Haemoglobin values. The mean haemoglobin was 12.4 ± 1.6 g/L (range 9.3-15.1). 
3.3.1.1 Glycaemic Data 
Analysis of glycaemic profiles. The 24-hour AUC glucose values and mean 24-
hour CGM data were significantly higher on the day off dialysis than the day on 
dialysis (5932.1 ± 2673.6 vs. 4694 ± 1988 mmol/3min/L, p=0.022 and 12.6 ± 5.6 
mmol/L vs. 9.8 ± 3.8 mmol/L, p=0.013, respectively), Figure 3.3.1. The difference in 
the 24-hour mean glucose levels for the day off dialysis to the day on dialysis 
ranged from -2.1 to 10.4mmol/L.  
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Figure 3.3.1 CGM data for day on (Day 1) and day off dialysis (Day 2), expressed 
as area under curve (AUC) glucose (A) and mean glucose (B) for each 24 hour 
period. Data for individual subjects are represented as triangles connected by lines. 
The mean ± SD for each 24 hour period is represented as a square. A. Mean ± SD 
area under the 3 minute glucose curve for the whole study group was 5932.1 ± 
2673.6 on the day off dialysis vs. 4694 ± 1988 mmol.3min/Lon the day on dialysis, 
p=0.022. B. Mean ± SD CGM glucose values for the whole group were 12.6 ± 
5.6mmol/L on the day off dialysis vs. 9.8 ± 3.8 mmol/L on the day on dialysis, 
p=0.013. 
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The AUC glucose profiles and the mean glucose values for the 6-hour 
nocturnal period from midnight to 6 am were significantly higher for the 
second than the first night (1541 ± 834 vs. 1137 ± 529 mmol/3min/L, p<0.05; 
and 12.9 ± 7.0 vs. 9.5 ± 4.4 mmol/L p<0.05, respectively). With a median 6-
hour mean nocturnal glucose difference of 4.2mmol/L (range -8.5 to 17.1 
mmol/L), Figure 3.3.2. 
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Figure 3.3.2 Nocturnal CGM data for the 6 hour period from midnight to 6 am for 
day on (Night 1) and day off dialysis (Night 2) expressed as area under curve (AUC) 
glucose (A) and mean glucose (B). Data for individual subjects are represented as 
triangles connected by lines. The mean ± SD for each 24 hour period is represented 
as a square. A. Mean ± SD area under the 3 minute glucose curve for the whole 
study group was 1541 ± 834 for the night of the day off dialysis (night 2) vs. 1137 ± 
529 mmol.3min/L for the night of the day on dialysis (night 1), p<0.05. B. Mean ± 
SD CGM glucose values for the whole group were 12.9 ± 7.0 mmol/L on night 2 vs. 
9.5 ± 4.4 mmol/L on night 1. 
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Analysis of hypoglycaemia. Four of the 17 subjects had CGM recordings of below 
2.5 mmol/L for more than 30 minutes; in 3, this occurred in the first 24-hour 
monitoring period. Examination of individual CGM profiles showed that 14/17 
subjects reached their glucose nadir (range 1.38-9.81mmol/L) within the first 24 
hours, with 10/17 having their lowest reading within 12 hours of starting dialysis. No 
subject reported any episode of symptomatic hypoglycaemia. 
Analysis of measured and predicted HbA1c values. Comparison was made 
between measured and predicted HbA1c values, where predicted HbA1c was 
calculated using the mean glucose value derived from CGM data and incorporated 
into the DCCT published formula. The mean ± SD measured HbA1c was 
significantly less than the mean ± SD predicted HbA1c (6.9 ± 1.2% vs. 8.6 ± 2.3%, 
p< 0.006), Figures 3.3.3. 
 
 
Figure 3.3.3 Linear regression plot showing the relationship between measured 
HbA1c and overall mean glucose from the 48-hour CGM period (blue); the 
reference line has been drawn in green, showing what the projected results look like 
based on the DCCT-derived formula. 
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3.3.1.2 Dietary Data 
Analysis of the food diaries. Two subjects failed to complete their 48-hour 
food diaries (subjects 6 and 15). Analysis of the 15 completed diaries showed 
no significant difference between recorded dietary intakes for the day on 
dialysis and the day off dialysis (1636 ± 603 kCal vs. 1702 ± 559 kCal, 
respectively, p = 0.596).  There was no trend towards greater food intake on 
either day, with 7 subjects recording a greater calorie intake during the day 
on dialysis verses 8 the day off dialysis, although the average meal frequency 
was greater on the non-dialysis day (3 meals on dialysis days vs. 4 meals on 
non-dialysis days). The timing of the dialysis shift did not appear to influence 
the energy intake.  
The total energy intake for each subject was significantly lower, both on dialysis 
days (mean 1636kCal/day) and off dialysis days (mean 1702kCal/day), than the 
estimated mean energy requirement (2000kCal/day), p = 0.01, (data not shown). An 
equal number of patients reported better perception of appetite on dialysis days and 
non-dialysis days, Figure 3.3.4. 
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Figure 3.3.4 Daily calorie intake for study subjects on dialysis and non-dialysis days 
is shown together with the calculated recommended daily intake for individuals. 
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Chapter 4: Discussion 
4.1 Cardiovascular Risk Factors in ESRD 
Chronic kidney disease has become an increasing public health concern, as the 
population of patients suffering from this condition is rapidly rising as a result of the 
obesity pandemic and subsequent type 2 diabetes. What concerns clinicians and 
scientists about this group is the high incidence of cardiovascular disease which 
contributes greatly to the high mortality rate seen in this population. Identifying the 
cause of this increased risk for developing cardiovascular disease has been a 
priority for decades, but the rapidly evolving nature of modern medicine and the 
dynamic demographics of the condition mean that to date cardiovascular risk 
factors in the ESRD population is the subject of much debate and controversy. A 
number of large, retrospective population based studies have been carried out on 
this population [5, 7, 132, 181, 467], and they have produced at times contradictory 
results. The lack of prospective studies looking at large groups of subjects with 
ESRD means not being able to distinguish the consequence from the cause. This 
has led to different theories in regards to morbidity and mortality risk factors in the 
ESRD population, one of which is the reverse epidemiology theory. Reverse 
epidemiology suggests that certain cardiovascular risk factors may have a reversed 
role in patients with ESRD, meaning they may actually be protective. For example, 
while obesity and high BMI is a well-known CVD risk factor in the general 
population, it is favourable in comparison to low BMI for the prolonged survival of 
patients on dialysis. 
When addressing CVD risk factors in the ESRD population, it is important to 
distinguish between the different groups within the ESRD population; those who are 
receiving renal replacement therapy and those who are not. The latter is the CKD 
group, which is divided into stages 1-5, where stages 1 and 2 have normal kidney 
function as measured by GFR, therefore loss of function starts at stage 3. The RRT 
group comprises of transplanted patients and those on dialysis, and the dialysis 
group is broken down into two main groups of peritoneal dialysis (CAPD) and 
haemodialysis (HD).  
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Figure 4.1.1 Classifications within the ESRD population. 
This study aimed to identify the role of four well-known cardiovascular risk factors 
for the general population in the ESRD population; obesity, hypertension, 
dyslipidaemia and diabetes. The ESRD population we chose to study was CKD 
patients with stages 3, 4 and 5 and MHD patients, as the first group has gradually 
deteriorating kidney function while the second group theoretically has gradual 
improvement of „artificial‟ kidney function. 
Once recruitment was completed, an initial analysis of the population was carried 
out to compare the two groups: CKD and MHD. In terms of event rates, the MHD 
group had higher CVE and death rates compared to the CKD group, which is 
expected. The total death rate for two years in the MHD group is 18.1%, which is 
approximately half of the published UK haemodialysis mortality rates of 18-20% 
[330], and this is almost three times more than the mortality rate in the CKD group 
(table 4.1.1 below; also see figure 3.1.11). 
  
195 
 
 
Table 4.1.1 Number of endpoints reached in the CKD and MHD subgroups over the 
24 months follow-up period. 
 
Effect of Risk Factors on CV events and mortality 
The higher incidence of cardiovascular disease and mortality in CKD and MHD 
patients is well documented [24, 468, 469], but it is the cause of this prevalence that 
has been subject to much debate. Researchers‟ theories on the roots of these 
problems have been as dynamic as the treatments used, and the rapid 
modernisation of medicine and dialysis techniques has led to new answers as well 
as new questions.  
Classically, vascular calcification has been recognised as one of the main causes of 
cardiovascular mortality in both the CKD and the MHD population, as it promotes 
arterial stiffness, left ventricular hypertrophy, cardiovascular events and mortality 
[469-473]. Other than the ESRD-specific risk factors for vascular calcification, which 
is mainly mineral metabolism abnormalities and extreme PTH levels [474-476], the 
remaining risk factors reported for vascular calcification is largely similar to those for 
cardiovascular disease in general: aging, hypertension, diabetes, dyslipidaemia and 
obesity [477, 478]. As discussed in the introduction, large epidemiological studies in 
the MHD population have shown a phenomenon referred to as „reverse 
epidemiology‟, which suggests these „classic‟ CV risk factors have a „reversed‟ role 
in this population [7]. According to the reverse epidemiology theory, what is 
perceived as a CV risk factor in one population, may have protective qualities in 
another population; more specifically that while markers of over-nutrition are 
considered CV risks in the general population, they may be associated with 
CKD MHD Total
No event 240 (77.9%) 116 (55.2%) 356 (68.7%)
CVE 47 (15.3%) 56 (26.7%) 103 (19.9%)
Death 21 (6.8%) 38(18.1%) 59 (11.4%)
Total 308 (100%) 210 (100%) 518 (100%)
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improved survival in the ESRD population who is specially at risk of malnutrition [59, 
184]. 
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4.1.1 BMI 
Body mass index (BMI) is the most widely used tool for assessing weight status in 
populations, and although it does not calculate the percentage of body fat, its ease 
of use and practicality means individuals can be categorised as either underweight, 
ideal weight, overweight or obese within a few minutes by using two common 
measurements that most people are already aware of; weight and height (BMI= 
weight (kg) / height 2 (m2)).  
However, how accurately obesity, which is fundamentally excess body fat, can be 
measured and categorised by BMI is a subject of controversy. Although most of our 
understanding of the effects of obesity on health is based on our BMI-based 
definition of obesity, epidemiologists have concluded that BMI is an inadequate 
measurement for cardiovascular risk of obesity [479], and some have gone further 
and demanded that BMI be abandoned [480]. Detailed studies have been carried 
out to look at the correlations between BMI and other measurements of body fat, 
such as waist to hip ratio and abdominal visceral fat measured by computed 
tomography, and their results have shown that BMI correlates very well with both 
measurements and thus some obesity experts see no reason for replacing BMI with 
other measurements of obesity [481], although this conclusion is still heavily 
debated.  
With the increasing prevalence of worldwide obesity, and in light of an ever 
increasing body of evidence that links obesity and overweight to CVD, cancer and 
mortality, it is at the very least intriguing to ponder the possibility of favourable 
effects of increased BMI. As postulated before (section 1.1.4.3.1), the „protective‟ 
effect of increased BMI in the MHD population that has been observed in some 
studies is most probably relative to the potentially lethal effect of malnutrition; in 
other words, while obesity is bad, malnutrition is worse. Nevertheless, it should not 
be forgotten that the observations that lead to reversed BMI effect theories in this 
population are all either cross-sectional or retrospective, and therefore inconclusive. 
The present study set out to prospectively follow a mixed representation of the 
ESRD population to the end of producing more reliable data on the true effect of 
BMI on CV events and mortality. 
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In the CKD group, of the 308 subjects BMI values were recorded for 263; the mean 
BMI in this group was 29.1 ± 6.2 kg/m2. In the MHD group, of the 210 subjects BMI 
values were recorded for 201 patients, and the mean BMI was 25.3 ± 5.9 kg/m2. 
The difference between BMI in the two groups is statistically significant, with a p-
value of <0.001.The lower mean BMI in the MHD group is consistent with data from 
similar populations [7, 482]. Taking into account that the MHD population is the one 
with greater risk of CV events and mortality, this data may be interpreted as 
showing that lower BMI is a greater risk factor for CVE and mortality, therefore 
giving weight to the reverse epidemiology theory.  
The fact that this MHD population is lighter in weight than its CKD counterpart is not 
unexpected; not only do MHD patients lose the accumulated fluid due to kidney 
failure, but they have also been known to be prone to loss of appetite and in severe 
cases, malnutrition [483, 484]. Also, the physical limitations that follow being 
dialysed for 4-5 hours, 3 times a week added to what is in many, if not most, cases 
long travel hours and waiting times, means that these patients also have limited 
access to food for a total of 1 day a week (average 6 hours a day, 3 times a week 
adds up to 18 hours a week – which is about one „awake‟ day). And while a mean 
BMI of 25.3 kg/m2 may seem healthy at first glance, it must be kept in mind that only 
those with BMIs greater than the mean will benefit from fewer meals (88 patients, 
50 of them male). For the other 122 patients, it is important to maintain their body 
weight in order to prevent weakness that may be followed by infections and/or 
malnutrition.  
In terms of risk for cardiovascular events (CVE) and mortality, the result of logistic 
regression analysis for BMI is summarized in the table below (table 4.1.2). 
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Table 4.1.2 Summary of 2-year follow up results in regards to the effect of BMI on 
CVE and mortality. 
 
As evident above, 24-months of prospective CVE and mortality data on a total of 
518 subjects was unable to reach significant results in terms of the ability of BMI in 
predicting CVE and/or mortality in any of the groups studied.  
There are different ways of expressing the effect of BMI on endpoints; one is to look 
at the effect of every single incremental increase in relation to the endpoint in 
question (which is what is shown above). Some studies look at the effect of different 
classifications, where subjects are divided into 4 groups of underweight, ideal 
weight, overweight and obese and the effect of each category on endpoints is 
analysed, and some just look at the effect of obesity, in which case subjects are 
categorised into two groups of obese and non-obese and endpoints are analysed in 
relation to that. In the population studied here, dividing subjects into four groups 
produced small numbers in each group; the subjects were therefore classified as 
either overweight or not overweight, using the cut off point of 25 kg/m2. When the 
cumulative hazard ratio for CVE and mortality are plotted for the two groups, the 
lack of effect of BMI is readily seen, as shown see figure 3.1.13.   
In the general population, the risk of death consistently increases as BMI rises, 
regardless of  age, gender, race and medical history [170, 485, 486], although the 
effect of increasing BMI is more pronounced in certain groups. As for similar studies 
in the MHD population, Fleischmann et al. report a 30% reduced risk of mortality for 
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every increment increase in a population of 1346 MHD patients [173], and Abbott et 
al. observed a similar improvement in survival in BMI values above 30 kg/m2 
(adjusted hazard ratio of 0.89) for 1675 MHD patients which could not be 
reproduced for their 1662 CAPD patients [175]. These findings were confirmed by 
large historical cohort studies using the USRDS data on haemodialysed patients 
[172, 177, 273], and by the Dialysis Outcomes and Practice Patterns Study 
(DOPPS), which was a large prospective study of 9714 patients on HD across the 
globe, that showed increasing BMI was associated with better survival in all 
subgroups of patients [164].  
The fact that the results of the present study did not reach significance can mean 
that the effect of BMI is too weak to reach significance in a population of this size 
and/or with this length of follow-up period, which in itself is a finding contrary to both 
the general population and the ESRD population. The fact that the subjects in this 
study are a mixture of both CKD and MHD could cause a mixed effect on mortality 
for different risk factors in the two groups, and when the results are broken down 
into subgroups, the smaller number may be contributing to the insignificance of the 
results. Of note in these results is the opposite direction of the OR for CVE and 
mortality in both the combined and the MHD population; while the OR above 1 for 
effect of BMI on CVE in all subgroups indicates higher BMI may be associated with 
higher event rate, the OR below 1 for effect of BMI on mortality in the MHD group 
can mean a favourable effect of BMI on survival, which is also observed in the 
combined population calculations. Of course, as none of these observations reach 
statistical significance, these theories cannot be verified unless the population is 
followed for a greater period of time and more endpoints are reached in all groups, 
which may push the results toward statistical significance.  
What remains is that despite its known short comings, BMI is still the most widely 
used measure for body size both in the general population and in ESRD despite the 
fact that it does not distinguish between fat mass and lean mass, nor does it give 
information on fat distribution. Beddhu et al. showed that in dialysis patients with 
similar BMI, those with lower muscle mass (urinary creatinine  0.55 g/day) had a 
higher risk of both cardiovascular and all-cause mortality [487]. In another study by 
Honda et al. protein-energy wasting measured by a subjective global assessment of 
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nutrition was shown to be equally prevalent in underweight, ideal weight and 
overweight ESRD subjects [488]. Honda‟s study did not show a significant effect for 
BMI on mortality, perhaps due to their small size of 328 patients, but protein-energy 
malnutrition was associated with increased mortality in all groups. Perhaps the ideal 
way to deal with this problem is to combine BMI, waist circumference, and 
nutritional assessment for a more refined prognostic element. Once such a 
measurement has been calculated for ESRD patients, clinical trials can determine 
whether weight loss can be effective in improving survival in some ESRD patients, 
and whether weight gain can mean the same in other ESRD patient.  
In summary: 
 BMI does not appear to have a significant effect on either CVE or mortality in 
this population 
 Interpretation of the trend (although weak) in the MHD population suggests 
the effect of increasing BMI on CVE is in the same direction as that of the 
general population (classic epidemiology), but its effect on mortality is in the 
opposite direction to that of the general population suggesting that higher 
BMI may have a favourable effect on survival in the MHD population (reverse 
epidemiology). 
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4.1.2 BP 
When measuring BP, the force of blood against blood vessels‟ walls is being 
measured; this means that both fluid overload and stiffness and/or narrowing of 
vessels can cause increased BP [489]. Patients with kidney disease often suffer at 
least one, if not both, of these conditions, and many patients suffer kidney disease 
as a result of existing essential or secondary hypertension. It is therefore not 
surprising that the majority of the subjects on the database either had high BP or 
were on antihypertensive medication. The importance of monitoring and controlling 
BP in kidney disease is well-known; not only is hypertension an easily treated 
condition with adverse effects on the cardiovascular system, but the kidneys are 
also at risk of further damage, in addition to the fact that kidney disease can also 
cause hypertension.  
BP has been widely investigated and shown to be directly correlated to CV mortality 
in the general population [162, 185, 490-494] (see figure 4.1.2). However, in the 
ESRD population, specifically in dialysed patients, BP has been among the 
controversial components of the reverse epidemiology phenomenon [7, 8] and 
many investigators have observed the link between low pre-dialysis BP and 
increased mortality [165, 195, 495-497].  
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Figure 4.1.2 Ischamic heart disease mortality rate in each decade versus usual BP at start of that decade. Figure reproduced with 
permission from  Lewington S, et al [498]. 
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It is known that BP values in MHD patients differ depending on the time it‟s 
measured in relation to dialysis, and although predialysis BP is the measure most 
often used to address BP in MHD patients, it is not known whether it is better 
correlated with long-term outcome compared to intradialysis or post-dialysis BP 
[499-501]. The effect of BP on CVE and/or mortality in the haemodialysed 
population is heavily debated; some observational studies have shown that 
hypertension is a risk factor for increased CV morbidity and mortality in long-term 
follow up of MHD patients [502-505], while some researchers have shown that 
higher BP is associated with better survival and that hypotension is the risk factor in 
their MHD subjects [506-510], highlighting BP as one of the factors of reverse 
epidemiology in this population. The lack of controlled trials to show survival benefit 
of BP control, either pharmacologic or through dialysis, adds to the inconclusivity of 
the present data.  
An important factor to keep in mind is that in populations with severe cardiac 
disease, low BP is usually a marker of severity of disease, and therefore it may not 
be surprising to find it correlates with increased morbidity and mortality [7]. 
Therefore, the discrepancy between the above mentioned observations may be due 
to the number of patients with severe CVD in each study cohort. 
To look at the effect of BP on CVE and mortality in this study population, mean SBP 
and DBP were compared between the subgroups, and logistic regression analysis 
was carried out for each population as well.  
 In the CKD group, of the 308 subjects BP values were recorded for 241; the mean 
SBP ± SD in this group was 138.0 ± 18.1 mmHg and the mean DBP ± SD was 73.9 
± 12.1 mmHg. In the MHD group, of the 210 subjects BP was recorded for 172 
patients, and the mean SBP was 152.4 ± 25.0 mmHg and mean DBP was 81.7 ± 
14.2 mmHg. The difference between both SBP and DBP in the two groups is 
statistically significant, with a p-value of <0.001 for both factors. The higher mean 
BP in the MHD group, the one with greater risk of CVE, suggests that this is in line 
with the general population and not in keeping with reverse epidemiology; the group 
with the higher BP has the higher CVE rate. Similar observations have reported 
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increased BP in the MHD population compared to both the general population and 
the CKD population [511, 512]. 
In terms of risk for cardiovascular events (CVE) and mortality, the result of logistic 
regression analysis for SBP and DBP is summarized in the table 4.1.3 below. 
  
 
 
Table 4.1.3 Summary of 2-year follow up results in regards to the effect of BP on 
CVE and mortality. 
 
As evident above, 24-months of prospective CVE and mortality data on a total of 
518 subjects showed mixed results for the relationship between BP and CVE and/or 
mortality in the different groups studied.  
The regression results for SBP show that in terms of its effect on the primary 
endpoint, CVE, no significant effect is seen in the two subgroups, whereas the 
combined population shows a statistically significant increase in CVE with 
increasing SBP. We can therefore assume that the reason no significance is 
achieved in the two subgroups is due to the smaller number of subjects, and the 
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fact that the OR in both groups is above 1.0, meaning that the direction of the effect 
is similar to that observed in the combined population, is in line with that theory. 
This means that not only is higher SBP a risk factor for CVE in the ESRD 
population, but it also suggests that there are no discrepancies between the MHD 
population, the CKD population and the general population. 
For the effect of SBP on mortality, the secondary endpoint, the only significant result 
was seen in the CKD group, where a statistically significant OR of less than 1.0 
means that mortality risk is reduced with increasing SBP in this group. Surprisingly, 
the OR for the MHD population is above 1.0, suggesting that the direction of the 
effect of SBP on mortality is different in MHD and in line with the general population 
where increased BP is associated with increased risk of mortality (although this 
finding is not statistically significant).  
Looking at the DBP regression analysis for its effect on CVE, no significant result 
was observed in any of the groups. Perhaps the only noteworthy observation here is 
the OR value below 1.0 in the MHD group; although lacking statistical significance, 
this result suggest the possibility of a reversed relationship, where increasing DBP 
lowers the risk of CVE in the MHD population. In his meta-analysis Agarwal has 
reported that in such studies where investigators are looking at the role of BP on 
CVE and mortality, analysing SBP and DBP separately leads to the observation that 
high SBP is a strong predictor of CVE while DBP may exhibit an inverse relationship 
[513]. This is exactly what this study‟s data has shown.  
As for the effect of DBP on mortality, the results are similar to SBP in that the only 
statistically significant finding is that increasing DBP lowers the risk of mortality in 
the CKD group. However, of note here is that the OR for the effect of DBP on 
mortality in both the combined population and the MHD group is below 1.0, and 
again although not statistically significant, in the same „reversed‟ direction as the 
effect in the CKD group.  
As 49.9% of the entire cohort studied have pre-existing CVD other than 
hypertension, and in the CKD group, a total of 161 patients (52.3%) have pre-
existing CVD while in the MHD group there are 98 patients (46.7%) with pre-existing 
CVD, it can be hypothesized that there are a greater number of patients with severe 
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CVD and/or heart failure in the CKD group, which would explain why this group is 
benefiting from increased BP. The lower than 1.0 OR for DBP in the MHD group is 
explained by Agarwal‟s observations that DBP retains an inverse relationship with 
CVE and mortality when considered as an independent factor in the MHD 
population [513]. 
In summary: 
 Systolic BP shows a significant effect on CVE in the combined cohort which 
is in the same direction as that of the general population (classic 
epidemiology). 
 In the CKD subgroup, increased systolic and diastolic BP are both 
significantly associated with decreased odds of death, which is in the 
opposite direction of the general population (reverse epidemiology) 
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4.1.3 Lipids 
While a complete lipid profile is needed for full insight into patients‟ balance (or lack 
of) of clinically important lipids, i.e. LDL cholesterol, HDL cholesterol, total 
cholesterol and triglycerides, it has long been established that high levels of serum 
cholesterol and triglycerides increase the risk of developing CVD in the form of 
coronary heart disease (CHD) and therefore subsequently increase mortality [163, 
492, 514, 515]. Since the onset of the obesity pandemic, these markers of over-
nutrition are fast rising in an increasing proportion of patients. But it has also been 
reported that in the ESRD population, specifically in the MHD population, high 
cholesterol levels are associated with improved survival [7, 166, 516-518]. It is 
unlikely, although not improbable, that this observation can be attributed to 
unknown protective effects of high TC in the ESRD population. As low TC and TG 
levels are indicative of under-nutrition, or in severe cases malnutrition, it is more 
likely that the previously mentioned observed favourable effect of high TC is due to 
the relative survival advantage of over-nutrition to under- or malnutrition.  
In the cohort studied here, the effect of TC and TG on both CVE and mortality were 
analysed by comparison of means between subgroups, as well as logistic 
regression analyses in both groups.  
 Of the 308 subjects in the CKD group, 265 had recoded TC and TG values; the 
mean TC ± SD in this group was 4.5 ± 1.5 mmol/l and the mean TG ± SD was 1.86 
± 1.06 mmol/l. In the MHD group, of the 210 subjects lipids were recorded for 196 
patients, and the mean TC ± SD was 3.8 ± 0.95 mmol/l and mean TG ± SD was 
1.67 ± 0.85 mmol/l. The difference between mean TC in the two groups is 
statistically significant, with a p-value of <0.001, but the p-value for the difference of 
mean TG in the two groups is just above the cut-off for statistical significance at 
0.051. The lower mean TC and TG in the MHD group, the group with higher CVE 
risk, suggests that this is may be a „reverse epidemiology‟ observation; the group 
with the lower lipid levels has the higher CVE and mortality rate. As mentioned 
above, several other studies have reported similar observations. 
The lower TC and TG in the MHD group is expected to an extent, as BMI was also 
lower in the MHD group; however, while the significant difference in BMI between 
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the two groups did not seem to have conclusive effects on endpoints, logistic 
regression analyses for TC and TG reveal significant effects on both CVE and 
mortality (Table 4.1.4). 
 
 
Table 4.1.4 Summary of 2-year follow up results in regards to the effect of lipids on 
CVE and mortality. 
 
The table 4.1.4 shows that 24-months of prospective CVE and mortality data on a 
total of 518 subjects exhibit mixed results for the relationship between TC and TG 
and CVE and/or mortality in the different groups studied.  
The regression results for TC show that in terms of its effect on the primary 
endpoint, CVE, no significant effect is seen for the MHD group, whereas the 
combined population and the CKD group both show a statistically significant 
decrease in CVE risk with increasing TC. This result is counter intuitive and in 
contrast to what is observed in the general population, where higher TC is 
synonymous with higher risk of CVE. What is interesting here is that this 
observation of „reverse epidemiology‟ is seen in the CKD group and not the MHD 
group. Although the OR for the MHD group is below 1.0, indicating that the 
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relationship may be reversed here as well, it is much higher than the OR for the 
CKD group. We can therefore assume that the reason significance is observed in 
the combined population is the strong effect in the CKD group, which has a larger 
number of subjects. This could mean that the effect of TC on CVE in the ESRD 
population is reversed compared to the general population; the data produced by 
this study is insufficient in determining whether this effect is only present in the non-
dialysed CKD population or also in the MHD population. Longer follow-up of the 
cohort may lead to significant results in the MHD population.  
For the effect of TC on mortality, the secondary endpoint, the results seem to reflect 
that of the effect of TC on CVE; significant results seen in the CKD group as well as 
the combined cohort, where a statistically significant OR of less than 1.0 means that 
mortality risk is reduced with increasing TC in these groups. Again, the OR for the 
MHD population is also below 1.0 here, but larger in comparison to the OR for 
mortality in the CKD group. These results indicate that reverse epidemiology of TC 
exist in the CKD cohort, but not at present in the MHD group. Whether the 
statistically insignificant result in the MHD group is due to smaller sample size 
and/or not enough follow-up for TC‟s weaker „reversed‟ effect to exhibit can only be 
addressed by longer follow-up of the cohort. With time and as more subjects reach 
endpoints, the effect of TC on mortality should either reach significance with an OR 
of less than 1.0, or the OR may go above 1.0 and the results may remain 
statistically insignificant, in which case we can postulate that either TC does not 
affect mortality in the MHD population, or that its effect is in the same direction as 
the general population.  
Looking at the TG regression analysis for its effect on CVE, no significant result was 
observed in any of the groups. But interestingly, the OR value observed is below 1.0 
in all groups; although lacking statistical significance, this suggests the possibility of 
a reversed relationship, such as that seen for TC in relation to CVE, where 
increasing TG lowers the risk of CVE in the ESRD population.  
The results for the effect of TG on mortality are quite interesting; the entire cohort 
and both subgroups show statistically significant OR of well below 1.0, meaning 
increasing TG lowers the risk of mortality in all groups. This result is clearly „reverse‟ 
in comparison to the general population, where increased TG is a risk factor for 
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mortality [141, 519]. The importance of this result maybe in that it suggests that with 
enough endpoints, all the results in this block (effect of lipids on endpoints) would 
reach statistical significance. The fact that significant „reversed‟ results are observed 
in both the CKD and the MHD group also shows that as far as reverse epidemiology 
of TG is concerned, there are no discrepancies between ESRD subgroups, and that 
whatever the reason for this reversed result, it is not being corrected through 
dialysis. If one can now find the missing link that causes this reversal of effect in the 
ESRD population – perhaps a mediator with effects on TG that cannot be dialysed 
out – one can then design future trials that would focus on enhancing survival in this 
population. 
It is important to rule out the effect of lipid-lowering drugs, specifically statins, when 
looking at outcomes in relation to lipid levels. Many researchers have observed 
statins‟ favourable effects on survival in the general population, but studies such as 
the Deutsche Diabetes Dialyse Studie (4D) trial [520] and the more recent „A Study 
to Evaluate the Use of Rosuvastatin in Subjects on Regular Haemodialysis: An 
Assessment of Survival and Cardiovascular Events‟ (AURORA) trial [521] have 
shown that while statins lower lipid cholesterol levels in patients on MHD, they have 
no effect on CVE or mortality in this population. In the present study, to rule out the 
effects of statin therapy, the differences between the MHD and CKD groups in 
relation to statin use and lipid levels were analysed. The results showed similar TC 
and TG levels in those on statin therapy and not on statin therapy in both groups as 
shown in figure 3.1.18).  
Risk analysis for effect of statins on CVE and mortality showed no significant 
results. The fact that statin therapy has no effect on endpoints in the present cohort 
means that the reversed effect of TC and TG on mortality and the reversed effect of 
TC on CVE are not linked to favourable anti-inflammatory side-effects of statins 
[522-524]. Keeping that in mind, it seems that the profound negative effect of low 
TC and TG on mortality can be attributed to under-nutrition and its subsequent 
adverse outcomes, such as infection. Also, since there is usually a relatively high 
prevalence of malignancy in the ESRD population [525] it is possible that the low 
lipid levels are secondary to cancer cachexia in this group, further explaining the 
higher mortality in the lower lipids levels group. However, this does not seem to be 
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the case in the present population, as the prevalence of malignancy is 8% in the 
whole cohort, 7% in the CKD group and 9% in the MHD group; although this is more 
than twice the prevalence in the UK general population which is estimated at 3.2% 
[526], it is almost the same as the prevalence of cancer in the population of 65 and 
over living with cancer, which is estimated at 7.5% [527]; and as the mean age for 
this cohort is 66 (±15) years, it is almost in line with the general population. 
In summary: 
 The effect of TC and TG in this population is reversed in certain subgroups  
 Increasing TC reduces the risk of both CVE and mortality in the CKD 
population, but not in the MHD population  
 Increasing TG reduces the risk of mortality in both the CKD and the MHD 
group, but has no effect on CVE in either group  
 We can therefore postulate that because the „reversed‟ effect of TC on both 
endpoints is only present in the CKD group and not the MHD group, the 
cause of this reversal is removed through dialysis  
 TG has similar effects in both groups and is significantly affecting mortality 
but not CVE, suggesting a different mechanism to TC for its effects on 
outcome   
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4.1.4 Diabetes and Glycaemic control. 
In the MHD group 43.3% of the subjects have diabetes, compared to 59.4% in the 
CKD group (the prevalence of diabetes in the UK ESRD population is about 23% 
[330, 528]). While the incidence of diabetes in the MHD group is similar to that of 
other ESRD populations (44% in the US MHD population according to USRDS), it 
may be over-represented in the CKD group. This is most likely a sampling error led 
by the fact that patient records are kept in greater detail for patients with diabetes 
and therefore more likely to be included in this database. Patients with diabetes and 
kidney disease have comprehensive records in both the renal and diabetes 
departments, and are also seen at closer intervals; therefore a bias in consecutive 
sampling is difficult to avoid. The greater number of patients with diabetes in the 
CKD group compared to the MHD group may also be a result of more diabetic 
patients either not progressing to later stages of CKD, or dying before they start 
haemodialysis. To rule out each of these theories, large numbers of patients must 
be prospectively followed through the different stages and onto dialysis. 
Logistic regression analysis for the effect of diabetes on endpoints revealed that 
diabetes had significant „traditional‟ results in all subgroups, except for CVE in the 
CKD group where it failed to reach significance (see table 4.1.5). This means that 
diabetes is a risk factor for both CVE and mortality in the MHD population, as well 
as for mortality in the CKD population. Its effect on CVE in the CKD population is 
unclear at present, and only further follow-up can show whether diabetes has an 
adverse effect on CVE outcome in the CKD population. Although the present 
literature shows no evidence at the moment that diabetes in itself may be protective 
against CVE in the MHD population and therefore a component of reverse 
epidemiology, there are studies that show diabetes has no effect on CVD outcomes 
in this group [132] [529].  
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Table 4.1.5 Summary of 2-year follow up results in regards to the effect of diabetes 
on CVE and mortality. 
 
When it comes to glycaemic control within the diabetic ESRD population, Williams 
et al. showed a reversed relationship between HbA1c levels and CVE and mortality 
in the MHD population [132], while most observe better outcomes with tighter 
control [446, 530, 531]. Regression analyses were not carried out for HbA1c effects 
on CVE and mortality because of the smaller numbers in the diabetic subgroups 
and the fact that the study was not powered to analyse HbA1c. 
HbA1c is the most widely used marker of glycaemic control in patients with 
diabetes. Among the 183 CKD patients with diabetes, 171 had a recent HbA1c 
value recorded (within the past 6 months). The mean HbA1c in this group was 
7.5%±2.0% (range: 0.9%-14.8%), slightly above the ADA recommendation of <7% 
[532]. The mean HbA1c of the MHD group, however, was 6.8%±1.6% (range: 4.5%-
13%) in the 86 subjects with recent HbA1c values out of the 91 with diabetes. 
Comparison of mean HbA1c between the two groups showed significance, with a p-
value of 0.003. It was also observed that with the progression of CKD stage in figure 
3.1.10 (from 3 to 4 to 5 and onto MHD), mean HbA1c values dropped, and this 
decrease was statistically significant (p=0.001). Other studies have described 
similar observations in this population [529, 533]. 
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This improvement of glycaemic control with progression of kidney failure can be 
explained by the lowering of BMI through the stages which suggests calorie loss 
which can contribute to better glycaemic control. Secondly, it is probable that 
patients with higher HbA1c‟s who are poorly controlled do not go on to MHD, which 
may be because they do not survive long enough to go on to RRT or that they 
stabilize in the CKD stage and do not progress. 
In summary: 
 Diabetes increases the risk of both CVE and mortality in the combined cohort 
 In the CKD subgroup, diabetes significantly increases the risk of mortality, 
but not CVE 
 In the MHD subgroup, diabetes significantly increases the risk of CVE, with a 
trend towards increasing the risk of mortality, as well 
 Glycaemic control also seems to be important, with the trend showing 
increasing risk of both CVE and mortality with HbA1c above 7.0% in the 
combined population 
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4.1.5 Other risk factors 
There are many other identified risk factors for both CVE and mortality, several of 
which are mentioned in the introduction. This study is not powered to look at all the 
contested risk factors in renal disease, but it is important to look at the effect of 
important factors that may be altering survival outcomes.  
Ethnicity 
Analysis of the effect of ethnicity on CVE suggested the „Black‟ ethnic group had the 
highest risk of developing CVEs (HR=6.154, 95%CI: 2.141, 17.684, p=0.001), while 
the „White‟ ethnic group has the highest risk for mortality (Hazard Ratio=10.558, 
95%CI: 1.388, 80.314, p=0.023) (figure 3.1.17). This agrees with the present 
literature on the effect of ethnicity on survival in the ESRD population which reports 
better survival outcomes in the Asian ethnic group [534] and the ethnic groups that 
are categorised as Black [535-538] (see figure 4.1.3). 
 
 
Figure 4.1.3 Kaplan-Meier survivor function for unadjusted survival on 
haemodialysis by race/ethnicity among patients with ESRD for at least three 
months. Figure reproduced with permission [538] 
217 
 
When the population is broken down into the subgroups, regression analyses show 
that White ethnicity has the highest risk of mortality in both CKD and MHD groups, 
although the risk is greater in the MHD group, and Black ethnicity has much lower 
risk in both groups in comparison (figure 3.1.20). This finding is in agreement with 
present literature, where Black ethnicity is shown to be associated with better 
survival on haemodialysis [27]. However, the risk of CVE is higher among the Black 
ethnic group in comparison to the White ethnic group in both the CKD and MHD 
groups (figure 3.1.19).  
Interestingly, the Asian ethnic group seem to have a relatively low risk of CVE in the 
CKD group, but the highest risk of CVE in the MHD group. One explanation for this 
finding may be that the Asian subjects in the MHD group have more co-morbidities 
compared to their CKD counterparts. Another noteworthy point is that while the 
ethnic group categorised as „Mixed‟ consists of a relatively small proportion of 
patients (about 1% of the whole cohort), they show the highest risk for CVE in the 
CKD population – the lack of a line corresponding to Mixed ethnicity in the hazard 
plots of the MHD group is due to the fact that no subjects in this group were 
categorised as having Mixed ethnicity.  
Unfortunately, the small sample size in each ethnic subgroup prevented me from 
analysing effects of each risk factor on endpoints within these subgroups. As 
mentioned in the introduction, present literature implies that the reverse effect of 
cholesterol on survival in the haemodialysed population does not exist among Black 
individuals on MHD [300]. Longer follow-up period resulting increased number of 
events may allow further investigation of this point in the present cohort. 
Under-nutrition 
Poor nutrition seems to be essentially at the centre of all hypotheses surrounding 
reversed epidemiology findings, and it often goes hand in hand with inflammation to 
form the malnutrition-inflammation complex syndrome or the MICS. While the 
effects of inflammation will be looked at in detail in the next section, it is worth 
noting the nutritional discrepancies between the different groups.  
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Perhaps one of the questions most in need of an answer in the ESRD population is: 
what is the best marker for nutrition in this population? In the general population, 
BMI and lipid profile are the main surrogates of nutrition used in day to day practice. 
Using the same markers in the present ESRD population would tell us that the MHD 
population is less nourished than the CKD group, as their BMI, TC and TG is lower. 
But this comparison does not distinguish between those with „over-nutrition‟ and 
„under-nutrition‟. 
Co-morbidities 
ESRD is a long-term complication that is almost always secondary to a pre-existing 
condition, and patients with ESRD often suffer multiple long term conditions which 
are referred to as co-morbidities. When looking at the CVE and mortality rate in this 
population, it is important to keep in mind the effect of these co-morbidities. Up to 
five co-morbidities were recorded for each subject on the database, and although all 
statistical analyses were adjusted for co-morbidities, because the majority of 
subjects had at least one co-morbidity the results did not differ greatly before and 
after adjusting. But this does not mean the presence of co-morbidities cannot be 
used to explain outcomes.  
The most recurring co-morbidities in subgroups within the present cohort are listed 
in table 4.1.6 below. Subjects may have any number of co-morbidities at the same 
time, which is why the numbers are only to show the frequency of occurrence and 
do not add up to the total number of patients in the subgroups. Diabetes is not 
categorised as co-morbidity, as it is analysed as an independent risk factor in this 
study. 
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Table 4.1.6 Frequency of most common co-morbidities within the cohort studied. 
Pr-existing CVD remained the most prevalent condition even after deletion of 
hypertension (HTN), which may be a consequence of renal failure in some subjects. 
 
The most prevalent co-morbidity in this cohort is pre-existing CVD, and notably 
hypertension. However, it is difficult to distinguish between hypertension that was 
present before onset of kidney disease and hypertension that is caused by renal 
failure; pre-existing CVD remains the most prevalent co-morbidity even when HTN 
was deleted. This is important because subjects who start dialysis with diagnosed 
CVD have a 57% greater risk of developing non-fatal MI and 14% greater risk for 
cardiac death [539].  
The second most common condition in the MHD population is hyperparathyroidism, 
which is an outcome of ESRD (section 1.3). The rate of malignancy in the CKD 
group is 6.8%, which is acceptable considering the prevalence rate of malignancy in 
the UK population over 65 years old is reported at 7.5% [540] and the mean age for 
this group is 67 years. The prevalence rate in the MHD group is 10%, which is 
CKD (308) MHD (210)
Pre-existing CVD HTN (172) Pre-existing CVD HTN (132)
IHD (77) IHD (66)
PVD (75) PVD (39)
AF (15) AF (17)
CVA (7) CVA (12)
All others (13) All others (12)
Dyslipidaemia (69) Hyperparathyroidism (47) [plus 
Parathyroidectomy (14)]
Gout (23) Dyslipidaemia (32)
Cancer (21) Cancer (21)
COPD (19) Chronic Infection (TB/Hep B/Hep C) (20)
Hypothyroidism (17) Gout (19)
Hyperparathyroidism (11) COPD (16)
Chronic Infection (TB/Hep B/Hep C) (5) Hypothyroidism (10)
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higher than that of the CKD group, especially considering that this is a younger 
group, with a mean age of 64 years. Whether the higher prevalence of cancer in the 
MHD group is due to an increased incidence of malignancy as a result of the 
haemodialysis process itself, or secondary to other conditions that are common in 
this population (for example inflammation) is unknown. Specifically designed 
randomised controlled trials are needed to address this question and therefore 
reduce cancer rates, and ultimately mortality rates, in this population. 
In summary: 
 Ethnicity may have an effect on CVE and mortality outcome in both the CKD 
and MHD population, with White race at highest risk of mortality in both 
subgroups and Black race at highest risk of CVE in both subgroups 
 A marker of malnutrition specific to the ESRD population is needed to better 
establish its role in CVE and mortality in this population, as surrogate 
markers such as BMI, TC and TG can be misinterpreted in this population  
 The ESRD population is a complex one where subjects usually suffer 
multiple comorbidities that all possibly contribute to the high incidence of 
CVE and mortality in this population 
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4.2 Insulin Resistance and Inflammation in ESRD 
A subgroup of subjects from the entire cohort were recruited to form a „sub-cohort‟ 
from whom blood samples were taken and stored for further analysis; insulin 
resistance (HOMA-IR), inflammation (hs-CRP) and total adiponectin levels were 
quantified. This sub-cohort consists of 105 subjects, 55 of them are categorised as 
CKD (CKD 3=17, CKD 4=20, CKD 5=18) and 51 are on MHD. While insulin 
resistance quantification was carried out on all of the 106 subjects, inflammation 
and adiponectin measurements were available for 92 subjects. As with the previous 
part of the study, the mean values were compared between the subgroups to 
observe any significant differences between the groups. 
As this sub-cohort is part of the bigger cohort, 24-month follow-up data is also 
available for these subjects (table 4.2.1 below, also see figure 3.2.4). 
 
 
Table 4.2.1 Number of endpoints reached in the CKD and MHD subgroups within 
the sub-cohort. 
 
  
CKD MHD Total
No event 40 (72.7%) 37 (72.5%) 77 (72.6%)
CVE 12 (21.8%) 11 (21.6%) 23 (21.7%)
Death 3 (5.5%) 3 (5.9%) 6 (5.7%)
Total 55 (100%) 51 (100%) 106 (100%)
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4.2.1 Insulin Resistance 
Insulin resistance is a known predictor of CVE and cardiovascular death in the 
general population [358, 360, 541-543].  Insulin resistance is a common link 
between obesity, hypertension, dyslipidaemia and diabetes, and therefore it is 
important to understand its behaviour in ESRD. Patients with chronic kidney 
disease develop insulin resistance, and this is due to loss of kidney function [331, 
544], insulin resistance inducing adipokines such as TNF-alpha and leptin [333, 
334, 545], reduced secretion due to increased intracellular calcium (caused by PTH 
imbalance) [341, 342], and physical inactivity [332]. It has also been shown that 
insulin resistance can be the cause, rather than consequence, of CKD in non-
diabetic subjects [345, 347, 350, 352].  
To quantify insulin resistance, the HOMA of insulin resistance (HOMA-IR) index was 
used, where a fasting glucose sample and 3 consecutive fasting insulin samples (5 
minutes apart) were incorporated into the HOMA calculator (©The University of 
Oxford 2004, available to download from http://www.dtu.ox.ac.uk). In addition to 
HOMA-IR, HOMA of beta-cell function (%B) and HOMA of insulin sensitivity (%S) 
were also calculated; %B and %S are expressed as percentages of a normal 
reference population. As the distribution of HOMA-IR, %B and %S were not normal 
(Shapiro-Wilk test of normality p-values<0.001) in the subgroups of the sub-cohort, 
the  Mann-Whitney U test was used to compare means between the subgroups that 
had relatively small numbers of subjects, and a one-way ANOVA test was used to 
compare means between the CKD and MHD subgroups. 
The calculations revealed that there was statistically significant difference between 
HOMA-IR and %S means between all subgroups (CKD and MHD, and with 
diabetes and without within each group – see table 4.2.2 below), but the difference 
between mean %B values did not reach statistical significance in any of the 
subgroups. The fact that HOMA-IR and %S behave similarly is due to the nature of 
the measure; %S is simply the reciprocal of HOMA-IR [378]. Having said that, it is 
important to keep in mind that while %S values may be used in subjects on insulin 
therapy, its use has not been validated among patients receiving exogenous insulin. 
As for %B, it cannot be used for subjects on insulin therapy as it measures beta-cell 
functionality based on insulin secretion, which cannot be accurately measured in 
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subjects receiving exogenous insulin [378]. Therefore, the only index that can be 
used in all subgroups is HOMA-IR. 
 
 
Table 4.2.2 Summary of HOMA indices within the different subgroups of the „sub-
cohort‟; comparison of means between the CKD and MHD groups is carried out 
using a one-way ANOVA test, and the comparison of means between the 
subgroups within the subgroups is carried out using the Mann-Whitney U test, which 
is a non-parametric test that compares means between two independent groups 
that are not normally distributed, as is the case here. 
 
Comparing HOMA-IR between CKD and MHD group shows significantly higher 
HOMA-IR in the CKD group (p=0.004); in the MHD group, the diabetic patients 
predictably have significantly higher mean HOMA-IR. Of note is that the mean 
HOMA-IR in the non-diabetic subjects in the MHD group is below 1.0; this means 
that it is lower than general population with „normal‟ insulin sensitivity. This suggests 
that while loss of kidney function causes insulin resistance, haemodialysis may 
correct the situation, and subjects‟ insulin resistance returns to normal, and maybe 
HOMA2-IR %B %S
Mann-Whitney 
U Results
ANOVA
Results
All (105) 2.08±202
(0.40-11.50)
121.61±112.59
(9.50-697.90)
99.0±75.80
(8.70-279.90)
- -
CKD-all (55) 2.63±2.31
(0.40-11.50)
140.81±145.12
(13.80-697.90)
73.57±59.01
(8.70-263.00)
-
P(IR)= 
0.004
P(%B)= 
0.076
P(%S)<
0.001
CKD-DM 
(33)
3.29±2.56
(0.60-11.50)
133.22±154.20
(13.80-697.90)
51.68±36.42
(8.70-157.60) P(IR)= 0.003
P(%B)= 0.135
P(%S)= 0.004CKD-non-
DM (22)
1.65±1.46
(0.40-5.70)
152.19±133.03
(49.10-549.70)
106.41±71.06
(17.50-263.00)
MHD-all 
(50)
1.50±1.46
(0.40-6.60)
101.68±55.35
(9.50-244.80)
126.08±83.43
(15.10-279.90)
-
MHD-DM 
(19)
2.45±1.85
(0.40-6.60)
96.46±74.13
(9.50-244.80)
82.79±80.28
(15.10-263.50) P(IR)= 0.001
P(%B)= 0.142
P(%S)= 0.001MHD-non-
DM (31)
0.91±0.70
(0.40-4.10)
104.87±40.99
(51.90-212.10)
152.62±74.74
(24.20-279.90)
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even below that. The cause of this lower insulin resistance than the general 
population, if true, may be a result of low BMI and an under-nourished state in these 
subjects. These results are comparable to those reported by other similar studies, 
where insulin resistance was shown to improve on dialysis [546-548]. However, it is 
important to note that the use of HOMA-IR has not been specifically validated in 
haemodialysed subjects; to attempt to overcome this as much as possible, I drew 
the blood samples for HOMA analysis from the patients right before they started the 
dialysis process.  
Regression analyses were carried out to look at the effect of HOMA-IR on CVE and 
mortality, as with other risk factors in the whole cohort. Logistic regression did not 
show a significant effect for IR on CVE or mortality in the combined cohort or its 
subgroups.  
The fact that CKD subjects have markedly elevated IR compared to the general 
population seems to go hand in hand with the fact that these subjects have higher 
incidence of CVE, for which IR is a proven risk factor of in the general population. 
However, as the MHD population has an even higher incidence of both CVE and 
mortality, it would be expected that if anything, they should be more insulin 
resistant. The fact that this is not the case may be due to a „reversed‟ effect of IR on 
endpoints in the MHD population, and this hypothesis is in part confirmed by the OR 
below 1.0 for CVE and death in the MHD group, although this result is not 
statistically significant, the trend is toward a reverse effect. Longer follow-up may 
lead to significant results in this subgroup, which can then be used to support the 
hypothesis. 
In summary: 
 Insulin resistance as measured by HOMA-IR increases with decreasing renal 
function (increasing CKD stage), but returns to near normal levels in the 
MHD population 
 In this population, increased HOMA-IR did not increase risk of CVE or 
mortality in the combined cohort or either subgroup 
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4.2.2 Inflammation 
It was earlier explained that inflammation may induce an insulin resistant state and 
therefore be potentially responsible for CVD in insulin resistant individuals [405] 
(section 1.2.2.1). Inflammation is also present in both pre-dialysis CKD and on 
dialysis [414] and this is thought to be caused by a number of factors, including the 
accumulation of serum cytokines [415]. However, inflammation is primarily a 
concern for the dialysis population, and it has been used to explain the high CVD 
rate in this population [549, 550]. The logical assumption would then be that 
because inflammation is high in dialysis, so is insulin resistance. As discussed in 
the previous section, in this sub-cohort study insulin resistance was lower in the 
dialysis population, and that in itself is contrary to that logic. To see if the 
relationship between inflammation and insulin resistance is similar to that of the 
general population, a reliable marker of inflammation was measured in the sub-
cohort, as well. CRP is an acute phase reactant that is commonly used as a marker 
of systemic inflammation, and a high sensitivity CRP test was used for this study, as 
this test allows for the more accurate measurement of CRP at lower levels.  
Hs-CRP was measured in 92 subjects within the sub-cohort; 48 in the CKD 
subgroup and 44 in the MHD subgroup. As hs-CRP was not normally distributed in 
this sub-cohort (Shapiro-Wilk test, p<0.001), the Kruskal Wallis non-parametric test 
was used to compare means between subgroups (instead of the ANOVA, which 
assumes normality). For comparison between the larger subgroups, the student‟s t-
test was used [466] . These tests showed that hs-CRP significantly increased with 
loss of renal function, and was higher among the MHD population. 
Looking at the effect of inflammation on endpoints, logistic regression was carried 
out for the whole sub-cohort, as well as the CKD and MHD subgroups. Log hs-CRP 
was used in the analyses, as hs-CRP was not a normally distributed variable. Hs-
CRP showed a statistically significant effect in increasing the risk of CVE 
considerably in the CKD subgroup. It also showed significantly increased risk of 
mortality for the whole sub-cohort. Hs-CRP did not show a significant effect on 
mortality in the subgroups, or on CVE in the MHD group. Keeping in mind that the 
MHD group has significantly higher hs-CRP (p=0.003), this may mean that the MHD 
population have become resistant to the effects of the chronic inflammatory state on 
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the cardiovascular system. On the other hand, these results might be related to the 
relatively small sample size or the relatively short follow-up time, and may change 
with longer follow-up and more endpoints.  
It is interesting that the MHD population studied here has a more inflammatory state 
compared to the CKD population, and is more insulin sensitive at the same time. 
Given the rich body of literature citing inflammation as an important factor in the 
pathogenesis of insulin resistance (as described in sections 1.2.1.4 and 1.2.2.1), 
perhaps the coexistence of these two conditions in the MHD population can also be 
classified as reverse epidemiology.  
In summary: 
 Hs-CRP levels in this population are highly elevated in some patients, but do 
not seem to form a pattern in regard to CKD stage and/or MHD status 
  Increased hs-CRP is associated with increased risk of CVE in the CKD 
subgroup, but not in the MHD subgroup 
 Increased hs-CRP seems to increase the risk of mortality in the combined 
cohort 
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4.2.3 Adiponectin 
Adiponectin is thought to be important in regulating both insulin resistance and 
inflammation (detailed in section 1.1.4.3.2); it „improves‟ both conditions and has 
been shown to be cardio-protective. Total adiponectin was measured to see 
whether it retained these qualities in the ESRD population and also if it was 
correlated with either insulin resistance or inflammation in this sub-cohort. 
Comparison of mean total adiponectin levels between the different subgroups 
shows that total adiponectin consistently increases with progression of renal failure 
(p=0.041) but is lower in MHD, although it is still higher than the level in CKD stage 
3. When comparing the means between the whole CKD subgroup and the MHD 
subgroup, the difference is not statistically significant, although the mean total 
adiponectin in both groups is well above the normal range in the general population 
(which is reported to be an estimated 10 ± 5 ug/mL [246, 551] in normal weight non-
diabetic individuals). The fact that the difference between mean total adiponectin 
levels in CKD and MHD subgroups is not significant could explain why the CVE 
rates between these two subgroups are similar (21.8% in the CKD group and 21.6% 
in the MHD group).  
To look at the effect of total adiponectin on endpoints, logistic regression analyses 
were performed in the whole sub-cohort, as well as the CKD and MHD subgroups. 
Interestingly, total adiponectin did not have a statistically significant effect on CVE in 
the whole sub-cohort or the CKD and MHD subgroups, but it did have a negative 
effect on mortality in the whole group and in the MHD subgroup; increasing total 
adiponectin increased the risk of death in these groups. This result is 
counterintuitive as adiponectin is thought to be protective. This finding may be 
secondary to the inflammatory state that is present in these individuals (adiponectin 
is anti-inflammatory and therefore increases in inflammatory states), or it may be 
due to reduced clearance by the kidneys. Another explanation may be that although 
total adiponectin is elevated, the isoforms circulationg in these subjects have 
different physiological properties than those in the general population. 
The fact that increased total adiponectin is associated with increased risk of 
mortality in this sub-cohort agrees with the limited literature on the subject. In non-
ESRD subjects, the cardio-protective nature of adiponectin is mostly observed in 
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cross-sectional studies [552-554], and prospective studies such as that carried out 
by Kistorp et al. showed that high, rather than lower, adiponectin is associated with 
greater all-cause mortality rate [168]. A few cross-sectional studies on subjects with 
type 1 diabetes have also shown an increased prevalence of CVD and retinopathy 
with higher adiponectin levels [555-557]. Although experimental evidence strongly 
confirms the role of adiponectin in reducing CVD risk, epidemiologic studies have 
not yet reached a conclusive role for the molecule. In the CKD population, both non-
dialysed and dialysed, studies have observed a cardio-protective nature for 
adiponectin [558-560], but none showed adiponectin to be similarly associated with 
all-cause mortality.  
Menon et al. used frozen samples and follow-up data from the Modification Diet in 
Renal Disease Study [561] to look at the effect of adiponectin on CV death and all-
cause mortality in the cohort, which consisted of subjects with CKD stage 3 and 4. 
Their results showed a direct relationship between adiponectin and all-cause as well 
as CV mortality [562]. The results of the present study confirm these findings.  
In summary: 
 Total adiponectin levels increase with decreasing renal function but are not 
normalised with haemodialysis 
 Total adiponectin levels are similarly significantly higher than normal in the 
CKD and MHD group 
 In this population, higher adiponectin is associated with increased mortality in 
the combined group as well as in the MHD subgroup, but has no significant 
effect on CVE 
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4.3 Glycaemic Control in Haemodialysis 
The need to balance glycaemic targets to avoid hypoglycaemia with the risks of 
microvascular disease from hyperglycaemia requires accurate glycaemic 
assessment.  This is especially so for diabetic patients on MHD who have a high 
prevalence of microvascular and macrovascular disease and are at an increased 
risk of asymptomatic hypoglycaemia during HD [563].  Continuous subcutaneous 
glucose monitors are ideally suited for diabetic patients on MHD, as unlike the 
HbA1c they can examine short-term glycaemic changes around the time of dialysis 
and are unaffected by urea, RBC life-span and RBC production. 
The subjects in this study were typical of the UK type 2 diabetes MHD population 
with a long duration of diabetes (18.8 ±7.6 years) and high prevalence rates of 
established vascular disease (15/17). This preliminary study suggests that CGM 
offers clinically useful data for such a high risk group.  
4.3.1 Reliability of HbA1c 
The need to set the appropriate glycaemic targets for type 2 diabetic patients with a 
high CVD risk was highlighted by the Action to Control Cardiovascular Risk in 
Diabetes study (ACCORD) [439] and the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) [442] 
randomized controlled trials.  These studies recruited subjects at high risk of CVD 
and neither showed any CVD benefit from targeting HbA1c levels below 6.5% and 
7%, respectively.  The ACCORD study actually showed a small increase in overall 
mortality when targeting HbA1c below 6.5%.  That low HbA1c levels may not confer 
survival benefit in ESRD was also suggested by a one year follow-up study of 
23,000 American diabetic subjects [132].  By contrast good glycaemic control prior 
to dialysis does appear to have some CVD benefit [446]. Thus, it may be necessary 
for HbA1c targets originally based on low CVD non-CKD populations to be re-
evaluated for diabetic haemodialysis patients. 
The HbA1c is a measure of the irreversible non-enzymatic glycation product of one 
or both NH2-terminal valines of the beta-hemoglobin chain. In ESRF the HbA1c 
assay can be affected by interference from carbamylated haemoglobin formed from 
urea-derived isocyanate that accumulates in uraemia [448]. However advances in 
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reverse-phase cation exchange HPLC analyzers, as used in this study, allow for 
greater haemoglobin peak separation [564].  
Shortened red blood cell (RBC) life-span or increased RBC production [451] can 
occur in ESRD and both can falsely lower HbA1c values by reducing the RBC 
glycaemic exposure time. However, a study of 23 MHD patients on regular 
erythropoietin therapy and with stable haemoglobin values, concluded that it was 
the ambient glucose concentration rather than RBC life-span that was the major 
determinant, as no correlation between RBC life-span and HbA1c measured by 
either immunoassay or HPLC was shown [452]. Starting or increasing erythropoietin 
treatment could, by increasing RBC production, falsely lower HbA1c values by 
increasing the proportion of younger RBCs and thereby reducing glucose exposure 
time. In the present study all subjects had stable haemoglobin values and their 
erythropoietin doses had remained constant over the preceding 3 months.  
In this study of stable diabetic MHD out-patients the HbA1c value obtained using a 
methodology unaffected by ureamia and the predicted HbA1c derived from 48 hour 
CGM profiles were discordant by 1.7% (6.9 ± 1.2% vs. 8.6 ± 2.3%). The lack of 
correlation between the laboratory HbA1c value and the haemoglobin 
concentration, erythropoietin dose, urea or serum albumin suggests that these 
variables do not explain the observed differences in the laboratory HbA1c values 
and the predicted HbA1c. However the sample size may have been too small to 
detect weak associations between laboratory HbA1c and these variables.   
It is highly likely that the degree to which the HbA1c under-reported glycaemic 
profiles in these subjects led to a false sense of clinical reassurance concerning 
their diabetic management, and prevented changes to their diabetic medications. 
The clinical implications of this study are that HbA1c analyses that are not affected 
by carbamylated haemoglobin may still under-report HbA1c in stable MHD patients. 
4.3.2 Effect of dialysis on glycaemia 
The present study showed over a 2 day period that the GlucoDay®S CGM device 
recorded significantly higher glucose profiles on the day off dialysis than the day on 
dialysis and that the overall level of glycaemia was higher than the laboratory 
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HbA1c suggested.  
The CGM glucose values during the first 24-hour monitoring period (day of dialysis), 
including the six-hour nocturnal period were significantly less than the second 24-
hour monitoring period. During the hours of midnight to 6.00am, the only common 
time all subjects were resting and not eating, the magnitude of this difference 
ranged from -8.5 to 17.1 mmol/L, with a median difference of 4.2 mmol/L. These 
differences in glucose profiles were not explained by the difference in 24-hour 
energy intake, changes in medication or dialysis shift. However, there are potential 
limitations over the accuracy of the food diaries, as data was collected over 48 
hours only and was self-reported. The food data did highlight that all subjects were 
likely to be malnourished as they consumed less than their recommended intake. 
The CGM data also showed that 4 subjects had hypoglycaemia, <2.5 mmol/L over 
30 minutes or more, and that this occurred within 24 hours of dialysis in 3 subjects. 
The lowest glucose recording for all subjects was within the first 24-hour period, 
with the majority being within 12 hours of dialysis.  
The differences between the days on and off dialysis also suggest that for some 
patients‟ increases in medication doses should be given on the days off dialysis to 
improve control, while hypoglycaemic therapy may need to be reduced for the day 
on dialysis or delayed according to the time of dialysis.  
Larger studies on MHD populations will be required to determine if data from CGM 
should be used for medication adjustments around dialysis days in order to optimise 
glycaemic control and avoid hypoglycaemia. 
In summary: 
 HbA1c may not be a reliable tool for assessing glycaemic control in diabetic 
subjects on MHD, as it often underestimates glycaemia 
 Glycaemic profiles of haemodialysed diabetic subjects are significantly 
different on dialysis and on off-dialysis days 
 Patients are at risk of hypoglycaemia within the first 12 hours of being 
dialysed 
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 The calorific intake of subjects in this study was significantly lower than their 
recommended daily intake 
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4.3 Study Limitations 
This is a cohort study, where patients with ESRD are prospectively followed and the 
endpoints under investigation are CVE and mortality. Ideally, in a cohort study 
subjects are recruited at a single point in treatment or disease and followed over 
time, whereas in this study subjects were recruited from all ages, with differing 
degrees of renal failure, and differing durations of diabetes and haemodialysis. 
While this is more practical as it provides us with data in a shorter duration of follow-
up, the limitation caused by this is that our cohort may be representing survivors on 
haemodialysis or with diabetes, and therefore biased. Subjects that have survived 
longer on MHD and have fewer or less serious co-morbidities may be over-
represented and this would lower the risks associated with endpoints. Similarly, in 
the CKD population, subjects with longstanding CKD 3 or 4 may have stabilized and 
therefore not have an equal risk for endpoints compared to their counterparts. If 
these points were to be taken into account for a future study, such a study would 
need a much longer follow-up duration in order to produce results, which would 
perhaps be impractical. 
The other limitation is that because patients were recruited from an already existing 
patient population, the data used is the information collected for patient care in 
practice, which is limited in both nature and quality. Although this type of study is 
valuable in that it uses readily available data and therefore considerably reduces 
costs, the data collected is not necessarily all of what is needed to answer specific 
research questions, risk factor data may be missing for some patients. However, the 
fact that laboratory tests were done at a centralised laboratory means that their 
results are quality controlled and standardised. Lastly, this study did not capture any 
silent MIs.  
The fact that the serum samples were a one-off sample and follow-up samples were 
not taken limits this study. Follow-up samples would have helped establish whether 
increase or decrease in the measured factors leads to better outcomes. The study 
was initially designed to recruit 20 subjects right before starting MHD to collect 
samples from, and take follow-up samples from 8 weeks into MHD. Unfortunately, 
most of the subjects approached did not agree to take part in the study within the 
given timeframe, and of the few who did (a total of 7), only one actually completed 
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the study with a follow-up sample. Once this part of the study is carried out, 
individual changes in insulin resistance, inflammation and adiponectin can be 
correlated with outcomes, and a clearer role can be described for these factors in 
ESRD. 
Studies designed to look at effects of different factors on survival outcomes usually 
require follow-up over a long period of time; examples of such studies include the 
Framingham Study, the UKPDS and the EDIC/DCCT study. As the mortality rate is 
quite high in the ESRD and especially in the dialysed population, such very long 
studies are impractical. For this patient population, with an annual mortality rate of 
around 20%, a follow-up period of five years is practical and can reveal useful 
additional information, as the majority of patients would have reached an endpoint 
by then. Longer follow-up time means that more patients are likely to fall out of 
ICKTI‟s care and therefore be lost to follow-up. Revisiting the present database at 
months 36, 48 and 52 is recommended to continue follow-up and maximise the use 
of its data. The implementation of the NHS Care Records Services (CRS) in the 
near future (scheduled for launch at Imperial College Healthcare NHS Trust in mid-
2010) means that detailed follow-up of patients will most likely become less difficult, 
and even if patients move out of the Trust‟s care, an integrated comprehensive 
digital recording database will be at hand to monitor mortality. 
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Chapter 5: Conclusions 
5.1 Cardiovascular risk factors in ESRD 
In the combined cohort, high systolic blood pressure, diabetes and low total 
cholesterol were identified as risk factors for cardiovascular events. BMI, diastolic 
blood pressure and triglycerides had no significant effect on risk of cardiovascular 
events. Risk factors for all-cause mortality were slightly different, with diabetes, low 
total cholesterol and low triglycerides as significant risk factors for mortality. BMI 
and systolic and diastolic blood pressure did not have a significant effect on risk of 
death in this cohort. 
In the CKD subgroup, the only significant risk factor identified for cardiovascular 
events was low total cholesterol. BMI, systolic and diastolic blood pressure, 
triglycerides and diabetes had no significant effect on risk of cardiovascular events 
in the CKD subgroup. The risk factors for all-cause mortality in the CKD subgroup 
were identified as:  diabetes, low systolic and diastolic blood pressure, low total 
cholesterol and low triglycerides. BMI did not have a significant effect on risk of 
death in the CKD subgroup.  
In the MHD subgroup, only diabetes was a significant risk factor for cardiovascular 
events. BMI, systolic and diastolic blood pressure, total cholesterol and triglycerides 
had no significant effect on risk of cardiovascular events in the MHD subgroup. The 
only risk factor for mortality in this subgroup was low triglycerides. The presence of 
diabetes also had a strong trend towards increasing risk of death in this population, 
but the result did not reach statistical significance. BMI, systolic and diastolic blood 
pressure and total cholesterol had no significant effect on risk of death in the MHD 
subgroup. 
These results confirm the study‟s first hypothesis: „patients on haemodialysis have 
different cardiovascular risk factors compared to CKD patients‟. However, although 
it was initially thought that „reverse epidemiology‟ is present in the MHD population, 
in the cohort studied here it is the CKD population that shows aspects of reverse 
epidemiology (BP, TC and TG), and this reversal of risk factors was overall more 
evident for all-cause mortality risk, and less so for cardiovascular risk. 
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5.2 Insulin resistance and inflammation in ESRD 
In the sub-cohort study, it was observed that Insulin resistance as measured by 
HOMA-IR increases with decreasing renal function (increasing CKD stage), but 
returns to near normal levels in the MHD population.  
None of the potential risk factors thought to be involved in cardiovascular event risk, 
i.e. insulin resistance (HOMA-IR), inflammation (hs-CRP) and total adiponectin, 
showed a significant effect on risk of cardiovascular events in this study. However, 
elevated hs-CRP and total adiponectin levels had a significant effect on increasing 
the risk of death. HOMA-IR did not affect risk of mortality in this group. 
In the CKD group within the sub-cohort, high hs-CRP was identified as a 
cardiovascular risk factor. HOMA-IR and total adiponectin did not have a significant 
effect on cardiovascular risk in this group. None of the factors studied here showed 
a significant effect on risk of mortality in the CKD group within the sub-cohort. 
In the MHD group within the sub-cohort, none of the potential risk factors studied 
had a significant effect on risk of cardiovascular events. High total adiponectin was 
identified as a predictor of mortality in this group, while HOMA-IR and hs-CRP had 
no significant effect on risk of death in this MHD subgroup. 
The results confirm the study‟s second hypothesis: „although the MHD population is 
known to be insulin resistant, insulin sensitivity is improved once patients 
commence haemodialysis compared to the preceding late CKD stages‟. Moreover, 
these results show that changes in insulin resistance are independent of changes in 
hs-CRP and total adiponectin. They also suggest that insulin resistance may not be 
an important predictor of outcome in the ESRD population.  
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5.3 Glycaemic control on haemodialysis 
This part of the study showed that HbA1c may not be a reliable tool for assessing 
glycaemic control in diabetic subjects on MHD, as it often underestimates glycaemia 
even in subjects with stable haemoglobin. Furthermore, the study identified a 
potentially dangerous pattern in the glycaemic profile of diabetic subjects on MHD: 
that mean glucose values are consistently significantly lower on dialysis days 
compared to non-dialysis days. This effect seems to be independent of food intake, 
as there was no significant difference in calorific intake between on and off dialysis 
days in this population.  
It was also observed that the majority of subjects had their lowest glucose levels 
within the first 12 hours of being dialysed, which can put these subjects at an 
increased risk of asymptomatic hypoglycaemia during this time. Furthermore, it was 
observed that the total calorific intake of subjects in this study was significantly 
lower than their recommended daily intake, which suggests better dietetic input may 
be beneficial for this population. 
These results confirm the study‟s third hypothesis: „HbA1c may not be an accurate 
measurement of glycaemic control among the haemodialysed population with 
diabetes, thus warranting new methods for assessing glycaemic control in this 
population‟. Given the significant variability in glycaemic profiles of this population, it 
is perhaps better not to use long term estimates of glycaemia, but rather more 
frequent short and medium term indicators of circulating glucose, which may help 
better tailor hypoglycaemic treatment for diabetic subjects on MHD. 
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5.4 Future Research 
The present study is based primarily on 24-month follow up data of the cohort 
described. Longer follow up time will lead to more endpoints, and the statistical 
analyses will become more powerful as number of endpoints increase. Most „risk 
engine‟ studies run for a minimum of 5 years; with the 20% cardiovascular event 
rate over 24 months, the ideal amount of time for this study to follow its subjects 
would be 10 years, or until all subjects have reached an endpoint. Lack of statistical 
significance for some risk factors may then be interpreted more robustly. 
As this study was observational in design, it did not explore potential mechanisms 
for its findings. Further research is needed to identify potential regulatory 
substances that may be involved in causing the discrepancy between risk factors in 
the CKD and MHD populations.  
To determine whether the increased insulin resistance observed in the CKD 
population is a result of accumulation of insulin due to loss of kidney function or the 
result of a metabolic change in the subjects, a further study could be designed to 
look at insulin mediated glucose uptake of adipocytes in these subjects. Adipocytes 
could be donated by renal transplant recipients, which would include both CKD and 
MHD patients and allow for comparison of adipocyte behaviour in the two 
populations.  
To further explore the effect of haemodialysis on glycaemia, future research is 
needed to compare glycaemic profiles of diabetic and non-diabetic subjects to 
establish whether the variability observed in the diabetic population in this study is 
present in the non-diabetic population, and if so whether the non-diabetic 
haemodialysed patient is at risk of haemodialysis induced asymptomatic 
hypoglycaemia. Further studies should also be designed to identify better markers 
for glycaemia, as HbA1c may not be a reliable marker in these subjects.  
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Appendix II: Statistical analysis of effect of risk factors on endpoints 
Summary of study objectives 
PART 1 Analysis plan 
1. To compare the risk of occurrence of any CV events between levels of: 
a. BP, lipid (cholesterol or HDL), diabetes status and BMI 
b. If diabetes status is important, subanalysis of diabetic subjects will be 
conducted using HbA1c 
2. To compare the risk of time to first CV event between levels of: 
a. BP, lipid (cholesterol or HDL), diabetes status and BMI 
b. If diabetes status is important, subanalysis of diabetic subjects will be 
conducted using HbA1c 
3. To compare the risk of time to all-cause death event between levels of: 
a. BP, lipid (cholesterol or HDL), diabetes status and BMI 
b. If diabetes status is important, subanalysis of diabetic subjects will be 
conducted using HbA1c 
 
PART 2 Analysis plan 
4. Subgroup analysis of primary dataset (ntotal=518) by haemodialysis status (nY=210, 
nN=307, nmissing=1): To compare the risk of occurrence of any CV events (during the 2-
year follow up) between levels of SBP, DBP, total cholesterol, triglycerides, diabetes 
status and BMI 
5. Subgroup analysis by haemodialysis status: To compare the risk of occurrence of death 
(during the 2-year follow up) between levels of SBP, DBP, total cholesterol, 
triglycerides, diabetes status and BMI 
6. Analysis of HOMA dataset: To compare the risk of occurrence of any CV events (during 
the 2-year follow up) between levels of adiponectin and HOMA-IR. Analysis will be 
repeated with adjustment for confounding by CKD stage. 
7. Analysis of HOMA dataset: To compare the risk of occurrence of death (during the 2-
year follow up) between levels of adiponectin and HOMA-IR. Analysis will be repeated 
with adjustment for confounding by CKD stage. 
 
PART 3 Analysis plan 
8. Analysis of HOMA dataset: To compare the risk of occurrence of any CV events (during 
the 2-year follow up) between levels of HOMA-IR and CRP. Analysis will be repeated 
with adjustment for confounding by CKD stage. 
9. Analysis of HOMA dataset: To compare the risk of occurrence of death (during the 2-
year follow up) between levels of HOMA-IR and CRP. Analysis will be repeated with 
adjustment for confounding by CKD stage. 
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10. Analysis of HOMA dataset: Subgroup analysis by haemodialysis status: To compare the 
risk of occurrence of any CV events (during the 2-year follow up) between levels of 
adiponectin, HOMA-IR and CRP. 
11. Analysis of HOMA dataset: Subgroup analysis by haemodialysis status: To compare the 
risk of occurrence of death (during the 2-year follow up) between levels of adiponectin, 
HOMA-IR and CRP.  
12. To compare the risk of occurrence of death (during the 2-year follow up) between levels 
of SBP, DBP, total cholesterol, triglycerides, diabetes status and BMI 
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Results 
 
Objective 1: Results of “end of 2 year” CVE risk analysis (logistic model) 
Covariates 
Univariable 
analysis or 
Adjusted for 
ANYCONDIS 
Analysis set  
(Actual no. 
subjects in 
analysis) 
FAS (N=518) 
DAS (N=274) 
Odds ratio 
(OR) for 1 
unit increase 
in covariate 
(Note for 
DIABETIC it 
is comparison 
between 
diabetics to 
non-diabetics) 
95% CI of OR p-value  
SBP FAS (n=410) 1.011 (1.002,1.021) 0.023 
SBP adjusted FAS (n=410) 1.010 (1.001,1.020) 0.035 
DBP FAS (n=402) 1.004  (0.989, 1.021) 0.560 
DBP adjusted FAS (n=402) 1.005 (0.989,1.022) 0.531 
TC FAS (n=449) 0.681 (0.550,0.844) <0.001 
TC adjusted FAS (n=449) 0.709 (0.570,0.882) 0.002 
HDL FAS (n=301) 0.550 (0.281,1.060) 0.074 
HDL adjusted FAS (n=301) 0.577 (0.298,1.118) 0.103 
BMI FAS (n=464) 1.017 (0.984,1.050) 0.318 
BMI adjusted FAS (n=464) 1.015 (0.983,1.048) 0.374 
DIABETIC FAS (n=495) 1.622 (1.074,2.449) 0.021 
DIABETIC 
adj’d 
FAS (n=495) 1.506 (0.989,2.293) 0.056 
HBA1C DAS (n=224) 1.053 (0.905,1.224) 0.505 
HBA1C 
adjusted 
DAS (n=224) 1.055 (0.907,1.227) 0.486 
Note: ANYCONDIS is binary: “0” if no comorbidities and “1” if 1 or more comorbidities.  
SBP=systolic blood pressure (mmHg), DBP=diastolic blood pressure (mmHg), TC=total 
cholesterol (units?), HDL=high density lipoprotein (units?), BMI=body mass index (kg/m
2
), 
DIABETIC=status indicator for having diabetes, HBA1C=HbA1c. 
 
Comments: 
 Negligible confounding by adjusting for any comorbidity (ANYCONDIS). 
 Effect of TC is not intuitive. What is happening in this study population? 
 I did not attempt to build a CVE risk (glm) model with multiple covariates because 
such a model would definitely include TC, which is nonsensical. 
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Covariates 
Univariable 
analysis or 
Adjusted for 
ANYCONDIS 
Analysis set  
(Actual no. 
subjects in 
analysis) 
FAS (N=518) 
DAS 
(N=274) 
X 
increment  
Odds 
ratio 
(OR) for 
X unit 
increase 
in 
covariate 
95% CI of 
OR 
p-value  
SBP FAS (n=410) 10 1.118 (1.016,1.23) 0.023 
SBP adjusted FAS (n=410) 10 1.109 (1.007,1.221) 0.035 
DBP FAS (n=402) 10 1.049  (0.892, 1.234) 0.560 
DBP adjusted FAS (n=402) 10 1.054 (0.894,1.240) 0.531 
TC FAS (n=449) 1 0.681 (0.550,0.844) <0.001 
TC adjusted FAS (n=449) 1 0.709 (0.570,0.882) 0.002 
HDL FAS (n=301) 1 0.550 (0.281,1.060) 0.074 
HDL adjusted FAS (n=301) 1 0.577 (0.298,1.118) 0.103 
BMI FAS (n=464) 5 1.085 (0.924,1.275) 0.318 
BMI adjusted FAS (n=464) 5 1.078 (0.916,1.264) 0.374 
DIABETIC FAS (n=495) 1 1.622 (1.074,2.449) 0.021 
DIABETIC 
adj’d 
FAS (n=495) 1 1.506 (0.989,2.293) 0.056 
HBA1C DAS (n=224) 1 1.053 (0.905,1.224) 0.505 
HBA1C 
adjusted 
DAS (n=224) 1 1.055 (0.907,1.227) 0.486 
  
279 
Objective 2: Results of 2 year follow up time to CVE analysis (Cox proportional 
hazards model) 
Covariates 
Univariable 
analysis or 
Adjusted for 
ANYCONDIS 
Analysis set  
(Actual no. 
subjects in 
analysis) 
FAS (N=518) 
DAS (N=274) 
Hazard ratio 
(HR) 
95% CI of HZ p-value  
SBP FAS (n=410) 1.010 (1.000,1.020) 0.017 
SBP adjusted FAS (n=410) 1.010 (1.001,1.020) 0.028 
DBP FAS (n=402) 1.000 (0.990, 1.020) 0.680 
DBP adjusted FAS (n=402) 1.000 (0.989,1.020) 0.660 
TC FAS (n=449) 0.722 (0.606,0.860) <0.001 
TC adjusted FAS (n=449) 0.748 (0.626,0.893) 0.001 
HDL FAS (n=301) 0.565 (0.213,1.030) 0.061 
HDL adjusted FAS (n=301) 0.604 (0.336,1.090) 0.092 
BMI FAS (n=464) 1.020 (0.988,1.040) 0.280 
BMI adjusted FAS (n=464) 1.010 (0.986,1.040) 0.340 
DIABETIC FAS (n=495) 1.530 (1.070,2.190) 0.020 
DIABETIC 
adj’d 
FAS (n=495) 1.440 (1.000,2.070) 0.050 
HBA1C DAS (n=224) 1.040 (0.920,1.180) 0.520 
HBA1C 
adjusted 
DAS (n=224) 1.040 (0.923,1.180) 0.500 
Note: ANYCONDIS is binary: “0” if no comorbidities and “1” if 1 or more comorbidities.  
SBP=systolic blood pressure (mmHg), DBP=diastolic blood pressure (mmHg), TC=total 
cholesterol (units?), HDL=high density lipoprotein (units?), BMI=body mass index (kg/m
2
), 
DIABETIC=status indicator for having diabetes, HBA1C=HbA1c. 
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Objective 3: Results of 2 year follow up time to DEATH analysis (Cox proportional 
hazards model) 
Covariates 
Univariable 
analysis or 
Adjusted for 
ANYCONDIS 
Analysis set  
(Actual no. 
subjects in 
analysis) 
FAS (N=518) 
DAS (N=274) 
Hazard ratio 
(HR) 
95% CI of HZ p-value  
SBP FAS (n=421) 1.010 (0.997,1.020) 0.140 
SBP adjusted FAS (n=421) 1.010 (0.996,1.020) 0.190 
DBP FAS (n=413) 0.986 (0.964, 1.010) 0.220 
DBP adjusted FAS (n=413) 0.987 (0.964, 1.010) 0.240 
TC FAS (n=461) 0.647 (0.489,0.858) 0.002 
TC adjusted FAS (n=461) 0.675 (0.507,0.898) 0.007 
HDL FAS (n=309) 0.366 (0.128,1.040) 0.060 
HDL adjusted FAS (n=309) 0.404 (0.146,1.120) 0.081 
BMI FAS (n=475) 0.983 (0.942,1.030) 0.450 
BMI adjusted FAS (n=475) 0.983 (0.941,1.030) 0.440 
DIABETIC FAS (n=507) 1.820 (1.050,3.150) 0.033 
DIABETIC 
adj’d 
FAS (n=507) 1.700 (0.974,2.960) 0.062 
HBA1C DAS (n=232) 0.973 (0.816,1.160) 0.760 
HBA1C 
adjusted 
DAS (n=232) 0.972 (0.815,1.160) 0.750 
Note: ANYCONDIS is binary: “0” if no comorbidities and “1” if 1 or more comorbidities.  
SBP=systolic blood pressure (mmHg), DBP=diastolic blood pressure (mmHg), TC=total 
cholesterol (units?), HDL=high density lipoprotein (units?), BMI=body mass index (kg/m
2
), 
DIABETIC=status indicator for having diabetes, HBA1C=HbA1c. 
 
Comments: 
 Negligible confounding by adjusting for any comorbidity (ANYCONDIS). 
 Effect of TC is not intuitive. What is happening in this study population? 
 I did not attempt to build a CVE or DEATH survival model with multiple covariates 
because such a model would definitely include TC, which is nonsensical. 
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Objective 4: Results of subgroup analysis by haemodialysis status for “end of 2 year” 
CVE risk analysis (logistic model) 
 
Analysis sets recap 
 FAS n=518 
 FAS with observed CVE outcome n=506 
Let define analysis sets: 
 Patients on haemodialysis (HAS-Y) n=210 
 Patients not on haemodialysis (HAS-N) n=307 
 Patients with unknown haemodialysis status n=1 
Finally, let define HAS-Y and HAS-N with observed CVE outcome: 
 Patients on haemodialysis and with observed CVE outcome (HAS-Y) n=208 
 Patients not on haemodialysis with observed CVE outcome (HAS-N) n=298 
 
Covariates 
Univariable 
analysis  
Analysis set  
HAS-Y 
(N=210)  
HAS-N 
(N=307) 
(Actual no. 
subjects in 
analysis) 
 
 
X 
increment  
Odds 
ratio 
(OR) for 
X unit 
increase 
in 
covariate 
95% CI of 
OR 
p-value  
SBP HAS-Y 
(n=179) 
1 1.001 (0.989,1.014) 0.830 
SBP  HAS-N 
(n=231) 
1 1.012 (0.993,1.031) 0.217 
DBP HAS-Y 
(n=171) 
1 0.988 (0.967,1.010) 0.299 
DBP  HAS-N 
(n=231) 
1 1.000 (0.972,1.028) 0.981 
TC HAS-Y 
(n=194) 
1 0.924 (0.676,1.262) 0.619 
TC  HAS-N 
(n=255) 
1 0.589 (0.419,0.828) 0.002 
TG HAS-Y 
(n=183) 
1 0.952 (0.667,1.357) 0.784 
TG  HAS-N 
(n=253) 
1 0.921 (0.679,1.248) 0.594 
BMI HAS-Y 
(n=201) 
1 1.047 (0.997,1.100) 0.066 
BMI  HAS-N 
(n=263) 
1 1.037 (0.988,1.088) 0.137 
DIABETIC HAS-Y 
(n=207) 
1 2.538 (1.417,4.546) 0.002 
DIABETIC  HAS-N 
(n=288) 
1 1.488 (0.792,2.795) 0.217 
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Note: SBP=systolic blood pressure (mmHg), DBP=diastolic blood pressure (mmHg), 
TC=total cholesterol (units?), TG=Triglycerdes (units?), BMI=body mass index (kg/m
2
), 
DIABETIC=status indicator for having diabetes. 
 
Comments: 
We have trawled through the data with many tests without controlling the type 1 error 
anywhere. All analyses are therefore exploratory and need to be confirmed with a more 
focussed study. 
 
There is some evidence for interaction with haemodialysis status in effect of diabetic status. 
There seems to be some evidence for interaction in effect of TC, although this is probably 
driven by the few high TC values seen in the non-haemodialysis group.  
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Objective 5: Results of subgroup analysis by haemodialysis status for “end of 2 year” 
death risk analysis (logistic model) 
 
Analysis sets recap 
 FAS n=518 
 FAS with observed death outcome n=518 
Let define analysis sets: 
 Patients on haemodialysis (HAS-Y) n=210 
 Patients not on haemodialysis (HAS-N) n=307 
 Patients with unknown haemodialysis status n=1 
 
Covariates 
Univariable 
analysis  
Analysis set  
HAS-Y 
(N=210)  
HAS-N 
(N=307) 
(Actual no. 
subjects in 
analysis) 
 
 
X 
increment  
Odds 
ratio 
(OR) for 
X unit 
increase 
in 
covariate 
95% CI of 
OR 
p-value  
SBP HAS-Y 
(n=180) 
1 1.013 (0.998,1.029) 0.095 
SBP  HAS-N 
(n=240) 
1 0.958 (0.926,0.990) 0.011 
DBP HAS-Y 
(n=172) 
1 0.986 (0.958,1.014) 0.327 
DBP  HAS-N 
(n=240) 
1 0.929 (0.879,0.982) 0.010 
TC HAS-Y 
(n=196) 
1 0.864 (0.576,1.296) 0.480 
TC  HAS-N 
(n=264) 
1 0.500 (0.284,0.880) 0.016 
TG HAS-Y 
(n=185) 
1 0.546 (0.310,0.964) 0.037 
TG  HAS-N 
(n=261) 
1 0.468 (0.219,0.998) 0.049 
BMI HAS-Y 
(n=203) 
1 0.994 (0.934,1.059) 0.856 
BMI  HAS-N 
(n=272) 
1 1.028 (0.955,1.105) 0.465 
DIABETIC HAS-Y 
(n=209) 
1 2.032 (0.997,4.146) 0.051 
DIABETIC  HAS-N 
(n=297) 
1 3.846 (1.101,13.433) 0.035 
Note: SBP=systolic blood pressure (mmHg), DBP=diastolic blood pressure (mmHg), 
TC=total cholesterol (units?), TG=Triglycerdes (units?), BMI=body mass index (kg/m
2
), 
DIABETIC=status indicator for having diabetes. 
 
Comments: 
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We have trawled through the data with many tests without controlling the type 1 error 
anywhere. All analyses are therefore exploratory and need to be confirmed with a more 
focussed study. 
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Objective 6: Results of HOMA dataset analysis for “end of 2 year” CVE risk analysis 
(logistic model) 
 
Note: HOMA dataset does not contain any CVE or DEATH variables. Need to merge in this 
data from the primary dataset. 
 
Analysis sets  
 HOMA FAS n=107 
 HOMA FAS overlapping with primary dataset n=95 
 HOMA FAS overlapping with primary dataset and with observed CVE outcome 
n=88 
 HOMA FAS overlapping with primary dataset and with observed CVE 
outcome+CKD known n=88 
 
Covariates 
Univariable 
analysis or 
Adjusted for CKD 
stage and/or 
interaction  
Analysis set  
FAS 
(N=107)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
inc  
Odds ratio 
(OR) for X 
unit increase 
in covariate 
95% CI of 
OR 
p-value  
Adiponectin FAS (n=74) 1 0.982 (0.959,1.005) 0.118 
Adiponectin+CKD  FAS (n=74) 1 0.980 (0.956,1.004) 0.097 
Adiponectin+CKD 
stage+interaction 
FAS (n=74) 1 CKD3: 0.989 
CKD4: 0.963 
CKD5: 0.983 
(0.934,1.045) 
(0.912,1.018) 
(0.955,1.012) 
0.713 
0.181 
0.242 
HOMA no data     
HOMA +CKD  no data     
HOMA +CKD 
stage+interaction 
no data     
Note: CKD is trinary: stage “3”, “4” or “5”.  
Model for Adiponectin+CKD include CKD as categorical variables. 
Model for Adiponectin+CKD+ interaction includes CKD as categorical variables and 
interactions with adiponection. 
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Objective 7: Results of HOMA dataset analysis for “end of 2 year” death risk analysis 
(logistic model) 
 
Note: HOMA dataset does not contain any CVE or DEATH variables. Need to merge in this 
data from the primary dataset. 
 
Analysis sets  
 HOMA FAS n=107 
 HOMA FAS overlapping with primary dataset n=95 
 HOMA FAS overlapping with primary dataset and with observed death outcome 
n=95 
 HOMA FAS overlapping with primary dataset and with observed death 
outcome+CKD known n=94 
 
Covariates 
Univariable 
analysis or 
Adjusted for CKD 
stage and/or 
interaction  
Analysis set  
FAS 
(N=107)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
inc  
Odds ratio 
(OR) for X 
unit increase 
in covariate 
95% CI of 
OR 
p-value  
Adiponectin FAS (n=81) 1 1.031 (1.004,1.058) 0.024 
Adiponectin+CKD  FAS (n=80) 1 1.041 (1.004,1.079) 0.029 
Adiponectin+CKD 
stage+interaction 
FAS (n=80) 1 CKD3: 1.000 
CKD4: 1.025 
CKD5: 1.043 
(0.000,1e75) 
(0.927,1.135) 
(1.003,1.085) 
1 
0.626 
0.036 
HOMA no data     
HOMA +CKD  no data     
HOMA +CKD 
stage+interaction 
no data     
Note: CKD is trinary: stage “3”, “4” or “5”.  
Model for Adiponectin+CKD include CKD as categorical variables. 
Model for Adiponectin+CKD+ interaction includes CKD as categorical variables and 
interactions with adiponection. 
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Objective 8: Results of HOMA dataset analysis for “end of 2 year” CVE risk analysis 
(logistic model) 
 
Note: new HOMA dataset (“15.07.09 Data Sheet for statistical analysis with ALL 
HOMAs.xlsx”) contains an additional variable “endpoint”. This variable has factor levels = 
(“CVE”, “dead”, “no data”, “no event”). It is a mixture of CVE events and DEATH events 
and woll not identify overlap between these two events in the same subject. As such this 
variable cannot be used on its own. I will need to cross-check this variable with the primary 
dataset. 
 
           PRIMARY 
HOMA       cve no cve <NA> 
  CVE       23      0    0 
  dead       3      3    0 
  no data    0      0   15 
  no event   0     59    4 
  <NA>       0      0    0 
 
Analysis sets  
 HOMA FAS n=107 
 HOMA FAS overlapping with primary dataset n=95 
 HOMA FAS overlapping with primary dataset and with observed CVE outcome 
n=88 
 HOMA FAS overlapping with primary dataset and with observed CVE 
outcome+CKD+HDx known n=88 
 HOMA FAS not overlapping with primary dataset and with observed CVE outcome 
n=4 
 HOMA FAS not overlapping with primary dataset and with observed CVE 
outcome+CKD+HDx n=4 
 
For consistency with analysis in Objective 6, the analysis in Objective 8 will be based on the 
n=88, i.e. not n=88+4. 
  
288 
 
Covariates 
Univariable 
analysis or 
Adjusted for CKD 
stage and/or 
interaction  
Analysis set  
FAS 
(N=107)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
inc  
Odds ratio 
(OR) for X 
unit increase 
in covariate 
95% CI of 
OR 
p-value  
Adiponectin 
See analysis objective 6 
Adiponectin+CKD  
Adiponectin+CKD 
stage+interaction 
HOMA FAS (n=87) 1 1.171 (0.937,1.464) 0.165 
HOMA +CKD  FAS (n=87) 1 1.158 (0.925,1.449) 0.200 
HOMA +CKD 
stage+interaction 
FAS (n=87) 1 CKD3: 1.778 
CKD4: 1.543 
CKD5: 1.042 
(0.100,31.70) 
(0.815,2.922) 
(0.784, 1.385) 
0.695 
0.183 
0.777 
logCRP FAS (n=74) 1 1.485 (0.982, 2.246) 0.061 
logCRP +CKD  FAS (n=74) 1 1.523 (0.994, 2.334) 0.053 
logCRP +CKD 
stage+interaction 
FAS (n=74) 1 CKD3: 1.701 
CKD4: 2.307 
CKD5: 1.319 
(0.538, 5.371) 
(0.809, 6.583) 
(0.793, 2.192) 
0.365 
0.118 
0.286 
Note: CKD is trinary: stage “3”, “4” or “5”. logCRP=log transform of CRP values. 
Model for HOMA+CKD include CKD as categorical variables. 
Model for HOMA +CKD+ interaction includes CKD as categorical variables and 
interactions with HOMA. 
Model for logCRP+CKD include CKD as categorical variables. 
Model for logCRP +CKD+ interaction includes CKD as categorical variables and 
interactions with logCRP. 
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Objective 9: Results of HOMA dataset analysis for “end of 2 year” DEATH risk 
analysis (logistic model) 
 
Note: new HOMA dataset (“15.07.09 Data Sheet for statistical analysis with ALL 
HOMAs.xlsx”) contains an additional variable “endpoint”. This variable has factor levels = 
(“CVE”, “dead”, “no data”, “no event”). It is a mixture of CVE events and DEATH events 
and woll not identify overlap between these two events in the same subject. As such this 
variable cannot be used on its own. I will need to cross-check this variable with the primary 
dataset. 
 
           PRIMARY 
HOMA       alive dead <NA> 
  CVE         23    0    0 
  dead         0    6    0 
  no data      5    0   10 
  no event    61    0    2 
  <NA>         0    0    0 
 
Analysis sets  
 HOMA FAS n=107 
 HOMA FAS overlapping with primary dataset n=95 
 HOMA FAS overlapping with primary dataset and with observed DEATH outcome 
n=95 
 HOMA FAS overlapping with primary dataset and with observed DEATH 
outcome+CKD+HDx known n=94 
 HOMA FAS not overlapping with primary dataset and with observed DEATH 
outcome n=2 
 HOMA FAS not overlapping with primary dataset and with observed DEATH 
outcome+CKD+HDx n=2 
 
For consistency with analysis in Objective 6, the analysis in Objective 8 will be based on the 
n=88, i.e. not n=88+4. 
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Covariates 
Univariable 
analysis or 
Adjusted for CKD 
stage and/or 
interaction  
Analysis set  
FAS 
(N=107)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
inc  
Odds ratio 
(OR) for X 
unit increase 
in covariate 
95% CI of 
OR 
p-value  
Adiponectin 
See analysis objective 7 
Adiponectin+CKD  
Adiponectin+CKD 
stage+interaction 
HOMA FAS (n=94) 1 1.146 (0.823, 1.597) 0.419 
HOMA +CKD  FAS (n=93) 1 1.143 (0.812, 1.609) 0.442 
HOMA +CKD 
stage+interaction 
FAS (n=93) 1 CKD3: 1.000 
CKD4: 1.276 
CKD5: 1.058 
(0.000,infinity) 
(0.762, 2.137) 
(0.667, 1.678) 
1 
0.354 
0.810 
logCRP FAS (n=81) 1 1.032 (1.000, 1.064) 0.051 
logCRP +CKD  FAS (n=80) 1 1.035 (0.992, 1.080) 0.109 
logCRP +CKD 
stage+interaction 
FAS (n=80) 1 CKD3: 1.000 
CKD4: 1.084 
CKD5: 1.033 
(0.000, 
infinity) 
(0.914, 1.287) 
(0.993, 1.074) 
1 
0.355 
0.106 
Note: CKD is trinary: stage “3”, “4” or “5”. 
Model for HOMA+CKD include CKD as categorical variables. 
Model for HOMA +CKD+ interaction includes CKD as categorical variables and 
interactions with HOMA. 
Model for CRP+CKD include CKD as categorical variables. 
Model for CRP +CKD+ interaction includes CKD as categorical variables and interactions 
with CRP. 
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Objective 10: Results of subgroup analysis by haemodialysis status for HOMA dataset 
analysis for “end of 2 year” CVE risk analysis (logistic model)  
 
 
Covariates 
Univariable 
analysis  
Analysis set  
HAS-N 
(N=55) 
HAS-Y 
(N=51)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
inc  
Odds ratio 
(OR) for X 
unit increase 
in covariate 
95% CI of 
OR 
p-value  
Adiponectin HAS-N 
(n=31) 
1 0.979 (0.944, 1.014) 0.240 
Adiponectin HAS-Y 
(n=43) 
1 0.984 (0.954, 1.014) 0.292 
HOMA HAS-N 
(n=38) 
1 1.315 (0.963, 1.796) 0.085 
HOMA HAS-Y 
(n=49) 
1 0.996 (0.655, 1.513) 0.986 
logCRP HAS-N 
(n=31) 
1 2.008 (1.005, 4.010) 0.048 
logCRP HAS-Y 
(n=)43 
1 1.273 (0.717, 2.262) 0.409 
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Objective 11: Results of subgroup analysis by haemodialysis status for HOMA dataset 
analysis for “end of 2 year” DEATH risk analysis (logistic model)  
 
 
Covariates 
Univariable 
analysis  
Analysis set  
HAS-N 
(N=55) 
HAS-Y 
(N=51)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
inc  
Odds ratio 
(OR) for X 
unit increase 
in covariate 
95% CI of 
OR 
p-value  
Adiponectin HAS-N 
(n=37) 
1 1.016 (0.961, 1.074) 0.575 
Adiponectin HAS-Y 
(n=43) 
1 1.042 1.001,1.083) 0.041 
HOMA HAS-N 
(n=44) 
1 1.415 (0.909, 2.201 
) 
0.123 
HOMA HAS-Y 
(n=49) 
1 0.866 (0.374, 2.001) 0.736 
CRP HAS-N 
(n=37) 
1 1.025 (0.936, 1.123) 0.592 
CRP HAS-Y 
(n=43) 
1 1.797 (0.715, 4.518) 0.213 
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Objective 12: Results for “end of 2 year” death risk analysis (logistic model) 
 
Analysis sets recap 
 FAS n=518 
 FAS with observed death outcome n=518 
 
Covariates 
Univariable 
analysis  
Analysis set  
FAS 
(N=518)  
(Actual no. 
subjects in 
analysis) 
 
 
X 
increment  
Odds 
ratio 
(OR) for 
X unit 
increase 
in 
covariate 
95% CI of 
OR 
p-value  
SBP FAS (n=421) 1 1.010 (0.997, 1.023) 0.146 
DBP FAS (n=413) 1 0.985 (0.962, 1.009) 0.230 
TC  FAS (n=461) 1 0.635 (0.466, 0.864) 0.004 
TG FAS (n=447) 1 0.504 (0.322, .788) 0.003 
BMI  FAS (n=475) 1 0.982 (0.937, 1.028) 0.428 
DIABETIC  FAS (n=507) 1 1.869 (1.047, 3.334) 0.034 
Note: SBP=systolic blood pressure (mmHg), DBP=diastolic blood pressure (mmHg), 
TC=total cholesterol (units?), TG=Triglycerdes (units?), BMI=body mass index (kg/m
2
), 
DIABETIC=status indicator for having diabetes. 
 
Results are marginal over the subgroup results in Objective 5. 
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Appendix III: Comparison of means 
Supplementary Table 1: 
 
 
Supplementary Table 1 Comparison of mean BMI values in different subgroups of 
the study cohort. Mean BMI values, expressed as kg/m2, and standard deviations 
(SD) are shown for the entire cohort („combined‟), the CKD group as a whole 
(„CKD‟), the subsets of different CKD stages (CKD3, CKD 4 and CKD 5) and MHD 
groups. p-values are derived from comparisons of means carried out using the 
ANOVA test. 
 
Supplementary Table 2: 
 
 
Supplementary Table 2 Comparison of mean systolic BP values in different 
subgroups of the study cohort. Mean SBP values, expressed as mmHg, and 
standard deviations (SD) are shown for the entire cohort („combined‟), the CKD 
group as a whole („CKD‟), the subsets of different CKD stages (CKD3, CKD 4 and 
CKD 5) and MHD groups. P-values are derived from comparisons of means carried 
out using the ANOVA test. 
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Supplementary Table 3: 
 
 
Supplementary Table 3 Comparison of mean diastolic BP values in different 
subgroups of the study cohort. Mean DBP values, expressed as mmHg, and 
standard deviations (SD) are shown for the entire cohort („combined‟), the CKD 
group as a whole („CKD‟), the subsets of different CKD stages (CKD3, CKD 4 and 
CKD 5) and MHD groups. P-values are derived from comparisons of means carried 
out using the ANOVA test. 
 
Supplementary Table 4: 
 
 
 
Supplementary Table 4 Comparison of mean total cholesterol values in different 
subgroups of the study cohort. Mean TC values, expressed as mmol/l, and standard 
deviations (SD) are shown for the entire cohort („combined‟), the CKD group as a 
whole („CKD‟), the subsets of different CKD stages (CKD3, CKD 4 and CKD 5) and 
MHD groups. P-values are derived from comparisons of means carried out using 
the ANOVA test. 
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Supplementary Table 5: 
 
 
Supplementary Table 5 Comparison of mean triglyceride values in different 
subgroups of the study cohort. Mean TG values, expressed as mmol/l, and standard 
deviations (SD) are shown for the entire cohort (combined), the CKD group as a 
whole (CKD), the subsets of different CKD stages (CKD3, CKD 4 and CKD 5) and 
MHD groups. P-values are derived from comparisons of means carried out using 
the ANOVA test. 
 
Supplementary Table 6: 
 
 
 
Supplementary Table 6 Comparison of mean HbA1c values in different subgroups 
of the study cohort. Mean HbA1c values, expressed as %, and standard deviations 
(SD) are shown for the entire cohort („combined‟), the CKD group as a whole 
(„CKD‟), the subsets of different CKD stages (CKD3, CKD 4 and CKD 5) and MHD 
groups. P-values are derived from comparisons of means carried out using the 
ANOVA test. 
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Supplementary Table 7: 
 
 
Supplementary Table 7 Summary of HOMA-IR ± SD in the CKD and MHD 
subgroups, as well as the subgroups within the CKD group; the Kruskal Wallis test 
was used to compare means between the CKD 3, CKD 4, CKD 5, and MHD 
subgroups, while the student t-test was used to compare means between the CKD 
and MHD groups. 
 
  
CKD-All (55) CKD 3 (17) CKD 4 (20) CKD 5 (18) MHD (50)
HOMA-IR 2.63±2.31 1.78±1.30 2.52±2.73 3.57±2.33 1.50±1.46
Kruskal-Wallis 
Results
P=0.001
T-test P=0.002
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Supplementary Table 8: 
 
 
Supplementary Table 8 Comparison of means ± SD (range) for markers of 
inflammation for the CKD and MHD subgroups, as well as the subgroups within the 
CKD group; the Kruskal Wallis test was used to compare means between the CKD 
3, CKD 4, CKD 5, and MHD subgroups, while the student t-test was used to 
compare means between the CKD and MHD groups 
  
Hs-CRP Log hs-CRP
All (92)
8.92±18.94
(0.17-157.13)
0.55±0.59
(-0.77-2.20)
CKD- All (47)
5.62±11.35
(0.19-72.47)
0.36±0.57
(-0.72-1.86)
CKD 3 (16)
7.97±17.57
(0.19-72.47)
0.39±0.66
(-0.72-1.86)
CKD 4 (18)
5.43±7.62
(0.49-31.98)
0.42±0.53
(-0.31-1.50)
CKD 5 (13)
2.98±3.28
(0.22-11.56)
0.23±0.52
(-0.66-1.06)
MHD (44)
12.64±24.37
(0.37±157.13)
0.79±0.51
(-0.43-2.20)
Kruskal Wallis
Results 
P=0.003 P=0.003
T-test Results P=0.103 P=0.232
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Supplementary Table 9: 
 
 
Supplementary Table 9 Comparison of means ± SD (range) for adiponectin for the 
CKD and MHD subgroups, as well as the subgroups within the CKD group; the 
Kruskal Wallis test was used to compare means between the CKD 3, CKD 4, CKD 
5, and MHD subgroups, while the student t-test was used to compare means 
between the CKD and MHD groups. 
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Appendix IV: Ethics documents 
 
Supplement 1: Letter of invitation  
 
         Department of   
Endocrinology 
           Extension: 34682 
        
 
 
 
Re: Study Ref Number: 06/Q0406/148 
 
Short Title: CV Risk Factors & Insulin Resistance in Renal Impaired Patients 
 
 
 
Dear  
 
I am writing to invite you to take part in a research programme connected with your 
treatment at the West London Renal and Transplant Centre. Please find enclosed a 
patient information sheet giving more details. If you have any questions, please do 
not hesitate to contact us. I look forward to meeting you at your forthcoming clinic 
appointment. 
 
Yours sincerely 
 
 
 
Dr Sara Kazempour A. 
 
Clinical Research Fellow 
 
 
Invitation letter version 1.2, 27.11.2006 
Supplement 2: Patient information sheet 
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   Hammersmith Hospital 
Du Cane Road 
London 
W12 0HS 
 
Tel: 020 8383 1000 
www.hhnt.org 
 
Registration Number: 06/Q0406/148 
 
INFORMATION SHEET for RESEARCH PARTICIPANTS 
 
Version 1.3, 27.11.2006 
 
Study title 
 
Identifying cardiovascular risk factors in diabetic and non−diabetic patients with different 
degrees of renal impairment and measuring their insulin sensitivity by using the HOMA 
(Homeostatic Model Assessment) index. 
 
Invitation Paragraph 
 
You are being invited to take part in a research study in which we are looking at the role of 
risk factors for heart disease in renal patients. We are investigating this because there have 
been some investigations that suggest risk factors for heart disease in renal patients may 
be different than for other people. Before you decide whether or not to participate it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with friends, 
relatives and your GP if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether or not you wish to take part.  
 
If you decide to take part, please let us know beforehand if you have been involved in any 
other study during the last year. If you decide not to take part your treatment will not be 
affected by your decision. You are free to withdraw at any time without explanation and 
your subsequent treatment will not be affected. 
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Thank you for reading this. 
 
What is the purpose of the study? 
 
The purpose of this study is to investigate whether there are differences in risk factors for 
heart disease in patients with compromised kidney function and the general population. We 
hope this will help us understand how to prevent heart disease more effectively in patients 
with kidney disease. The study will take about twenty minutes of your time while we discuss 
whether you would like to take part and formally seek your consent. You will then be seen 
between one and three times over the next two years, each time for about twenty minutes, 
where three small fasting blood samples will be taken at five minute intervals. This will be 
done at the same time as your routine clinic visit and you will not be asked to make any 
additional trips to the hospital.  
 
Why have I been chosen? 
 
We have chosen to ask you to take part in this study, because you have kidney disease 
and you do/do* not have diabetes. We are asking 850 people to take part in this initial 
study. (* delete as appropriate). 
 
Do I have to take part? 
 
It is up to you decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form, you will also be 
given a copy of the consent form. If you do decide to take part you are still free to withdraw 
at any time and without giving a reason. This will not affect the standard of care you 
receive. 
 
What will happen to me if I take part? 
 
If you do decide to take part we would like your permission to take your height, weight and 
waist circumference and access your medical records for your latest laboratory test results. 
We will also ask you to fast for half a day before coming in at your next clinic visit; if you are 
diabetic and are taking insulin, we will ask you to delay your morning dose of insulin while 
you are fasting. Where we will take three small (5ml, about one teaspoon full) tubes of 
blood from you while you are having the routine blood tests that you will need as part of 
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your care. You may be asked to permit us to repeat this one or two times over the next two 
years. 
 
This is a Prospective study which means that we will collect the data we need over the 
next two years and calculate the risk of heart disease associated with each factor. In 
addition to identifying risk factors for heart disease in people with impaired kidney function, 
we will also be measuring insulin resistance, which is a condition that regularly develops 
with kidney disease and can be a cause of heart disease in these people.  
 
What do I have to do? 
 
You do not need to make any alterations to your lifestyle to take part in this study. You 
should continue taking any medicines you are on and continue the rest of your life as 
normal on the day of the clinic appointment. 
 
What are the side effects of taking part? 
 
The only side effect that may arise from taking part in this study is due to fasting. This will 
be minimised by exclusion of anyone not medically fit enough, and limitation of length of 
fast. If you are diabetic, we will also ask you to delay your morning dose of insulin while you 
are fasting, so that there will be no increased chance of having a hypo. The volume of blood 
we are taking is well within the range of what is normally taken at a routine diagnostic blood 
test. 
What are the possible disadvantages and risks of taking part? 
 
As stated above there are no obvious risks to taking part in this study. 
 
What are the possible benefits of taking part? 
 
There is no benefit to you personally from taking part in this study. The study is aimed at 
helping us identify risk factors for heart disease among people with reduced kidney 
function. 
 
What if there is a problem? 
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Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 2. 
In case you feel the need to make a complaint, you can contact: 020 8383 4682.    
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it and you would not be 
identified in any publications emanating from the study. 
 
Contact for further information 
 
For further information contact Dr Sara Kazempour, Department of Endocrinology, 
Hammersmith Hospital. Tel 020 8383 4682 or email s.kazempour@imperial.ac.uk.   
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
 
Part 2  
 
What will happen if I don’t want to carry on with the study? 
 
As explained before, if you decide not to take part your treatment will not be affected by 
your decision. You are free to withdraw at any time without explanation and your 
subsequent treatment will not be affected. 
 
What if there is a problem? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone‟s negligence, then you may have 
grounds for a legal action but you may have to pay for it.  Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms would be available to you. 
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Complaints:  
 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions 020 8383 4682.  If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure (or Private Institution).  Details can be obtained from the hospital. 
 
Notifying your GP 
 
With your permission if you decide to take part in this study we would like to inform your 
GP. This will help keep your GP fully informed and also give him or her the opportunity to 
raise any concerns you may have on your behalf. 
 
What will happen to any samples I give? 
 
During the course of this study, we will be asking you to allow us to take up to three blood 
samples over two years. These samples will be used to measure your body‟s sensitivity to 
insulin, a hormone that regulates blood sugar. The data obtained will be recorded, and any 
excess samples will be destroyed. 
 
Will any genetic tests be done?  
 
No. 
 
What will happen to the results of the research study? 
 
We will aim to publish the results of this study in a medical journal. We will also use the 
results to direct further research in the area. 
 
Who is organising and funding the research? 
 
The research is organised by Dr Jeremy Turner and Imperial College. The organisation 
funding this research is the King Faisal Foundation. 
 
Who has reviewed the study? 
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The study has been reviewed by the Hammersmith research ethics committee as well as 
the Imperial College Higher Degrees Research Committee. 
 
 
Thank you for taking time to read this and if you decide to take part in the study, thank you, 
again. 
 
Dr Sara Kazempour 
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Supplement 3: Consent form 
 
Hammersmith Hospital 
Du Cane Road 
London 
W12 0HS 
 
Tel: 020 8383 1000 
www.hhnt.org 
Study Number: 06/Q0406/148 
Patient Identification Number for this trial: 
 
CONSENT FORM 
(version 1.3, 27.11.2006) 
 
Title of Project: 
 
Identifying cardiovascular risk factors in diabetic and non−diabetic patients with 
different degrees of renal impairment and measuring their insulin sensitivity by using 
the HOMA (Homeostatic Model Assessment) index. 
 
Name of Researcher: Dr Sara Kazempour Ardebili      
1. I confirm that I have read and understand the information sheet 
dated ...27/11/2006....  (version ...1.3…) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.         
        
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected.            
    
3. I understand that relevant sections of any of my medical notes and data collected 
during the study, may be looked at by responsible individuals from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to my records. 
                           
4. I agree to my GP being informed of my participation in the study.             
 
5. I agree to take part in the above study.       
 
________________________ ________________   ___________________ 
Name of Patient Date  Signature 
 
_________________________ ________________   ___________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
_________________________ ________________   ___________________ 
Researcher Date  Signature 
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Supplement 4: Follow-up questionnaire 
 
Study Registration Number: 06/Q0406/148 
Questionnaire Version 1.2 
 
Title of study: Identifying cardiovascular risk factors in diabetic and non−diabetic patients 
with different degrees of renal impairment and measuring their insulin sensitivity by using 
the HOMA (Homeostatic Model Assessment) index. 
 
What is the purpose of the study? 
The purpose of this study is to investigate whether there are differences in risk factors for 
heart disease in patients with compromised kidney function and the general population. We 
hope this will help us understand how to prevent heart disease more effectively in patients 
with kidney disease. This part of the study will take about 5 minutes of your time while we 
ask you to provide us with some information.  
 
Why have I been chosen? 
We have chosen to ask you to take part in this study, because you have kidney disease. 
We are asking 550 people to take part in this part of the study.  
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognized from it and you would not be 
identified in any publications emanating from the study. 
If you have any questions in regards to either this questionnaire or the study in general, 
please contact Dr Sara Kazempour at Hammersmith Hospital on 020 8383 4682 or by 
email: Sara.KazempourArdebili@imperial.nhs.uk. 
Regards, 
Dr S Kazempour 
 
Please continue to the next page. 
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Instructions: Please tick the appropriate answer to the questions below and return this 
sheet in the pre-paid, self-addressed envelope provided.  
 
Questions: 
1- Have you been admitted to the hospital in the past two years? Please tick: 
 
◊ Yes  
◊ No 
 
If no, please proceed to question 4. 
 
2- What was/were the reason/s for your hospital stay? 
 
 
3- Have you been admitted to the hospital to have any procedures performed on your 
heart?  
If yes, what? Please tick: 
◊ CABG (Coronary Artery Bypass Graft) 
◊ Coronary angioplasty / PTCA (Percutaneous Transluminal Coronary Angioplasty) 
◊ Any other interventions that treat coronary heart disease: (please specify) 
 
 
4- Have you been admitted for or diagnosed with any of the following in the past two 
years? Please tick: 
◊ Stroke 
◊ TIA (Transient Ischaemic Attack) 
◊ MI 
◊ Any other condition relating to the heart or vascular system: (please specify) 
 
Finally, please write your name and/or hospital number in the space below. Again, we 
assure you that this data will be kept confidential and will be anonymised prior to analysis. 
 
 First name: 
 Last name: 
 Hospital number: 
Thank you for answering these questions.   
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Supplement 5: Amendment to previous ethics application 
 
NOTICE OF SUBSTANTIAL AMENDMENT 
 
For use in the case of all research other than clinical trials of investigational medicinal 
products (CTIMPs).  For substantial amendments to CTIMPs, please use the EU-approved 
notice of amendment form (Annex 2 to ENTR/CT1) at 
http://eudract.emea.eu.int/document.html#guidance. 
 
To be completed in typescript by the Chief Investigator in language comprehensible to a lay 
person and submitted to the Research Ethics Committee that gave a favourable opinion of 
the research (“the main REC”).  In the case of multi-site studies, there is no need to send 
copies to other RECs unless specifically required by the main REC. 
 
Further guidance is available at http://www.corec.org.uk/applicants/apply/amendments.htm. 
 
 
Details of Chief Investigator: 
 
 
Name: Dr Anne Dornhorst 
Address: 
 
 
 
     Department Diabetes and Endocrinology 
Hammersmith Hospital 
Du Cane Road 
London 
W12 0NN 
 
Telephone 0208 383 4604 
E-mail:   a.dornhorst@imperial.ac.uk 
Fax:  
 
 
 
Full title of study: 
 
 
Quantifying the 24 hour glycaemic response of a 
low glycaemic index diet in free living people with 
type 2 diabetes treated with insulin: a pilot study 
 
 
Name of main REC: 
 
 
Hammersmith and Queen Charlotte’s & Chelsea 
hospitals 
 
REC reference number: 
 
 
2002/6260 
 
Date study commenced: 
 
 
2002 
 
Protocol reference (if applicable), 
current version and date: 
 
 
 
 
Amendment number and date: 
 
 
Version 5     24th July 06 
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Type of amendment (indicate all that apply in bold) 
 
(a) Amendment to information previously given on the REC application form 
 
Yes                No            
 
If yes, please refer to relevant sections of the REC application in the “summary of changes” 
below. 
 
(b) Amendment to the protocol 
 
Yes             No             
 
If yes, please submit either the revised protocol with a new version number and date, 
highlighting changes in bold, or a document listing the changes and giving both the previous 
and revised text. 
 
(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any 
other supporting documentation for the study 
 
Yes                No             
 
If yes, please submit all revised documents with new version numbers and dates, highlighting 
new text in bold. 
 
 
 
Is this a modified version of an amendment previously notified to the REC and given 
an unfavourable opinion? 
 
 Yes                No               
 
 
 
 
Summary of changes 
 
Briefly summarise the main changes proposed in this amendment using language 
comprehensible to a lay person.  Explain the purpose of the changes and their significance for 
the study.  In the case of a modified amendment, highlight the modifications that have been 
made. 
 
If the amendment significantly alters the research design or methodology, or could otherwise 
affect the scientific value of the study, supporting scientific information should be given (or 
enclosed separately).  Indicate whether or not additional scientific critique has been obtained. 
 
A recent audit under taken within our Trust on the diabetic care of patients 
receiving haemodialysis showed their diabetic ‘control,’ as assessed using the 
standard biochemical indictor of control (HbA1c), was better than expected. In 
addition the frequency of reported hypoglycaemic episodes was less than 
expected. 
 
We would like to assess diabetic haemodialysis patient‟s glycaemic control now using a 
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„Glucoday‟ Monitor‟ to see whether the standard HbA1c measurement in these patients 
provides an accurate reflection of their day to day blood glucose control. We also wish to 
assess whether any dietary changes on the days of dialysis is affecting overall glycaemic 
control 
 
This amendment differs from the original protocol in a number of ways: 
 
1. The continuous monitor used will be a „Glucoday‟ rather than the previously used 
„minimed monitor‟. The Glucoday monitor although made by a different 
manufacturer it is used clinically in a similar manner to that of the minimed 
monitor. 
2. The patients will only be required to wear the monitor for one 48 hour period, this 
will cover one day on dialysis and an adjacent day when they are not on dialysis. 
3. The patients will be asked to complete a food diary, during the time they are being 
monitored. 
4. The subjects will be recruited from the haemodialysis units in the west London 
region (as covered by the West London Renal and Transplant Centre, 
Hammersmith Hospital). 
 
 
 
 
Any other relevant information 
 
Applicants may indicate any specific ethical issues relating to the amendment, on which the 
opinion of the REC is sought. 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of enclosed documents 
 
Document Version Date 
Information Sheet for Research Participants 5 25th July 2006 
Participant Consent Form 5 25th July 2006 
Letter to GP  1 25th July 2006 
Documentation of Changes to Protocol - 25
th July 2006 
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Supplement 6: Patient information sheet for CGM study 
 
INFORMATION SHEET FOR RESEARCH PARTICIPANTS 
You will be given a copy of this Information Sheet 
 
Title of Project: 
Quantifying the 48-hour glycaemic control in diabetic patients on haemodialysis who 
are eating a low glycaemic index diet as appropriate for diabetes and kidney 
disease. 
 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following the information carefully and discuss 
it with friends, relatives, and your doctor, if you wish. Ask us if there is anything that 
is not clear or if you would like more information. 
 
We will be happy to let you have a copy of the leaflet entitled “Medical Research 
and You” published by Consumers for Ethics in Research (CERES). This leaflet 
gives more information about medical research and looks at some questions you 
may want to ask.  If you would like a copy please ask.  
 
What is the purpose of the study? 
 
We know that being on haemodialysis effects people in many different ways.  We 
are interested in looking at how it may affect your blood sugar control.  Diet is 
important in patients who have kidney failure and diabetes.  Low glycaemic index 
starchy foods such as pasta, fruit and beans are reported to help low glucose levels 
after a meal. There is no data in people outside of the laboratory situation, going 
about their normal living or indeed on dialysis. There is a new meter that can sense 
blood sugar every couple of minutes for 2 days.  For the first time, this allows the 
possibility of determining the effect of diet when people are at home and on dialysis. 
We believe that the introduction of a low glycaemic index diet, which contains many 
slowly absorbed starchy foods, will improve blood glucose control over 24-hours.  
 
What is being tested? 
 
We know that low glycaemic index carbohydrates like those that you are 
encouraged to eat as part of your usual diabetic and renal diet help to lower blood 
sugars. There is little information on the effect of this advice when given verbally 
and the effect on blood sugars when people have a free choice of what to eat. We 
are particularly interested in seeing how haemodialysis affects your choice of foods 
on the days you are being dialysed and those days you are not, and how these food 
choices may affect your blood sugars. 
 
Why have I been chosen? 
 
We have asked you to take part in this study because you have diabetes and are 
receiving haemodialysis. We are keen to discover more about the affects that 
haemodialysis and a low glycaemic diet have on your blood sugar levels. We want 
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to see if you blood sugars are different during a day you are being dialysed 
compared with a day you are not being dialysed, and if any difference in blood 
sugar on the dialysis days can be explained by differences in the choice of 
carbohydrates you eat on day you are dialysed. 
 
What is involved and what will I have to do? 
 
The study lasts for 2 days.  On the 1st day we will fit a blood glucose monitor that 
detects the level of glucose in the blood every couple of minutes.  You will have a 
special electrode placed under the skin on your tummy and this may hurt a little 
while it is placed.  You should not feel it once it is in. The investigators are happy to 
show you the device before you decided whether to take part or not. It is not any 
more painful than a normal blood sugar test. You will then wear this machine for 48 
hours.  The monitor will be fitted when you attend for your dialysis and removed at 
your next session.  You will also be asked to fill in a food diary for the 48 hours 
while you are wearing the monitor.  
 
Are there any risks in taking part? 
 
There are no risks, other than a small amount of discomfort when the glucose 
sensor is placed. 
 
What are the possible benefits of taking part? 
 
We hope that the information from this study will give an indication whether the 
results from laboratory tests can be duplicated in people who have a free choice of 
food. This information will help decide the best dietary and treatment advice for 
people with diabetes on haemodialysis, and whether this advice should be different 
on dialysis and non-dialysis days 
. 
What happens when the research study stops? 
 
We will give all people who took part in the study a copy of the results.  
 
What if something goes wrong? 
 
In the event of your suffering any adverse effects, as a consequence of your 
participation in this study, you will be compensated through the Imperial College 
School of Medicine‟s “No Fault” Compensation Scheme. 
 
Will my taking part in this study be kept confidential? 
 
All information, which is collected about you during the course of the research, will 
be kept strictly confidential. Any information about you, which leaves the hospital, 
will have your name and address removed so that you cannot be recognised from it. 
We will seek your permission to tell your GP about the study before you start on the 
research project.  
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What will happen to the results of the research study? 
 
The results of the research study will be published in a peer-reviewed journal. In 
addition, they will be available to everyone who took part in the study within six 
months of the study finishing. Individuals will not be identified in any 
report/publication. 
 
Who is organising and funding the research? 
 
The research is organised by the Department of Diabetes and Kidney Medicine at 
Hammersmith Hospital. 
 
Who has reviewed the study? 
 
The Hammersmith Hospitals Trust Research Ethics Committee has reviewed the 
study.  
 
Contact for Further Information 
 
If you wish to talk the study through or wish to raise a concern please write or ring 
Dr Anne Dornhorst or Dr Sara Kazempour at the Department of Diabetess, 
Hammersmith Hospital, Du Cane Road, London, W12 0HS.  Telephone No: 0208 
383 1000. 
 
Thank you for volunteering to take part in this study! 
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Supplement 7: Consent form for CGM study 
 
PARTICIPANT CONSENT FORM 
 
Title of Project: 
 
Quantifying the 48-hour glycaemic control in diabetic who are eating a low 
glycaemic index diet as appropriate for diabetes. 
 
The participant should complete the whole of this sheet him or herself. 
 
(Please tick each statement if it applies to you) 
 
I have read the Information Sheet for Patients and  
Healthy Volunteers        [    ] 
 
 
I have been given the opportunity to ask questions and  
Discuss this study.        [     ] 
 
 
I have received satisfactory answers to all my questions.  [     ] 
 
 
I have received enough information about the study.    [     ] 
 
 
The study has been explained to me by: 
Prof/Dr/Mr/Mrs/Ms_____________________________ 
 
I understand that I am free to withdraw from the study, 
at any time, without having to give a reason for  
withdrawing and without affecting my future medical care.  [      ] 
 
I agree to take part in this study.      [      ] 
 
Signed……………………………………..Date………………… 
 
(Name in Block Capitals)………………………………………... 
 
 
Investigator‟s signature…………………………..Date…………. 
 
(Name in Block Capitals)………………………………………... 
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Supplement 8: Patient food diaries 
 
Your  
3-Day  
Food Diary 
 
 
NAME: 
__________________________________________ 
 
 
 
DATE: _____________________ 
 
 
 
Thank you for agreeing to fill out this food diary.   
 
This record is designed to obtain accurate 
information about the type and quantity of food that 
you eat. 
 
Please answer the General Question section and then 
go on to the Food Record. 
318 
GENERAL QUESTIONS 
 
Which type of bread do you usually eat? 
White   
Brown   
Granary   
Wholemeal   
None   
 
Do you usually buy large or small loaves, sliced or unsliced? 
Large   
Small   
Sliced   
Unsliced   
 
If you eat any type of biscuit regularly, please specify which brands? 
 
__________________________________________________________________ 
 
Which type of milk do you usually use? 
Full cream milk (silver top)   
Semi-skimmed milk (red striped top)   
Skimmed milk (blue top)   
None   
 
How much milk do you usually use? 
1-2 pints daily   
½-1 pint   
¼-½ pint   
None   
 
How many tablespoons of milk do you take in tea and coffee? 
 
_____ tablespoons milk in a cup of tea / coffee 
 
 
Which brand of butter or margarine do you buy? 
 
_________________________________ 
 
What do you do with the visible fat on your meat? 
Eat most of the fat   
Eat as little as possible   
Eat some of the fat   
Don't eat meat   
 
Do you drink alcoholic drinks? Y / N 
 
If the answer is Yes, please indicate how many units you drink per week? 
_____  
 
1 unit = ½ pint beer/lager OR 1 glass wine OR 1 tot spirit. 
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FOOD RECORD 
 
Read through these instructions and the example carefully once or twice before you start.  
We would like you to record, as accurately as possible, what you eat and drink for 3 days 
as explained by your doctor. 
 
Please record ALL food and drink consumed.  Record at the time of eating and NOT from 
memory at the end of the day.  Keep this record sheet with you throughout the day.  You 
should include all meals and snacks, plus sweets, drinks etc.  When recording food eaten at 
meals, please include any sauces, dressing or extras eg: gravy, salad dressing, pickles, as 
well as the main food.  If you do not eat a particular meal or snack simply draw a line across 
the page at this point. 
 
Guidelines for describing food & drink: 
 
1. Please give details of method of cooking eg: grilled, boiled, roasted. 
 
2. Give as many details as possible about the type of food you eat: 
 
a) State brand name where applicable 
eg: 'Princes' sardines in tomato sauce OR 
'Sainsburys' half-fat Edam cheese. 
 
b) Name the type of biscuit, cake or cereal 
eg: Rich Tea, Madeira, Branflakes. 
 
c) Name the type of cheese, fish or meat 
eg: Cheshire cheese, haddock fillet, pork chop. 
 
3. Suggestions for recording quantity of food and drink: 
 
a) For many foods such as vegetables, cereals and some fruit a household  
measure is adequate, state the number of teaspoons (tsp) or tablespoons (tbsp) or 
cups, and whether level, rounded or heaped. 
 
b) All convenience foods have their weight on the packaging and this can  
be quoted 
eg: 150g carton Ski raspberry yoghurt OR 
½ 15 oz can baked beans. 
 
d) Cheese, fish, meat.  When possible, please weigh your portions of these  
foods.  Otherwise describe as well as you can. 
eg: 2 large thin slices ham OR 
2 small lamb chops (no fat eaten) OR 
Medium fillet of cod grilled with 1 tsp flora OR 
Cube of cheddar cheese the size of a matchbox. 
 
Remember to include everything you eat and drink including snacks and nibbles. 
Please do not change what you normally eat just because you are filling in this record. 
 
Look at the example of how to fill in you record - you may find this helpful. 
 
THANK YOU VERY MUCH FOR YOUR HELP 
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DIETARY RECORD SHEET - EXAMPLE 
 
 
DAY:  Tuesday  DATE: 1st January 2008 
 
TIME DETAILS OF FOOD & DRINK QUANTITY 
 EATEN 
Leave 
Blank 
7.45am Tea with  
Skimmed milk 
1 cup 
1 tbsp 
 
9am Branflakes (Kellogg's) 
Skimmed milk for cereal & drinks 
Wholemeal bread (large loaf) 
Flora extra light margarine 
Coffee 
3 heaped tbsp 
¼ pint 
1 medium slice 
1 tsp 
2 mugs 
 
11.10am Coffee with 
skimmed milk 
Apple (eaten with skin) 
1 mug 
1 tbsp 
1 medium 
 
1.15pm Sandwiches: 
wholemeal bread (Allinsons) large 
loaf, sliced 
Flora extra light margarine 
Ham (no fat) 
Tomato 
Banana 
Diet Tango 
 
4 slices 
 
4 level tsp 
2 thin slices 
1 large 
1 large 
1 can (330ml) 
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DAY:  Example  DATE: 1st June 1992 
 
TIME DETAILS OF FOOD & DRINK QUANTITY 
EATEN 
Leave 
Blank 
4.30pm Low Calorie squash made with 
concentrated squash 
KP roasted salted peanuts 
1 glass 
 
25g pkt 
 
715pm Chicken & mushroom casserole (home-
made with skimmed milk in the sauce) 
 
Jacket potato 
Broccoli, boiled 
Shape raspberry yoghurt 
Half mineral water/half natural orange 
juice 
Tea with  
skimmed milk 
4 heaped tbsp 
 
 
 
1 apple sized 
3 tbsp 
1 x 150g tub 
1 glass 
 
1 cup 
1 tbsp 
 
8pm Nothing.   
9.40pm Ovaltine made with: 
Ovaltine 
ordinary silver top milk, the rest water 
Rich Tea biscuits (Sainsburys). 
1 mug 
1 tsp 
½ mug 
2 
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DIETARY RECORD SHEET 
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